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Pathogenesis of autoimmune and auto-inflammatory diseases is induced by auto-
aggressive helper T (Th) cells (i.e. Th1 and Th17 cells), and can be controlled by 
regulatory T cells (Tregs) characterized by expression of the transcription factor 
Foxp3. Thus, development of autoimmunity is regulated by the balance of Tregs and 
Th1/Th17 cells. Prostaglandin E2 (PGE2) is a bioactive lipid mediator with immune-
modulatory potential that acts through 4 receptors (EP1-4). It has been shown that 
PGE2 facilitates Th1 and Th17 cell development and expansion, therefore promoting 
autoimmune inflammation. However, the role of PGE2 in Treg development and 
function is largely unclear. The aim of this PhD was to test the hypothesis that PGE2 
regulates Treg development, function and subsequent immune response.  
I observed that in vivo inhibition of endogenous PGE2 biosynthesis using a COX 
inhibitor resulted in increased Foxp3+ Tregs in various lymphoid organs. This 
response was prevented by addition of an EP4 agonist. PGE2-EP4 signalling 
particularly inhibits RORγt+ Tregs in the intestine. This was not observed in either 
antibiotic-treated mice or MyD88/TRIF double-knockout mice, suggesting gut 
commensal microbiota involvement. In addition, PGE2 has a role in microbiota-
dependent regulation of intestinal CD11c+MHCII+CD11b+CD103- mononuclear 
phagocytes (MNPs) which drive intestinal Treg expansion through production of type 
1 interferons. Consistent with these in vivo observations, gut microbial metabolites 
from indomethacin treated mice enhanced in vitro RORγt+ Treg differentiation in the 
dendritic cell- T cell co-culture system. Adoptive transfer of caecal microbiota from 
COX inhibitor- treated mice into naïve mice also provided protective benefits in a 
chemical (DSS)-induced colitis disease model.   
In summary, this work has demonstrated that PGE2 affects intestinal Tregs, indicating 
a novel mechanism for interaction of PGE2, the adaptive immune system and the gut 
microbiota in homeostasis within this environment. These findings increase our 
understanding of the role of PGE2 in development of inflammatory bowel disease and 





Auto-aggressive T helper cells (Th) cells (i.e. Th1 and Th17 cells) induce autoimmune 
and autoinflammatory disease pathogenesis, which is controlled by regulatory T cells 
(Tregs) characterised by expression of the transcription factor Foxp3. The balance of 
Tregs and Th1/Th17 regulates the development of autoimmunity. Prostaglandin E2 
(PGE2) is a lipid mediator with immune-modulatory potential, acting through 4 
receptors (EP1-4). It has been shown that PGE2 facilitates Th1 and Th17 cell 
development and expansion, therefore promotes immune inflammation. However, the 
effects of PGE2 on Treg development and function is largely unclear.  
I have studied this issue and found that PGE2 suppresses intestinal Tregs. While 
inhibition of endogenous PGE2 using a COX inhibitor increased intestinal Treg 
numbers, this could be reversed by an EP4 agonist. This effect of PGE2 was not 
observed in antibiotic-treated mice or MyD88/TRIF double knockout mice, suggesting 
the involvement of the gut microbiota. I further found that PGE2 suppressed 
CD11c+MHC-II+CD103-CD11b+ mononuclear phagocytes (MNPs) which promote 
intestinal Treg expansion through producing type 1 IFNs. Deficiency of IFNAR 
prevented COX inhibitor induced enhancement of intestinal Tregs and MNPs. More 
importantly, adoptive transfer of caecal microbiota from COX inhibitor treated mice 
into naïve mice reduced chemical (DSS)-induced colitis, which was correlated with 
increase in Tregs in the host intestine. In addition, while there were comparable Tregs 
in the gut of T cell-specific EP4 deficient and control mice in steady state, EP4 
deficiency in T cells prevented T cell-mediated chronic intestinal inflammation, which 
also correlated with increase in intestinal Tregs. Taken together, my results indicate 
a critical impact of PGE2 on intestinal Tregs and the development of intestinal 
inflammation, possibly through modification of the gut microbiota. 
These findings update our understanding of the well-known inflammation mediator, 
PGE2 in the development of inflammatory bowel disease and offer potential 
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Regulation of intestinal regulatory T cells by prostaglandin E2 
The immune system is highly dynamic and has evolved to protect the host organism 
from endless barrages of both internal potential threats and external pathogens. The 
immune system includes physical barriers, such as the skin and gut mucosal layer, 
and the complex cellular and molecular interactions of the innate and adaptive 
immune responses. The key functions of innate and adaptive immunity are to 
discriminate between invading antigens or harmless self-antigens and mount an 
appropriate response [1]. Occasionally the mechanisms in place to recognise our self-
antigens as non-threatening can be circumvented, which often leads to the immune 
system attacking our own tissues resulting in chronic inflammation and autoimmune 
disease such as Inflammatory Bowel diseases. An autoimmune disease is a chronic 
condition, but symptoms can vary between mild and debilitating, and having one such 
condition can increase a person’s susceptibly to developing others [2, 3]. These 
conditions can be treated, but currently not cured. There is no ‘specific’ treatment for 
these conditions due to the idiopathic nature of these diseases, but can range 
between anti-inflammatory drugs such as ibuprofen, immunosuppressive medication 
and physical therapy [4]. None of these treatments are curative, and can also have 
equally negative side-effects as explained in the following section. Researching cells 
that regulate the immune system, such as regulatory T cells and specific molecules 
that contribute to its function, such as prostaglandin E2 (PGE2), which is known to 
have both pro- and anti-inflammatory effects, can ensure development of better, more 










1.1  The Immune System 
The immune system consists of multiple components as mentioned above. In addition 
to physical barriers, multiple cell types are harnessed by the body to protect against 
both external and internal threats [5, 6].  
1.1.1 T cell development 
Naïve T cells develop within the thymus from hematopoietic stem cells (HSCs) 
recruited from the bone marrow (BM). There are two distinct thymocyte lineages, 
alpha beta (αβ) and gamma delta (ɣδ) [7, 8]. When progenitor T cells first enter the 
thymus from the BM, they lack the two main surface molecules (cluster of 
differentiation (CD)4 and CD8) that are associated with mature T cells and are called 
‘double negative’ thymocytes (DN CD4-CD8-). Cells are negatively selected for those 
which express T cell receptors (TCRs) which engage with a high affinity for peptides 
expressed by major histocompatibility complex (MHC)-I or MHC-II proteins on the 
cortical thymic epithelial cells (cTECs), and those that are unable to engage at all die 
via apoptosis. Cells are positively selected after TCRs engage with a peptide-MHC 
molecule complex with a reasonable affinity.  The αβ expressing thymocytes 
represent the majority of the T cell population, and these develop into two distinct 
subsets; CD4+ and CD8+ T cells [7, 8]. Thymocyte TCRs that bind to MHC-I-peptide 
complexes mature into CD8+ single positive cells (SP), whereas those that bind to 
MHC-II-peptide complexes mature into CD4+ SP cells.  These cells are classified as 
mature and exit the thymus to circulate in the blood or lymphatic system.  
In this thesis I will be focusing on CD4+ T cells, which shall be explained in further 
detail in the following sections. 
1.1.2 Maturation of CD4+ T cells 
Development of the adaptive, more specific immune response requires further 
interaction with cells important in the innate immune system. SP naïve CD4+ T cells 
exit the thymus and migrate within the lymphoid system prior to activation by antigen 
presenting cells (APCs). APCs, such as phagocytic dendritic cells (DCs) are part of 
the first line of defence. These cells process and present proteins on their surface to 
naïve CD4+ T cell TCRs via the MHC-II complex. In addition to T cell activation by the 
TCR, co-stimulation of the protein CD28 on the surface of the T cell similarly occurs 
via the CD80 (B7.1) or CD86 (B7.2) ligands, the combination of which regulates the 
specificity and strength of the response [9].  The final T cell effector subtype is 
dependent on the cytokines released by APCs during T cell activation (Fig. 1.1) which 
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is determined by the signal induced by Pathogen-Associated Molecular Patterns 
(PAMPs) through Toll-Like Receptors (TLRs), vital components of the innate immune 
response [10]. Following ligation of TLRs with a specific PAMP, a signal cascade is 
induced through adapter molecules, myeloid differentiation primary response 
88  (MyD88) and TIR-domain-containing adapter-inducing interferon-β (TRIF), 
inducing cytokine production [1].   
 
 
Figure 1.1: CD4+ Th cell differentiation. Naïve T cells migrate from the thymus and are 
activated by APCs in the peripheral lymphoid organs. In the presence of pro-inflammatory 
cytokines such as interleukin-12 (IL-12), naïve T cells differentiate into T helper (Th)-1 cells 
and IL-4 induces Th2 cells. The presence or absence of IL-6 determines whether transforming 
growth factor (TGF-β) induces either Th17 cells, or peripherally-derived Tregs (pTregs). 
Thymic-derived Tregs (tTregs) develop within the thymus, then migrate into the peripheral 
environment. Excessive T helper cell induction can result in autoimmunity and inflammatory 





1.1.3 Effector CD4+ T cells  
Effector CD4+ T cells are T helper cells (Th1, 2 and 17)  which have distinct roles in 
protecting against potentially harmful pathogens [11]. Th1 cell production of interferon 
gamma (IFNɣ) is important for the clearance of intracellular pathogens through 
activation of macrophages and enhanced microbicidal activity [11]. Th2 cells are 
involved in clearance of extracellular pathogens through cytokine mediated activation 
of eosinophils, and elevation of B cell derived IgE antibody which is important for 
clearing pathogens [12]. Th17 cells are thought to be involved in clearance of 
extracellular bacteria and fungi [13]. Th17 cells secrete IL-17A, IL-17F and IL-22, and 
are regulated by the transcription factor RAR-related orphan receptor gamma 
(RORɣt) [14]. Both IFNɣ and IL-4 have been shown to inhibit Th17 differentiation, and 
IL-4 production by Th2 cells can inhibit Th1 cell induction, suggesting that the Th cells 
are involved in regulation of each other [15].  Excessive activity of Th2 cells can result 
in allergies, whereas excessive Th1 and Th17 cells responses can cause 
autoimmunity development, such as inflammatory bowel disease (IBD) due to 
aberrant recognition of ‘‘self’’ peptide [15]. The aetiology of this condition is not exact, 
however it is believed to be due to excessive activation of immune cells against 
microbial or foreign antigens after disruption to the intestinal barrier [16]. Therefore, it 
is important to study the mechanism of regulation that prevents this occurring 
regularly.  
1.1.4 Regulatory T cells  
As described above, self-reactive T cells ‘should’ be eliminated in the thymus, a 
process known as ‘‘central’’ tolerance. However autoreactive T cells can escape 
negative selection and be a potential risk if they ever encounter the peptide antigens 
their TCRs responds to, thus mechanisms to maintain ‘peripheral’ tolerance are also 
required for a healthy immune system. Regulatory T cells (Tregs) are a subset of 
CD4+ T cells that suppress the immune response. These cells have been shown to 
suppress the immune response of mice following immunisation of antigens. In the 
1970’s, Gershon and Kondo initially demonstrated the function of ‘suppressor T cells’ 
by reporting the ability of these cells to suppress an antigen specific immune 






This finding was expanded by Sakaguchi in the 1990’s, when the ‘suppressor T cells’ 
were further characterised as CD4+CD25+ natural regulatory T cells (nTregs) [3]. 
CD25 is the high affinity receptor for the main cytokine interleukin-2 (IL-2) that 
promotes T cell proliferation. These nTregs suppressed inflammatory cell responses, 
and removal of these cells through addition of anti-CD25 antibody (αCD25) to 
splenocytes from a wild-type (WT) mouse and consequent injection of these nTreg 
depleted cells into athymic nude mice induced an autoimmune response [3]. The 
transcription factor and important Treg marker forkhead box P3 (Foxp3) was identified 
in 2000 as a key regulator of Treg cell development and function [21, 22]. The 
importance of this protein was demonstrated through use of scurfy mice which have 
deletion in the Foxp3 gene [21, 23]. These mice develop a severe and rapidly fatal 
lymphoproliferative disease and multiorgan autoimmunity due to inability to control 
autoreactive CD4+ T cells, however this was relieved by transfer of wild type Tregs 
[21, 23, 24]. 
In recent years it has become clear that there are different subsets of Tregs that 
contribute to immune regulation. Thymic derived Tregs (tTregs), initially termed 
‘natural’ Tregs, are CD4+CD25+Foxp3+ T cells that originate in the thymus and are 
largely self-antigen specific [25, 26]. These represent 5 - 10 % of circulating CD4+ T 
cells. Peripherally-derived Tregs (pTregs), previously named ‘induced/adaptive’ 
Tregs, arise from CD4+CD25-Foxp3- naïve T cells after activation in the peripheral 
environment by chronic or suboptimal foreign antigenic stimulation, helminth 
infections and commensal microbiota [25-27]. TGF-β regulates the balance of Tregs 
or Th17 cells depending on the availability of IL-6 [25]. Tregs generated in vitro from 
naïve T cells are named in vitro induced Tregs (iTregs).  
There is a subgroup of Tregs that do not express Foxp3, CD4+Foxp3- Type 1 
regulatory T cells (Tr1). These cells have had increased attention over the past 20 
years due to their role in peripheral tolerance, and are activated after long-term 
activation by an antigen whilst in the presence of IL-10 [28]. In 2013, a panel of surface 
markers unique for Tr1 cells were discovered including high expression of IL-10 and 
LAG-3, however there was no unique transcription factor associated with this cell type 
[28, 29]. These cells also act in specific local environments in response to specific 
antigens throughout the body similar to pTregs.  
The different subgroups shall be referred to as Tregs when discussing the 




Figure 1.2: Signalling pathways that mediate Foxp3 induction. Multiple signalling 
pathways, acting via the TGF-β receptor, T cell receptor and IL-2 receptor can result in Foxp3 
expression. The CD28 pathway can enhance Foxp3 expression via Phosphoinositide 
phospholipase C (PLC) signalling, however if the alternate phosphatidylinositide 3-kinase 
(PI3K) pathway is activated, Foxp3 induction may be inhibited. Image adapted from [30-32]. 
Foxp3 expression can be initiated by numerous mechanisms and a combination of 
TCR activation and cytokine signalling (Fig. 1.2).  TGF-β is critical for de novo 
induction of Foxp3 expression in T cells through activation of the transcription factor 
SMAD (i.e. Smad3 and Smad4), via activin receptor-like kinase 5 (ALK5), which bind 
to the Foxp3 promoter and enhancer to initiate gene expression [30]. IL-2 is another 
molecule known to be important in the activation and development of Tregs, which 
acts through its receptor CD25 via stimulation of the Janus tyrosine Kinase (JAK)/ 
Signal Transducer and Activator of Transcription (STAT)-5 pathway to maintain Foxp3 




It was reported that stimulation of the TCR activates the transcription factor cyclic 
adenosine monophosphate (cAMP) response element-binding protein (CREB) which 
binds to the Foxp3 gene locus and facilitates Foxp3 gene transcription [30]. However, 
a recent paper did suggest that CREB deletion in T cells resulted in an increased level 
of Tregs, and fewer Th17 cells [33, 34]. This is thought to be due to its role balancing 
Tregs and pro-inflammatory Th17 cells [33, 34].  Phosphoinositide phospholipase C 
(PLC) can also be activated after TCR stimulation, which acts via calcineurin and 
nuclear factor of activated T cells (NFAT) for Foxp3 expression [35]. The co-
stimulatory molecule CD28 has dual roles with regard to Foxp3 expression. 
Stimulation can activate PLC to positively up-regulate Foxp3 expression, but can 
likewise activate phosphatidylinositide 3-kinase (PI3K) and protein kinase B (AKT) 
[30]. Activation of the PI3K/AKT pathway is thought to prevent Foxp3 gene 
transcription [30, 36].  
Numerous mechanisms have been proposed as to how Tregs suppress pro-
inflammatory CD4+ T helper cells. Tregs can mediate homeostasis through promoting 
B cell anergy, release of soluble cytokines such as interleukin-(IL)-10 and TGF-β, 
which can inhibit T cell proliferation and cytokine production [1]. Additionally IL-10 can 
disrupt DC maturation and APC expression of CD80/86 thus preventing further T cell 
activation by suppressing co-stimulation [1]. Tregs can similarly act via contact-
dependent mechanisms, such as the inhibitory receptor Cytotoxic T Lymphocyte 
Associated Protein-4 (CTLA-4) which can induce DC production of indoleamine 2,3-
dioxygenase (IDO) or granzyme- or perforin-dependent mechanisms which are toxic 
to responder cells [3]. 
A balance of these effector T cells and Tregs are vital within the body to prevent 
infection by harmful antigens, but also to protect against excessive inflammation 
which could have deleterious effects on tissues and the body. However, there are 
certain areas of the body which are more likely to encounter potentially pathogenic 
organisms or material, and thus requires a more active immune system to be present, 
adapted for this specific environment, such as the cilia, goblet cells, a mucosal layer 
and the immune cells within the nasal passage, the lungs and intestine. These areas 
of the body are continuously in contact with the external environment and foreign 





1.2 Intestinal Immune System 
1.2.1 Development of intestinal immunity 
The gastrointestinal (GI) epithelium at approximately 100 m2 is considered to be the 
largest immune interface with the environment, and is constantly exposed to non-
harmful stimuli, such as microbiota and food particles which normally would trigger an 
immune response [37]. Therefore, the gut requires sophisticated regulatory 
mechanisms to prevent an excessive immune response to these non-harmful stimuli 
[5, 38]. However, protection against harmful pathogens invading the gut is necessary 
and demonstrates the importance of a strong defence system within this environment. 
This defence includes non-specific mechanisms including digestive enzymes and 
pathogen-specific defence provided by the gut-associated lymphoid tissues (GALT) 
[6, 16, 39]. GALT itself is known to develop under the influence of the non-harmful 
microbiota and their resulting metabolites [16, 40].   
One method of preventing response to foreign proteins in food is known as ‘‘oral 
tolerance’’. In 1909, Besredka initially observed the effect of dietary antigens such as 
milk whey inducing oral tolerance, when guinea pigs administered rectally or orally by 
this antigen were resistant to sensitisation and allergy development after injection of 
the antigen at a later point [41]. This finding was supported in 1911 by Wells and 
Osborne who demonstrated that delivering proteins to guinea pigs from the weaning 
stage prevented allergic reaction development after future injection with the antigen 
[41]. The importance of T cells in induction of oral tolerance was demonstrated in the 
1970’s by experiments in which donor mice were fed with ovalbumin (OVA), and T 
cell enriched splenocytes from these mice were injected into naïve recipient mice 
which were resistant to OVA-induced inflammation compared to mice injected with 
splenocytes depleted of T cells [42]. Further studies examining oral tolerance in the 
intestine have been carried out using experiments such as depletion or suppression 
of antigen-specific T cells [42].  
It was then questioned whether tTregs or pTregs were more important for this 
process. Bilate used the process of crossing TCR transgenic mice (in which all the 
CD4+ T cells recognise OVA) with RAG-1 deficient mice, which produce no mature T 
or B cells, and injected the OVA antigen to induce an immune response [42, 43]. Oral 
exposure to the antigen resulted in increased CD4+CD25+Foxp3+ pTregs that had a 
strong suppressive ability both in vivo and in vitro [43]. 
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Another mode of immune tolerance is directed against the intestinal commensal 
microbiota. There are approximately 1 x 1014 gut microbes within the intestine, a 
combination of bacteria, viruses and fungi [44]. Their combined genetic information 
encodes 100 times the genes contained within the human genome [45]. The 
microbiota mostly acts in a symbiotic manner with the host but protection against 
potential threats is still important. Before birth, an individual’s gastrointestinal tract is 
sterile, but this becomes colonised by the mother’s microbiota during delivery [46]. 
The importance of a diverse gut microbiota is clear, and its composition can be 
influenced by a multitude of factors. The differences between delivery modes can 
massively affect microbial diversity. Infants born through caesarean section had a 
lower microbial diversity compared to those born vaginally, and this consequently 
resulted in a reduced Th1 response during the initial two years of life, pushing naïve 
T cells towards a Th2 phenotype, which indicates a greater risk of developing allergies 
[47]. A study published recently by Martinez II, K. A. et al (2017) demonstrated that 
mice pups delivered by C-section had significantly different gut microbiota compared 
to pups delivered vaginally [48]. The altered microbiome and reduced taxa of 
microbiota including Bacteroides and Clostridia, both known to be important for 
colonic Treg development, increased the risk of weight gain in pups, demonstrating 
the importance of a balanced microbiota in normal metabolic development, as well as 
the immune response [45, 48-50].  
The microbiota composition can be affected by antibiotic use for unrelated illnesses, 
however multiple studies have indicated that almost 50% of antibiotics that are 
prescribed, have been prescribed unnecessarily which is a serious problem at this 
current time [51].  Not only does this increase the risk of developing antibiotic resistant 
bacteria, but it can also cause microbial dysbiosis, which numerous studies have 
shown to be implicated in several gut pathologies such as Crohn’s disease and 
ulcerative colitis (UC) [52, 53]. The gut microbiota can additionally affect insulin 
resistance and the risk of diabetes development. It was shown that co-housing 
obesity-prone C57BL/6 mice from The Jackson Laboratory and obesity-resistant 
129S1/SvImJ from the same company suppressed the propensity for obesity 
development, and the most significant difference between these two strains of mice 
was their gut microbiota [54]. A greater microbial diversity correlates with a greater 
population of intestinal Tregs, and this is consequently more protective for the host 
[50, 55]. Therefore, a greater understanding of the influence of the gut microbiota on 
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the host immune system will be beneficial to develop more effective, less harsh 
treatment for intestinal conditions.  
Undigested fibrous food within the GI tract provides energy for the microbiota, and 
can be further broken down into by-products such as short-chain fatty acids (SCFAs) 
which contain a carbon number between two and six [44, 56]. Fermentation products 
can lower the intestinal pH and consequently influence the population of gut 
microbiota which inhabit this environment [57]. Butyrate is one of the most common 
SCFAs, and alongside certain gut microbiota such as Clostridia, Bacteroides and their 
metabolites, has been shown to induce intestinal pTreg differentiation and number, 
although they have little effect on nTregs [6, 45, 49]. TCRs expressed by intestinal 
Tregs have been shown to have increased reactivity to microbial antigens and this is 
thought to increase the speed of their activation and proliferation [58]. Clostridia can 
colonise the mucosal layer, and exert influence on the intraepithelial cells to produce 
TGF-β and IDO, both which are important in the differentiation and activation of Tregs 
respectively [59].    
Tregs, predominately within the GALT, are vital to maintain a homeostatic 
environment largely through secretion of IL-10 [16]. The importance of the gut 
microbiota in the regulation of the immune system is apparent due to colonic lamina 
propria Treg numbers and SCFAs being reduced in germ-free (GF) and antibiotic-
treated mice compared to WT mice [26, 60]. Similarly, it was demonstrated in an 
adoptive transfer model that Tregs from WT mice had a better suppressive ability 
compared to Tregs from GF mice [45]. Neuropilin-1 (NRP-1) and Helios, both markers 
of nTregs, are both expressed at a low level in Foxp3+ Tregs within this environment, 
indicating that the intestinal microenvironment favours induction of pTregs [26, 60].  
The intestine is a potentially inflammatory environment due to the microbes and food 
antigens amongst other factors that interact with the mucosal layer. Hence the co-
evolution of the intestinal immune system alongside the commensal microbiota is 
important to prevent excessive inflammation. Within this environment, tTregs, or naïve 
T cells that migrate to the colonic environment prior to differentiation into pTregs, 
suppress pro-inflammatory cells via multiple mechanisms, such as antagonising pro-
inflammatory effector T cells, through contact-dependent mechanisms such as 
cytotoxic T-lymphocyte-associated protein-4 (CTLA-4), and release of soluble 
cytokines such as IL-10 and TGF-β [3]. Sakaguchi. S, et al (1995) demonstrated that 
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removal of these cells elicited an autoimmune response to certain self-antigens which 
confirmed their importance in maintaining tolerance [3, 13].  
In inflammatory sites such as the intestine, Tregs can co-express effector T cell 
transcription factors, such as T-bet (Th1), GATA-3 (Th2) or RORɣt (Th17) which can 
enable a more effective suppressive ability for effector T cells, however they were 
also considered to be able to ‘return’ to the inflammatory phenotype depending on the 
situation [25]. Approximately 40 - 60 % of the colonic p-Treg population co-express 
RORγt, and the extent of co-expression correlated with microbial diversity [55]. This 
population was detected only at small levels in other tissues, for example mLNs and 
spleen [58].   
In vitro it was demonstrated that naïve CD4+ T cells expressed both RORɣt and Foxp3 
when cultured under Th17 inducing conditions, and depending on the balance of pro-
inflammatory cytokines and TGF-β levels, this determines whether the cell finally 
matures into a Treg or effector T cell phenotype [55]. It was thought that this 
intermediate phenotype could enhance immune cell flexibility for a specific and rapid 
response to stimuli [61]. However, it was demonstrated in vivo that RORɣt+Foxp3+ 
Tregs are highly stable within an inflammatory environment, as Treg specific genes; 
Foxp3, Ctla-4 and Eos, were highly demethylated, and are highly suppressive due to 
increase levels of membrane-bound (m)TGF-β, α4β7, a gut homing integrin and 
CD62L which is required for immune cell trafficking [55, 61, 62]. Sefik, E. (2015) et al, 
detected IL-17 in RORɣt+ Tregs from the small intestine, however the colonic RORɣt+ 
Treg population were not found to secrete IL-17, and these Treg populations were 
negatively affected by broad-spectrum antibiotic treatment [58]. Yang, et al (2016) 
demonstrated that these cells were closer to a Treg phenotype rather than an effector 
phenotype by isolating RORɣt+Foxp3-, RORɣt+Foxp3+ and RORɣt-Foxp3+ cells from 
transgenic mice expressing RORc(ɣt)-GFP and Foxp3-IRES-mRFP [62]. Using 
microarray analysis and next generational sequencing (NGS) it was clearly shown 
that there was closer clustering of genes between RORɣt+Foxp3+ Tregs and Foxp3+ 







The importance of these cells was demonstrated by Sefik, E. (2015) et al, through a 
trinitrobenzenesulfonic acid- (TNBS) induced colitis disease model, using WT or 
Foxp3-Treg specific RORɣt knock-out mice (Foxp3cre.Rorcfl/fl) [58]. There was 
increased disease activity score and pro-inflammatory cytokine production in the 
Foxp3-Treg specific RORɣt knock-out mice group compared to WT mice, 
demonstrating the importance of this subset of Tregs in regulating colonic 
inflammation [58]. Similarly, they repeated the TNBS disease model using GF mice, 
monocolonising with various microbes [58]. Disease severity correlated with amount 
of RORɣt+ Tregs, which similarly correlated with microbial colonisation demonstrating 
the importance of gut microbiota in the development of these cells [58]. 
Intestinal homeostasis is maintained by DCs that present processed microbial 
peptides on their surface to induce either effector or regulatory T cells, depending on 
the signals that were received by the TLRs [63]. Intestinal DCs were thought to have 
three main subsets; CD103+CD11b+, CD103+CD11b- and CD103-CD11b+ DCs, which 
can migrate to lymph nodes and instruct naïve T cells to mature into a distinct subtype 
[64]. During steady-state conditions, tissue-resident DCs are immature (iDCs), and 
express low levels of the processing molecule MHC and co-stimulation molecules 
[65]. Pathogen associated molecular patterns (PAMPs), which are molecules 
associated with pathogens and are then recognised by the innate immune system, or 
damage associated molecular patterns (DAMPs), which are endogenous danger 
signals that signal the body to internal cell death or stress, both of which can be 
recognised via TLRs, and initiates iDC maturation [65].  
TLRs are transmembrane members of the membrane pattern recognition receptor 
family (PRR), which are able to identify PAMPS and DAMPs. Activation of these 
receptors initiates various signal transduction pathways, promoting expression of 
genes involved in the immune response  [65]. TLRs detect a diverse range of PAMPs 
from and trigger an immune response cascade via adapter molecules, such as the 
myeloid differentiation primary response (MyD)88 and TIR-domain-containing 
adapter-inducing interferon-β (TRIF) [66]. These adapter molecules activate 
transcription factors, such as interferon-regulatory factor-3 (IRF-3) and nuclear factor 
kappa-light-chain-enhancer of activated B cells (NF-κβ) which result in increased 
expression of cytokines, e.g. tumour necrosis factor alpha (TNF-α) and interferon 
gamma (IFN-ɣ) [66]. This response enables to activation of the adaptive immune 
response through maturation of DCs and stimulation of other immune cells. Mature 
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DCs upregulate MHC expression, co-stimulatory molecules for T cell activation, e.g. 
inducible T-Cell co-stimulator ligand (ICOSL) and C-C chemokine receptor type 7 
(CCR7) which enables DC trafficking to local lymph nodes [65]. 
Migratory DCs (CD103+) express CD103, a TGF-β induced integrin chain. They are 
found at mucosal surfaces including the intestine and lung. Intestinal DCs are located 
throughout the villus and lymphoid tissue, vital for sampling and presenting both 
foreign and self-antigen to T cells [67]. They are thought to be vital in generating Tregs 
via TGF-β and retinoic acid (RA), a vitamin A metabolite but are also critical for 
mucosal Th17 cell differentiation [65, 68, 69]. RA can likewise be provided by the 
intestinal epithelial cells (IECs) which boosts DC expression of retinal 
dehydrogenases (RALDH) which aids metabolism of dietary vitamin A into RA in a 
positive feedback loop [65]. CD103+ DCs similarly help inhibit T cell proliferation 
through production of the enzyme IDO [65, 68, 69]. DCs within the intestinal 
environment are important for ‘sampling’ the lumen constituents, they then migrate to 
mesenteric lymph nodes (mLNs) to activate or suppress immune cells depending on 
the signals received, upregulating T cell expression of the gut homing molecule CCR9 
and αβ-integrin [37, 65]. Intestinal DCs are able to access luminal antigens via 
extension of their dendrites through the epithelial junctions [16]. At a steady state this 
can maintain a homeostatic environment via low levels of co-stimulatory molecules, 
anti-inflammatory cytokine production and low levels of PRR that are used to detect 
the environmental signals. 
Coombes. J. L et al (2007), demonstrated that in an in vitro cell culture with naïve T 
cells, only the CD103+ DC subset induced Foxp3 expression [68]. They also 
investigated the functional properties of CD103+ and CD103- DCs by culturing them 
overnight either alone or plus the PAMP lipopolysaccharide (LPS), a major 
component of the outer membrane of gram-negative bacteria, to stimulate TLRs [68]. 
They previously observed that CD103- DCs expressed a greater level of TNF-α 
compared to CD103+ DCs, regardless of whether DCs were stimulated or untreated. 
TLR stimulation further enhanced CD103- DCs production of the pro-inflammatory 
molecules TNF-α and IL-6 which are important for Th17 induction, suggesting that 
CD103- DCs are pro-inflammatory, potentially providing protective immunity against 





Microbiota, such as Bacteriocytes and dietary antigens are also able to induce tolerant 
DCs [67]. SCFAs act via G-protein coupled receptors (GPCRs) which are located 
throughout the body, however are expressed greatest on immune cells and intestinal 
tract epithelial cells [44]. Mice deficient for the butyrate receptor GPR109 had reduced 
colonic Tregs and were more susceptible to colitis and colon cancer [67]. Intestinal 
Tregs (and DCs) have the highest expression of the SCFA receptor GPR43 compared 
to those in the spleen and mLNs demonstrating the importance of microbial products 
on intestinal immune cell development [70]. SCFAs are dependent on this receptor to 
act as a HDAC inhibitor and stabilise Foxp3 expression through reduced Foxp3 gene 
methylation, thus enhancing suppressive abilities through IL-10 production [44, 71]. 
Colonic Tregs from a WT mouse had a greater demethylated Foxp3 region and 
increased stability within the intestinal environment compared to specific pathogen 
free (SPF) mice [6]. This can influence T cell cytokine profiles, reducing pro-
inflammatory cytokine expression and thus preventing excessive inflammation [44, 
71]. This has been demonstrated by delivery of SCFAs to GF mice, free of all 
microorganisms, which promoted an increase in Foxp3 gene expression [44]. The 
cooperation between gut microbiota and the immune system is demonstrated by the 
fact that one current treatment for IBD is immunosuppression, which demonstrates 
that gut tolerance has broken down, if the inflammation was due to disruptive 
microbiota, such a suppressed immune response would likely result in overwhelming 
infection [45]. 
More recently Nakahashi-Oda, C. et al (2016) demonstrated that the subset of CD103-
CD11b+F4/80- DCs had a key role in maintaining homeostasis at the rapidly changing 
interface of the intestinal epithelium, which involved the gut microbiota, while CD103+ 
DCs acted independently of the microbiome [6, 37]. They demonstrated that 
CD11b+CD103- DCs could produce IFNβ after stimulation by commensal bacteria, 
and consequently enhanced Foxp3+ Treg proliferation [6]. Type 1 interferons can also 








BMDCs were generated and cultured with or without caecal content from SPF mice 
[6]. The BMDCs only produced IFNβ when caecal content was present [6]. Production 
of IFNβ can be induced by stimulation of TLR4 by LPS and activation of the signal 
adapter protein TRIF. TRIF forms a complex with either TNF receptor associated 
factor 6 (TRAF6), to induce activation of NF-κB, or preferentially the serine/threonine 
protein kinase TANK binding kinase 1 (TBK1) which induces IRF3 to consequently 
express IFNβ [72, 73]. IFNβ signals via TLR-9 to inhibit intestinal inflammation [74].   
Interferons are vital for DC maturation, activation, MHC-II expression and can induce 
IL-12 to push Th1 cell development [75].  They are a critical intermediary during a 
response to pathogens and interact with viral, bacterial and antigenic molecules within 
tissue environments such as the intestine [75, 76]. They were first identified in the 
1950’s, and currently there are 13 known subtypes of human IFNα, and one version 
of IFNβ, IFNέ, IFNκ, IFNτ, IFNϭ [76]. Genes are expressed independently of one 
another, however act in a coordinate fashion, either paracrine or autocrine [76].  
Type 1 interferons can inhibit T cell migration from the lymph node which increases 
their ability to interact with DCs [75]. Multiple groups have shown Type 1 interferons 
to be involved in improving IBD symptoms. Kole, et al (2013) showed the importance 
of Type 1 interferon signalling in suppressing inflammation in T cell colitis [75]. 
CD4+CD45RBhi T cells were sorted from WT or IFNAR-/- mice (which lack a major 
receptor for Type 1 interferons) spleens and transferred into RAG mice. Both groups 
had similar disease severity due to RAG mice still able to signal via IFNβR [75]. 
Therefore, RAG and IFNAR-/- mice were crossed and sorted T cells from WT or 
IFNAR-/- mice were injected i.p to induce T cell colitis [75]. RAG/IFNAR-/- deficient mice 
injected with WT CD4+CD45RBhi T cells had a greater disease severity than mice 
injected with T cells from IFNAR-/- mice. Similarly co-transfer of Tregs and T cells into 
a double knockout host resulted in a loss of Foxp3 expression and these cells gained 
an effector phenotype, as colonic IFN signalling is important in maintaining Treg 
homeostasis and suppressive ability, thus effector cell number increases as there is 
reduced control [75]. Double knockout mice have similar numbers of Tregs compared 
to WT mice, as multiple signals can induced Tregs as previously discussed, but 
maintenance of Foxp3 expression and suppressive ability however is greatly affected 




Type 1 interferons can increase production of anti-inflammatory signals such as IL-
10, an IL-1R antagonist from mononuclear phagocytes, and regulatory suppressor of 
cytokine signalling (SOCS) proteins in mononuclear phagocytes and T cells [75]. 
Additionally, inhibiting IL-1β production and secretion, preventing Th17 cell 
differentiation is important within inflammatory settings. This involvement of IFNβ in 
regulating colonic inflammation was also demonstrated by other groups that saw 
CpG, mimicking microbiota signalling, induction of IFNβ via CD11c+ cells prevented 
DSS colitis induction [75]. Transcription of Ifn-β was dependent of the adapter 
molecule TRIF [75]. Genome wide association studies (GWAS) have furthermore 
identified type 1 interferon genes, such as Ifnar1 and Stat-3, downstream of the 
interferon receptor, as risk loci for IBD [76]. This demonstrates the importance of 
coordination between immune cells, gut microbiota and subsequent signalling in 
maintaining homeostasis within the intestine. 
1.2.2 Disruption of intestinal homeostasis 
During normal homeostatic conditions, intestinal immune cells, commensal microbiota 
and intestinal epithelial cells (IECs) are involved in communication with each other to 
ensure regulation against excessively reactive immune cells [37]. IECs can sense 
microbes and influence colonisation through secretion of compounds, and affect the 
immune system through penetration of the intestinal layer to activate immune cells 
[37]. Additionally, the mucosal layer, bactericidal compounds, and phagocytic innate 
immune cells are able to protect against bacterial infiltration through the intestinal wall 
[16]. However after disruption of the intestinal barrier and infiltration of microbiota, pro-
inflammatory Tconv cells are activated by presentation of antigens by APCs in lymph 
nodes depending on cytokines present [16]. These activated T cells proliferate and 
migrate into the circulation as memory and Tconv cells which will encounter the 









A breakdown in intestinal homeostasis results in an inflammatory state, and over a 
long period, this can cause conditions such as Crohn’s disease, a form of IBD [16]. 
This can affect the entire GI tract, however inflammation is mostly focused in the 
terminal ileum and colon [16]. Ulcerative colitis (UC) is another form of IBD where 
inflammation is restricted to the colonic mucosal layer [37]. There is no one exact 
cause of disease development, however it is thought to be a combination of 
environmental, genetic and host immune factors [37]. GWAS studies show that genes 
affected in patients with IBD are related to interactions of the gut microbiota with the 
intestine [16]. Additionally, multiple groups (Gardlick, R. 2015, Leclerc, M. 2011, Pace, 
N. R. 2010,  Engstrand, L. 2010), have shown that gut microbiota is altered in IBD 
patients compared to healthy controls, which may be a reason for the disruption of 
the homeostatic environment [77-80]. This demonstrates the importance of the 
interaction of the gut microbiota with the intestine in maintenance of homeostasis. 
Hart et al (2005) saw a greater number of activated DCs expressing the marker CD40, 
and TLRs TLR2 and 4, in IBD patients compared to healthy controls [16, 81]. 
Additionally, it was shown that Crohn’s disease patients had DCs expressing a higher 
level of the pro-inflammatory cytokines IL-12 and IL-6, pushing naïve T cells towards 
a Th17 phenotype compared to healthy controls [16, 81]. This demonstrates the 
importance of understanding the mechanism behind DC tolerance as development of 
an unnecessary pro-inflammatory phenotype is damaging and could be a potential 












1.3 Prostaglandins in Immunity and Inflammation 
1.3.1 Prostaglandin biosynthesis   
 
 
Figure 1.3: Prostaglandin synthesis. The phospholipid membrane is reduced to arachidonic 
acid by phospholipase A2. This product is then further converted into prostaglandins by the 
enzymes cyclooxygenase (COX)-1 or COX-2, which are greatly upregulated due to infection 
or injury. Non-steroidal anti-inflammatory drugs (NSAIDs) inhibit COX activity via blocking the 
channel where AA binds. The relative prostaglandin synthases which are produced by various 
cells at site of infection or injury, determine the final subtype of prostaglandin that is formed. 
Prostaglandin E2 is formed due to the activity of PGE2 synthase (mPGES-1 or -2). This 
prostaglandin is the focus of this project, and exerts its immunomodulatory activity via four 
receptors, eicosanoid prostanoid (EP)-1 – 4. Figure adapted from [82]. 
Prostaglandins (PGs) are metabolised from phospholipids, by phospholipase A2 
(PLA2) into arachidonic acid (AA), a 20-carbon unsaturated fatty acid, then 
cyclooxygenase (COX)-1 or COX-2 metabolises AA into PGG2 as a response to 
harmful stimuli (Fig. 1.3) [83, 84]. COX-1 is constitutively active in homeostatic 
conditions and expressed at a low level by most cells. It is required for production of 
prostaglandins for ‘housekeeping’ roles such as maintenance of the intestinal 
epithelial layer [83, 84]. COX-2 is a highly regulated, inducible enzyme after pro-
inflammatory stimuli [85].  
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The structure of COX-1 and COX-2 are very similar, but the active site in COX-2 is 
larger than in COX-1, a beneficial feature for developing treatments for a specific COX 
enzyme [86].  
Non-steroidal anti-inflammatory drugs (NSAIDs) competitively inhibit both COX 
enzymes active sites [83, 84]. The downstream product of these enzymes, PGG2 is 
then further converted into an intermediate compound, PGH2, prior to the interaction 
with various PG synthases produced at this site of inflammation which determines the 
final subtype of prostaglandin formed [87, 88]. Prostaglandin synthases consist of 
oxidoreductase and isomerase which can finally produce the final PG subtype; 
prostaglandin D2 (PGD2), prostaglandin E2 (PGE2), Prostaglandin F2α (PGF2α), 
prostacyclin (PGI2) and thromboxane (TXA2) [83]. The respective synthase expressed 
by cells at the scene determine the PG outcome, however PGE2 is the most 
physiological abundant [88]. 
PGE2 was focused on for this thesis and is converted from PGH2 via membrane-
bound PGE synthases (mPGES-1 and mPGES-2) or cytosolic PGE synthase [84]. 
The majority of PGE2 produced  within the body is from APCs and stromal cells, 
however prostaglandin-endoperoxide synthase (PTGS2), also known as 
cyclooxygenase, has been shown to be increased in T cells after T cell activation [84]. 
Cytosolic PGE synthase and mPGES-2 are regularly synthesised to maintain a basal 
levels of PGE2 within the body, however mPGES-1 is upregulated by pro-
inflammatory stimuli such as IL-1β, TNFα or bacterial LPS TLR signalling [84]. 
Prostaglandin synthase enzymes are associated with the Golgi membrane, thus when 
PGE2 is produced, it is transported across the membrane via an ATP-dependent 
multidrug resistance protein - 4 or diffusion to act either in an autocrine or paracrine 
fashion [83]. PGE2 is the most abundant prostaglandin within the body and is 
expressed by most cells. PGE2 also plays important roles in physiological processes 
such as maintaining blood pressure as well as influencing the immune system [84]. 
This molecule exerts its activity via the four rhodopsin-like 7-transmembrane-






EP2 and EP4 both activate the cAMP-PKA pathway via PGE2 stimulation of Gs and 
adenylyl cyclase, and EP4 can induce PI3K/Akt signalling (Fig. 1.3) [83, 89]. However, 
EP2 is resistant to desensitisation, and has a lower affinity to PGE2 compared to EP4 
[85, 87]. The variance in their sensitivities is due to the difference in the length of their 
C-terminal sequence [84]. EP4 has a longer C-terminus which result in its rapid 
agonist desensitisation and internalisation. Phosphorylation of residues on the EP4 C 
terminal chain by PKA and G protein-coupled receptor kinases (GRK) recruits β-
arrestin-1 which activates c-Src [90]. This in turn activates the epidermal growth 
receptor (EGFR) and initiates downstream PI3K and AKT signalling [90]. The isoform 
EP1 down-regulates cAMP and initiates Ca2+ signalling through Gq activation of 
phosphatidylinositol metabolism (Fig. 1.3) [83, 89]. cAMP is a derivative of adenosine 
triphosphate (ATP), and converted by an isoform of the adenylyl cyclase (of which 
there are 10) [84]. These vary between cells, and thus have different downstream 
effects, which gives this molecule a strong mechanism to regulate targeted signalling 
[84]. Finally, stimulation of the PGE2 receptor EP3 can also inhibit cAMP production 
and increases intracellular levels of Ca2+ after coupling via Gi or G12 [83, 89]. EP3 
and EP4 are the most widely receptors through murine tissue and have the greatest 
affinity for PGE2 [83]. Whereas EP1 is only expressed within certain tissues such as 
the stomach and lungs, and EP2 is the least abundant [83]. EP receptors are well 
conserved between mice and humans, therefore in vivo mice models can translate 
into human studies [89]. 
These receptors are expressed at different levels in multiple cell types and 
environments, and their various sensitivities and ability to desensitise results in the 
ability to activate different signal pathways in response to similar signals [87, 91]. 
Additionally, there are three splice variants of EP3 observed in murine tissue, and 
eight for humans, adding to the diversity of the PGE2 signal [87].  
1.3.2 Prostaglandin E2 and the immune response 
PGE2 was initially identified as a biologically active molecules in the 1960’s, and has 
been shown to play a role in influencing the role of multiple biological functions, such 
as blood pressure, intestinal membrane barrier protection, and haematopoiesis, due 
to the diverse expression of receptors on various cell types [87]. PGE2 can also 
increase the risk of malignancies due to angiogenesis and suppression of apoptosis 





Under homeostatic conditions, PGE2 is involved in regulation of many biological 
processes such as; gastrointestinal barrier integrity, fertility, blood pressure, and the 
immune response [83]. Levels are regulated by the balance of prostaglandin synthase 
and 15-hydroxyprostaglandin dehydrogenase (15-PGDH) [87]. It is likewise involved 
in the processes leading to the classic signs of inflammation; rubor, tumour and pain 
[83, 84]. This information and due to the elevated levels observed at inflammation 
sites, has resulted in consideration of PGE2 as a pro-inflammatory mediator [93].  Over 
decades, groups have used COX-2, mPGES-3 and EP deficient mice to confirm the 
role of PGE2 in inflammation, however this has demonstrated that PGE2 has both a 
role in the pro- and anti-inflammatory immune response [84]. 
Previous groups have looked at disease models to determine the role of the COX 
enzymes and prostanoids within a whole system. The involvement of prostaglandins 
in inflammation was initially considered in the 1970’s as treatment using NSAIDs, non-
specific COX inhibitors, prevented acute inflammation development, but this did not 
provide any information about the involvement of either COX isoform [93]. Through 
later work using mice deficient for either COX-1 or COX-2, more information has been 
collected which suggests that the involvement of either COX-1 or COX-2 depends on 
the tissue affected, how long it has been since damage occurred and what the initial 
stimuli was [93].  
Myers, et al (2000) demonstrated the importance of COX-2 in an inflammatory setting 
through a collagen-induced arthritis (CIA) model [93, 94]. COX-2 deficient mice had 
reduced inflammation and joint destruction compared to WT mice, whereas COX-1 
deficient mice had a similar disease severity compared to WT mice [93, 94]. This may 
be due to COX-2 being the enzyme upregulated greatest after an inflammatory signal, 
hence inhibition of this enzyme expression would prevent an inflammatory 
prostaglandin response, whereas disruption of the housekeeping cyclooxygenase 
enzyme COX-1 would cause problems with various tissues that are maintained due 







However, using a model of dextran sodium sulphate (DSS) colitis, it was 
demonstrated that COX-2 deficient mice had more severe symptoms compared to 
both COX-1 deficient and WT mice [93, 95]. This could be caused by the disruption 
to the intestinal epithelial barrier as a consequence of inhibition of PGE2 production 
and migration of commensal microbiota enhancing inflammation [93, 95]. This is 
supported by evidence that IBD patients taking NSAIDs can experience exacerbated 
intestinal inflammation [93, 96-98]. This demonstrates that unspecific inhibition of 
COX or more specific inhibition of prostaglandins through the body would have 
variable results and could have severe side-effects, therefore it is important to 
understand the role of prostaglandins in more specific environments and their 
mechanisms of action to be able to regulate this. Especially as inhibiting prostaglandin 
formation pushes AA towards leukotriene formation which can both increase 
neutrophil infiltration and enhance inflammation via this molecule [93]. 
Trebino, C.E. et al (2003) used mice deficient for mPGES-1 and induced CIA [83, 99]. 
They observed that WT mice had worse disease symptoms compared to mPGES-1 
deficient mice, while IL-6 and immunoglobulin (Ig)G2a anti-collagen antibody levels 
were similar between the two groups, demonstrating the importance of PGE2 in 
inflammation development [83, 99]. Increased inflammation is due to increased 
permeability of microvesicles within the local environment and thus increased blood 
flow and pro-inflammatory mediators at the inflamed site [84]. It was later considered 
that PGE2 also had a role in anti-inflammatory responses due to its ability to induce 
IL-10 production and supress pro-inflammatory cytokines in some situations to 
prevent excessive inflammation [87, 93]. Samuelsson, B. et al (2007), reviewed 
papers from multiple groups that used m-PGES-1 knockout mice to demonstrate the 
importance of PGE2 in regular physiology, and conditions such cancer and arthritis, 
thus leading to their suggestion of this molecule as a therapeutic target [100].  
PGE2’s role is even more complex with immune cells. The increased number of 
effector T cells detected in the lymph nodes is largely due to PGE2’s ability to induce 
DC co-stimulatory molecules, to both enhance activation and migration of cells [101]. 
DCs increased maturation, antigen uptake, and lymph node migration further 
enhanced this process [84]. Addition of an EP4 antagonist, to prevent PGE2 signalling, 





Macrophages predominantly produce TXA2 over PGE2 at resting state, however 
activation results in significant increase in PGE2 production [93]. The difference in 
prostanoid expression  may be down to changes in prostaglandin synthase present, 
for example after induction of an inflammatory response, IL-1β increases expression 
of glutathione-dependent PGE-synthase pushing production of PGE2 over TXA2 [93]. 
PGE2 can activate macrophages via its modulation of cAMP through the key receptors 
EP2 and EP4, this also increases IFN-ɣ and TNFα production [84]. As well as pro-
inflammatory functions, PGE2 can likewise have an anti-inflammatory effect. When 
macrophages encounter PGE2, this molecule inhibits the effector phenotype and 
pushes more regulatory functions and cytokines, such as IL-10, after activation of EP2 
[87, 88]. Macrophage killing ability is affected by reduction of nicotinamide adenine 
dinucleotide phosphate (NAPDH) oxidase, and nitric oxide radicals [88]. 
PGE2 can suppress the effector phenotype of natural killer (NK) cells, a type of 
lymphocyte in the innate immune system, and production of cytokines such as IFNɣ 
which is important for protection against both bacterial and viral infections, and 
cancerous cells [87, 104]. Suppression of PGE2 also prevents activation of 
macrophages and granulocyte [87, 88]. Thus, in conditions where there is over-
production of PGE2 this results in a defective innate immune response [84, 87, 88]. 
This is largely due to PGE2 - EP2 signalling, as inhibition of the murine EP2 receptor 
resulted in enhanced bacterial clearance by neutrophils and increased survival of 
mice infected with Pseudomonas aeruginosa [88]. Certain bacteria, such as 
Streptococcus pneumoniae are able to stimulate PGE2 production from neutrophils, 
acting in a protective manner suppressing the body’s first line of defence [88]. 
PGE2 has an anti-inflammatory activity with the innate immune response, however it 









PGE2 can influence B cells depending on their maturity status. Proliferation of 
immature B cells is suppressed if PGE2 is present and can induce apoptosis, whereas 
mature B cells are unaffected by PGE2 presence [92]. However B cell effector function 
can by influenced by PGE2 induced Ig class switching [92]. In mice, IgG1 and IgE are 
two classes that can be induced by PGE2, and consequently it can influence asthma 
and allergy development as these IgG subclasses contribute to a Th2 response [92]. 
However, it was observed that PGE2 prevented histamine release and mast cell 
degranulation in sensitised hamsters, which was worsened with indomethacin-
treatment [91, 93, 102]. This is likely due to PGE2 pushing naïve T cells towards a 
Th1 or Th17 phenotype, rather than Th2 [91, 93, 102].  
PGE2 is known to negatively affect TGFβ signalling [102]. Our group also showed 
(unpublished data), that TGFβ-related genes were reduced in microarray expression 
data from naive murine T cells cultured with PGE2. Increased levels of PGE2 and 
hepatocyte growth factor (HGF) have been observed to be increased in patients with 
thoracic malignancies after mesenchymal stem cells (MSCs) transplants. Fibrosis is 
a problematic side-effect of radiotherapy for these patients, and can result in 
respiratory failure. MSC transplants resulting in increased PGE2 and HGF reduced 
fibrosis due to reduction of TGβ-induced collagen and increased cAMP levels 
inhibiting fibrosis [105].      
High levels of PGE2 are observed during chronic inflammation, and can influence the 
adaptive immune response and development of inflammation by influencing cytokine 
production by epithelial cells, Tconv cell classes and DC phenotype [93]. 
1.3.3 Prostaglandin E2 and T cells 
PGE2 has a multitude of roles when it comes to T cells. The role of PGE2 as a T cell 
inhibitory molecule through adenyl cyclase and cAMP production, has been 
investigated since the 1970’s, however this occurred at micromolar concentrations 
[84, 106, 107]. It was later determined that nanomolar concentrations of PGE2 were 
involved in induction and proliferation of Th1 and Th17 cells, and also T cell 





In the 1970’s, it was shown that increased cAMP levels due to PGE2 signalling 
inhibited T cell activation. Thus, it was thought that PGE2 had an immunosuppressive 
activity, however it was then realised that the concentration, target and length of signal 
determined the response of PGE2 signalling [84, 108]. The initial findings reporting 
PGE2 to be an immunosuppressor were found to be due to inhibition of IL-2 production 
[84].  
In the next decade, more work was carried out determining the role of PGE2 on T cell 
proliferation and activation which introduced the concept of PGE2 concentrations and 
the maturation status of target cells potentially affecting the stimulus [84]. 
Mechanisms for immunosuppression were further investigated and it was observed 
that inhibition of Ca2+, IL-2 and the respective receptor expression was due to PGE2’s 
activation of the cAMP pathway [84].  This increase in cAMP also reduced internal 
potassium signalling and thus disrupted signal transduction via the GPCRs and 
affecting T cell activation and cell proliferation [84].  
Betz. M, and Fox. B, S, (1991) then introduced the concept that PGE2 could influence 
and prevent the differentiation of naïve T cells into Th1 and Th2 cells respectively 
through suppressing expression of IFNɣ (Th1) and enhancing IL-2, IL-4 and IL-5 (Th2) 
production [109]. Later studies demonstrated that the cytokine IL-12 and its receptor 
were also supressed by PGE2, while levels of IL-4, IL-10 and Il-13 were increased 
[109]. Various mechanisms for prevention of T cell activation by PGE2 have been 
suggested such as disruption of the protein-kinase C pathways reducing various 
mitogen-activated protein (MAP) kinase production which normally regulate survival, 




Figure 1.4: The role of PGE2 in autoimmunity and inflammatory disease development. 
APC stimulation due to infection or injury can significantly upregulate COX expression, 
enhancing PGE2 production. This can act on Th1 and Th17 EP receptors to enhance 
differentiation and proliferation of pro-inflammatory Tconv cells. Excessive activation of which 
can lead to development of autoimmunity and inflammatory conditions such as IBD. However, 
there is still discussion as to the mechanism by which PGE2 affects Tregs, cells required to 
suppress pro-inflammatory stimuli.   
Initially the pro-inflammatory role of PGE2 was thought to be dependent on its 
mechanism of neutrophil recruitment through Tconv cell production of IL-8, however 
the direct role of PGE2 on Tconv cells was then examined. Yao, C. et al (2009) 
demonstrated that at nanomolar concentrations of PGE2, naïve T cells could be 
converted to either Th1 or Th17 cells mediated through the EP2 and EP4 receptors 
and signalling via phosphatidylinositol-3-kinase and PKA (Fig. 1.4) [102]. This was 
further examined using contact hypersensitivity and experimental autoimmune 
encephalomyelitis (EAE) disease models, where reduced numbers of Th1 and Th17 
cells were detected in lymph nodes after administration of an EP4 antagonist [84, 
102]. Boniface, K. et al (2009) likewise demonstrated the role of PGE2 in human Th17 
polarisation via the EP2 and EP4 receptors [103].  
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PGE2 was shown to upregulate IL-1βR and IL-23R expression via EP2 cAMP-PKA 
signalling, consequently pushing naïve T cells towards the Th17 phenotype, whereas 
signalling via EP4 stimulates the PI3K pathway resulting in Th1 cell development [84, 
103]. 
1.3.4 Prostaglandin E2 and dendritic cells 
PGE2 can also induce DC co-stimulatory molecules, promoting T cell proliferation, 
additionally it can modify DC cytokine production consequently influencing naïve T 
cell differentiation [84]. For example, DCs cultured in the presence of PGE2 pushed 
naïve T cells towards the Th1 phenotype [84]. Whereas LPS stimulated DCs had 
increased IL-23 production when cultured with PGE2, suggesting that bacterial 
stimulation and PGE2 presence within the environment pushes naïve T cells towards 
a Th17 phenotype [84]. PGE2 can similarly induce DC surface co-stimulatory 
molecules such as CD70, OX40L, promoting T cell proliferation, and modify DC 
cytokine production which consequently influences naïve T cell differentiation [84]. 
Co-stimulatory markers were also observed to be upregulated on the surface of T 
cells, demonstrating a mechanism for sustained cellular interactions and antigenic-
specific responses [84]. PGE2 has been shown to suppress differentiation of RA 
producing DCs, and negatively regulate RALDH production via an inducible cAMP 
early repressor (ICER)-mediated blockade, the enzyme responsible for RA synthesis 
[110]. This is potentially as a protective mechanism against infection or damage, 













1.3.5 Prostaglandin E2 and regulatory T cells 
PGE2 is known to enhance proliferation of cells, and has been implicated in 
malignancies and anti-tumour immunity [111]. Baratelli, F. et al (2005) demonstrated 
that PGE2 enhanced the inhibitory ability of Tregs in vitro and induced Foxp3 
expression in naïve T cells, however this was using tumour supernatants from patients 
that overexpressed COX-2 or PGE2 at 13 or 26 μM [111]. However it was also thought 
that PGE2 can negatively affect Tregs due to suppression of  immune cell IL-2 
production via cAMP signalling, and additionally disruption of the TGF-β signalling 
pathway, consequently affecting Treg function [87]. Additionally, the recent paper by 
Wang. X, et al, (2017) suggested that cAMP signalling via CREB, which can be 
activated by PGE2 signalling via EP2 and EP4, aided differentiation of effector Th17 
cells, and negatively affected Foxp3+ Treg survival [34]. PGE2 can likewise induce 
apoptosis in resting mature T cells due to upregulation of c-Myc, consequently 
modifying the T cell subtypes present within an environment [92]. Most work up till 
now has been looking at the effect of PGE2 on effector T cells, the work on Tregs is 
not as clear and has not been demonstrated in an in vivo setting. Due to the clear role 
that PGE2 has enhancing effector T cells differentiation and proliferation, it follows that 
they have a role on suppression of the cells that would suppress their activation ability 
(Tregs) due to the importance of regulating immunity through controlling ratios of pro-












1.3.6 Prostaglandin E2 and the intestine 
PGE2 has both pro- and anti-inflammatory roles in the intestine. It is ‘cytoprotective’ 
and can prevent intestinal damage and ulceration, through reducing gastric acid 
secretion and enhancing secretion of protective mucous [86]. It can signal via the key 
receptor EP4, to activate the innate lymphoid cell - 3 (ILC-3) - IL-22 pathway, which 
can protect against gut epithelial barrier injury via enhancing mucin and tight junction 
gene expression (Fig. 1.5) [112]. PGE2 also enhanced ILC-3 IL-23-driven IL-22 
production, which is an epithelial regenerative factor, and colony stimulating factor-2 
(CSF-2) to push DC RA production to induce protective Tregs [39, 112].  Thus, due 
to PGE2’s alternate protective roles within the intestine and more widely through the 
body, such as protection of the intestinal barrier and suppression of pro-inflammatory 
neutrophil responses, NSAID long-term use is not a suitable treatment [112]. NSAIDs 
can severely exacerbate symptoms, especially as increased leukotriene production 
due to arachidonic acid after inhibition of COX-1 and COX-2 can increase neutrophil 
infiltration [113]. 
Although PGE2 has been shown to have a protective role in the intestine, upregulation 
of the molecule has also been observed during intestinal inflammation, as well as in 
various cancers [113]. Induction of inflammation within the intestine, enhances 
production of COX-2 and consequently secretion of PGE2 by intestinal tissue [113]. 
PGE2 can increase vascular permeability and prevent electrolyte absorption, resulting 
in some of the most common IBD symptoms, enhanced bowel movements and 
diarrhoea [113]. After acting in either an autocrine or paracrine fashion, PGE2 is 
metabolised by 15-PGDH in the colon into 15-keto-PGE2, then in the liver and kidney 
it is further broken down into 13,14-dihydro-15-keta PGE2 by Δ13-reductase [113]. 
Following β-oxidation and ὼ-oxidation, PGE-MUM is formed and excreted in the urine, 








For inflammatory bowel conditions; such as UC, it is important to monitor the mucosal 
healing of patients, as long-term damage can result in greater negative side-effects 
such as bacterial infiltration and sepsis [113]. However currently the methods to do 
this are very invasive, colonoscopy or biopsies and add further discomfort to patients 
[113]. Arai, Y et al (2014) looked at measuring the PGE2 metabolite, prostaglandin E-
major urinary metabolite (PGE-MUM) excreted in urine from patients with UC, as a 
sign of mucosal healing and compared to C-reactive protein (CRP) levels [113, 114]. 
This was considered due to the link between PGE2 levels and colonic inflammation, 
additionally increased levels were found to correlate with poor disease activity score 
[113, 114]. This marker was used because another key inflammatory marker, CRP, 
may not be increased even in patients with active colitis, so was not a reliable marker 
for this condition [113, 114]. This demonstrates the importance of PGE2 in intestinal 
inflammation, and treatment involving suppression of PGE2 is currently being 
considered to allow tissue recovery, suppression of disease relapse, and prevention 












Figure 1.5: The role of PGE2 in the intestine. PGE2 has both a pro- and anti-inflammatory 
response within the intestinal environment. PGE2 can be produced by various cells within the 
intestine, and can induce Th17 proliferation and activity, excessive activation of which can 
result in intestinal damage and inflammation due to potential bacterial infiltration. Whereas 
PGE2 can also act on ILC3s and enhance IL-22 production resulting in protection and 
maintenance of the intestinal barrier and the mucosal surface thus protecting the intestine from 
foreign pathogens and excessive inflammation. However, the role that endogenous PGE2 
plays on intestinal Tregs is not known. Figure adapted from [112, 115].     
The multitude of roles that PGE2 has within the immune system indicates that simple 
inhibition of prostaglandin production is not a long-term viable solution to reduce 
inflammation without causing severely negative side-effects. Therefore, research into 
how to manipulate this environment in a more specific and localised fashion, whilst 
enhancing anti-inflammatory Treg to suppress inflammation would benefit the 
300,000 people in the UK who have IBD (numbers taken from the UK Inflammatory 







1.3.7 Treatments targeting prostaglandin E2   
PGE2 has an important role in the immune system as previously discussed, therefore 
controlling this to influence disease development is important, and treatment to 
reduce inflammation due to this molecule has been used since the late 1800s. 
Acetylsalicylic acid (aspirin), originating from salicylate in willow bark, was initially 
introduced in 1897 and patented by Bayer in 1899, and since then multiple similar 
products have also been developed [117]. The NSAIDs initially developed were 
‘broad-spectrum’, in that they inhibited both COX-1 and COX-2, however the issue 
with this is that COX-1 is vital for homeostatic processes, such as maintaining gut 
barrier integrity therefore inhibition of both enzymes can have some significant side-
effects due to damage of the intestine [117]. However epidemiological studies showed 
a reduced risk of neuroinflammatory disease such as Alzheimer’s disease or 
Parkinson’s disease after long-term NSAID treatment, but the significant side-effect 
included intestinal bleeding [118, 119].  The issue is with the pharmacology of the 
NSAIDs; indomethacin, ibuprofen and aspirin are more active against COX-1 than 
COX-2, which affects the housekeeping roles of prostaglandins and as such cause 
greater gastrointestinal damage, but has less of an impact on the prostaglandin 
production within the inflammatory sites with upregulated levels of COX-2 [86].    
Therefore, more ‘specific’ NSAIDs were developed to inhibit COX-2 [117]. Celecoxib 
is an example of a specific COX-2 inhibitor, which prevents the risk of intestinal ulcers 
and bleeding, however they had significant side-effects and resulted in increased pro-
thrombotic risk and greater incidences of heart attacks and strokes [117].  
Intestinal inflammation due to conditions such as colitis would benefit from 
inflammatory cell suppression, however it is difficult to do this efficiently without 
exacerbating the condition. Therefore, this strengthens the importance of 







1.3.8 Genetic evidence for the role of PGE2 in inflammatory diseases 
Robb, T. C. et al (2017) observed that increased PGE2 production by dermis cells 
enhanced IL-17 and IL-22 production by Th17 and other activated T cells [120]. These 
cytokines are vital components of allergic contact dermatitis (ACD) and atopic 
dermatitis (AD) pathogenesis [120]. Patients are found to have increased levels of IL-
22 in the serum and inflamed skin compared to healthy controls which stimulated 
epidermal hyperplasia [120]. Laouini, et al (2005) observed that inhibition of PGE2 
increased Th2 and eosinophil cell infiltration, resulting in worse disease severity in 
ovalbumin-sensitised mice [121]. Whereas other groups, including Robb, et al (2017) 
observed that PGE2 pushes Th2 conversion and B cell infiltration, and via the key EP 
receptors, EP2 and EP4 also increased Th17 and Th22 pro-inflammatory cytokine IL-
17 and IL-22 production [120]. 
The intestine is a highly variable environment with the immune system and gut 
microbiota in close contact, thus maintaining homeostasis is key to preventing 
unnecessary colonic inflammation. Several groups have observed a link between 
long-term aspirin use and a reduced risk of colorectal cancer [122-126]. In 2009, the 
UK government published a Drug Safety Update permitting the prescription of low 
dose aspirin for patients who already have vascular disease [124, 127]. Following this, 
in 2015, the United States Preventative Services Task Force included colorectal 
cancer prevention in the recommendation for low dose aspirin, in addition to its 
protective role against cardiovascular disease [128]. Aberrant expression of the COX 
enzymes, notably COX-2 which is greatly upregulated in an inflammatory 
environment, increases PGE2 expression within both pre-malignant and malignant 
colorectal tumours [84, 129]. Fink, S. P. et al (2014) discovered that aspirins 
protection against colorectal cancer was even more effective in patients with elevated 
levels of mucosal hydroxyprostaglandin dehydrogenase-15 (15-PGDH), compared to 
those with low levels of this enzyme, suggesting that inhibition of prostaglandin 
synthesis enzymes, and robust degradation of PGE2 are required to reduce the risk 






COX enzymes and their consequent prostaglandin products were first implicated in 
colorectal tumorigenesis back in 1983 when Gardner’s syndrome patients, who 
develop multiple colon polyps, had a reduced adenoma burden after NSAID treatment 
[123, 129]. Excessive intestinal inflammation can result in cancer development, as 
well as IBD conditions. IBD patients also have an increased risk of colon cancer, it 
accounts for approximately 15 % of all deaths for IBD patients, this further cements 
the need for understanding the effects of PGE2 on cells within the intestine [130, 131]. 
The gene PTGER4, encoding EP4, has been suggested to be a susceptibility locus 
influencing a variety of human inflammatory and autoimmune diseases including 
multiple sclerosis (MS) and IBD [102, 132-136]. Matesanz, et al (2012) did a meta-
analysis of MS GWAS data, and detected the PTGER4 single nucleotide 
polymorphisms (SNP) rs4613763 to be suggestive of MS risk, and Esaki, et al (2010) 
demonstrated that EP4 deficient mice were protected from EAE development [133, 
137].  Risk of allergy development can also be increased by SNPs at the PTGER4 
locus rs7720838 [138]. Mutations in PTGER4 have similarly been shown to be 
involved in autoimmune conditions such as Ankylosing Spondylitis (AS) due to a 
polymorphism at SNP rs10440635 [139, 140]. This condition depends on the Th1 or 
Th17 response, however this suggests PGE2 can also affect the Th2 response, and 
the SNPs identified within this study can help identify elements that influence the 
balance between Th phenotypes [138]. Fungus or bacteria can activate the caspase-
associated recruitment domain 9 (CARD9) signalling pathway after activation of 
dectin-1 and dectin-2, and consequently enhance expression of PGE2 [139, 140]. 
Signalling via EP4 triggers Th17 induction through production of the cytokines IL-23 
and IL-17 which enhances risk of development of both Crohn’s and AS development 
[139, 140]. Additionally, PGE2 can aid bone remodelling which is a feature of AS [139, 
140]. Increased expression of this gene was detected in synovial biopsies from AS 
patients compared to controls [140]. 
Further studies saw that mutations at the PTGER4 locus rs7720838 and rs4495224 
correlated with PTGER4 expression, and this was shown to be an important 
susceptible gene for risk of IBD [141, 142]. This risk was due to increased ability for 
the transcription factors NFκB and X-box binding protein (XBP1) to bind, thus 




These GWAS studies provide evidence that the PGE2-EP4 signalling pathway is 
involved in immune system development. Thus, this further cements the importance 
of understanding the mechanism of PGE2 actions in vivo, and a benefit of looking at 
EP receptors is that they are well conserved between mice and humans, so using 
mouse models can allow translational work into human studies [89]. 
 
1.4 Rationale, Hypothesis and Aims for this study  
Emerging evidence has shown that PGE2 critically regulates inflammatory Th1 / Th17 
cells, but how PGE2 effects Tregs is not fully understood. Given the essential roles for 
both Th1/ Th17/ Treg cells, and the PGE2 signalling pathway in regulation of chronic 
inflammatory responses, it is imperative to study the precise mechanisms for how 
PGE2 affects Tregs, especially tissue-resident Tregs in steady state and under 
inflammatory conditions.  
1.4.1 Hypothesis 
The hypothesis for this PhD is that ‘‘PGE2 signalling inhibits Foxp3 expression and 
consequently affects Treg induction and function, which facilitates intestinal 
inflammation.’’    
1.4.2 Aims 
The aims of the thesis were:  
• To identify the role of PGE2 on in vitro Treg induction. 
• To determine the mechanism for how PGE2 regulates intestinal resident Tregs.  










2 Materials and methods 
2.1 Mice 
Wild-type C57BL/6 mice were obtained from Charles River or Harlan UK and housed 
at the University of Edinburgh animal facility at the Little France campus. The EP4 
knockout mice were generated by crossing C57BL/6 lox-flanked Ptger4 (EP4-floxed) 
mice with Lck-Cre mice (on C57BL/6 background) to generate mice with T cell-specific 
EP4 deletion [143]. Foxp3-YFP, IFNRA-/- and MyD88/TRIF DKO genetically modified 
mice (bred to congenicity on a C57BL/6J Ola Hsd background) were bred and 
maintained under specific pathogen-free conditions in accredited animal facilities at 
the University of Edinburgh [144-147].  Age- and sex-matched mice, older than seven 
weeks old, were used for experiments. Mouse tissue extraction was performed in 
accordance to U.K. Home Office legislation. Mice were analysed individually and none 
were excluded from the analysis, with the exception of exclusions due to technical 
errors in preparation of intestinal lamina propria lymphocytes (LPLs). All experiments 
were conducted under project licences issued in in accordance with the UK Scientific 
Procedures Act of 1986 and had local ethical approval. 
 
2.2 General Reagents 
2.2.1 Media 
2.2.1.1 Wash media  
During preparation of bone marrow dendritic cells (BMDCs), femurs removed from 
C57BL/6 mice were transferred into cryovials containing RPMI-1640 medium (Sigma 
Aldrich) to soften attached tissue. Contents of the marrow were flushed with wash 
medium (RPMI-1640) prior to re-suspending in cell culture medium (described below) 
for plating. 
2.2.1.2 Culture media  
For all in vitro human and murine cell culture, cells and compounds were re-
suspended in medium consisting of RPMI-1640 medium supplemented with 50 µM β-
mercaptoethanol (β-ME) (Gibco Life Technologies), antibiotics (penicillin and 
streptomycin, 100 U/ml, Gibco Life Technologies), 2 mM L-glutamine (PAA 
Laboratories Ltd) and filtered 10 % heat-inactivated foetal calf serum (FCS, Gibco Life 
Technologies). All subsequent references to FCS refers to FCS heat inactivated at 56 




Table 1: List of compounds used during experimental procedures, assay concentrations and 





Prostaglandin E2 10 -1000 nM Cayman Chemicals 
17-phenyl trinor PGE2 1000 nM Cayman Chemicals 
Butaprost (EP2 selective agonist) 1000 nM Cayman Chemicals 
L-902,688 (EP4 selective agonist) 1000 nM Cayman Chemicals 
PF-04418948 (EP2 selective 
antagonist) 
10,000 nM Cayman Chemicals 
L-161,982 (EP4 selective antagonist) 10,000 nM Cayman Chemicals 
db-cAMP 25,00 - 100,000 nM Sigma / Calbiochem 
H-89 10,000 nM Sigma / Calbiochem 
LY-294002 10,000 nM Sigma / Calbiochem 
Recombinant human TGF-beta 
(rhTGFβ) 
0.1 - 10 ng/ml Biolegend 
Indomethacin 
1– 5 mg/kg body 
weight/day 
Sigma 
Collagenase Type IV 1.25 mg/ml 
Gibco Life 
Technologies 
DNase-I 30 ug/ml Roche 
Recombinant mouse granulocyte-
macrophage colony stimulating 
factor (GM-CSF) 
20 ng/ml Miltenyi Biotec 
Phorbol 12-myristate 13-acetate 
(PMA) 
0.1 ųg/ml Sigma 
Ionomycin 1 ųg/ml Invivogen 







2.3 Immune Cell Isolation  
2.3.1 Isolation of cells from the spleen 
Spleens were removed from the mouse and macerated between microscope slides 
to form a single cell suspension in ice cold phosphate-buffered saline (PBS) (in-
house)/ 2 % FCS. Cells were filtered through a nylon mesh then spun at 400 x G-
force (g) in the Rotina 420R centrifuge (Hettich Zentrifuge) for 10 minutes, 
supernatant removed then Ammonium-Chloride-Potassium (ACK) lysing buffer 
(ammonium chloride 150 mM, potassium hydrogen carbonate 10 mM, 
Ethylenediaminetetraacetic acid (EDTA) Fisher Scientific 0.1 mM) was added for four 
minutes at room temperature (RT) to lyse red blood cells. PBS/2 % FCS was added 
to stop the lysis reaction, and cells spun again before being re-suspended in PBS/2 
% FCS prior to staining. Total cells were counted using a haemocytometer.  
All tissue culture was performed in class II safety cabinets using relevant plastics 
produced by Costar (Corning-Costar, Schiphol-Rijk, Netherlands).  
2.3.2 Isolation of cells from the mesenteric lymph nodes (mLNs) 
After removal from the mouse, the mLNs were mashed through a 40 ųM sterile nylon 
mesh cell strainer (Fisher Scientific) to form a single cell suspension in ice cold PBS/2 
% FCS buffer. Cells were spun at 400 x g for 10 minutes, and then re-suspended in 
PBS/2 % FCS prior to further use. 
2.3.3 Isolation of cells from the colon 
Intestinal lamina propria cells were isolated as previously described by Bain et al 
(2012) [148]. Colons were extracted and their contents removed by first using forceps 
to gently apply pressure, then cutting the colons open and swirling them in a petri-
dish containing ice cold PBS to remove excess faecal matter. Tissues were cut into 
small pieces into 50 ml centrifuge tubes containing cold 2 % FCS, 1X Hanks' Balanced 
Salt Solution (minus calcium chloride, minus magnesium chloride) (HBSS) (Gibco Life 
Technologies), and shaken vigorously in parallel for 30 seconds before poured 






The tissue was transferred into tubes containing cold 2 mM EDTA, HBSS; a chelating 
solution to aid dissociation and disaggregation of the tissues, then incubated for 15 
minutes at 37 oC while shaking at 200 RPM in the Orbital Incubator (Stuart Scientific 
SI 50). The tissue was poured back through the sieve, then washed after being 
transferred into a tube containing pre-warmed HBSS and shaken as above. In 
subsequent stages, all medium was pre-warmed.  
Tissues were poured through the sieve then transferred back into 2 mM EDTA, HBSS, 
and incubated for 30 minutes as before in the Orbital Incubator. The chelating solution 
was poured through the sieve, then tissues washed with HBSS before being 
transferred to gentleMACS tubes (Miltenyi Biotec) containing digestion solution 
consisting of; collagenase-4 (Gibco, Life Technologies) and DNase-1 (Roche) in cell 
culture medium.  
The tissue was further cut into smaller pieces and incubated at 37 oC for 30 minutes 
while shaking at 200 RPM. To further dissociate colonic tissue, the gentleMACS tubes 
were attached to the gentleMACS dissociator and the murine intestine programme 
was run. Subsequently, tubes were placed on ice and the colon single cell suspension 
was poured through 40 µM strainers and rinsed with PBS/2 % FCS. Cells were spun 
down at 400 x g for 10 minutes, and ACK buffer was added at room temperature. After 
3 - 5 minutes, ice cold PBS/2 % FCS was added, cells spun down then re-suspended 
in PBS/2 % FCS prior to further use.  
2.3.4 Isolation of cells from the small intestine 
To maximise cell viability during tissue processing, the small intestine was stored in 
ice-cold culture medium. Any excess fat or visible Peyer’s patches were gently 
removed from the small intestine before it was cut open and swirled in a petri-dish 
containing ice-cold PBS to remove excess faecal matter, then transferred into culture 
medium. The small intestine was cut into small segments and added to 50 ml 
centrifuge tubes containing extraction medium (culture medium and 0.5 M EDTA). 
Tubes were incubated for 15 minutes at 37 oC while shaking at 200. After the 
incubation, contents were drained through the sieves then transferred back into tubes 
containing pre-warmed culture medium, which were then shaken vigorously in parallel 
for 30 seconds. Contents were poured through the sieves as before, then transferred 





The tissue was chopped into smaller pieces, then incubated in the shaker at 37oC for 
15 minutes. The gentleMACS tubes were attached to the gentleMACS dissociator and 
the murine intestine programme was run. Subsequently, tubes were placed on ice 
and colons mashed through 40 µM strainers using a 2 ml syringe plunger (BD 
Plastipak), rinsed with PBS/2 % FCS. Cells were spun down at 400 x g for 10 minutes, 
and ACK buffer was added at room temperature. After 3 - 5 minutes, ice cold PBS/2 
% FCS was added, cells spun down then re-suspended in PBS/2 % FCS. Protocol 
was adapted by Aleksandra Prochera [149]. 
2.3.5 Isolation of cells from the bone marrow 
To prepare BMDCs, femurs were removed from C57BL/6 mice and transferred into 
tubes containing wash medium to loosen muscle tissue. The muscle tissue was 
dissected from the bone which was then briefly placed into 70 % ethanol to sterilise 
the exterior. The ends of the femur were trimmed using sterile, sharp scissors to 
expose the interior marrow shaft, and contents of the marrow were flushed with wash 
medium using a 1 ml insulin syringe with a 29 G × ½ needle. The cell suspension was 
transferred through a 40 µm cell strainer into a 50 ml falcon tube, then centrifuged at 
300 x g for five minutes and supernatant discarded. The cell pellet was re-suspended 
in ACK lysis buffer for 15 seconds then 10 % complete medium was added and 
centrifuged at 300 x g for five minutes. The cells were washed twice then counted 
using a haemocytometer prior to re-suspending the bone marrow cells at 1 x 107 
cells/ml in culture medium with 20 ng/ml recombinant mouse granulocyte-
macrophage colony stimulating factor (GM-CSF).  
Bone marrow cells were gently added to a petri-dish containing culture medium and 
20 ng/ml GM-CSF, for a final cell concentration of 4 x 105 cells/ml. The petri-dish was 
gently swirled to ensure that solutions were mixed, then cells were incubated at 37 
°C, 5 % CO2 and 95 % humidity in a CO2 incubator for three days. 
On day three, medium was replenished by gently adding warm 10 % complete 
medium with 20 ng/ml GM-CSF to each petri-dish. To minimise disturbance of cells, 
medium was pipetted down the edge of the petri-dish. The petri-dish was gently 
swirled to ensure solutions were mixed then incubated for a further three days. This 
medium replenishment was repeated on day six, and on day nine, bone marrow 
derived cells (BMDCs) were harvested by collecting the non-adherent cells after 
gently swirling the plate [150]. 
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The cell suspension was centrifuged at 300 x g for five minutes then re-suspended in 
PBS/2 % FCS prior to further use. 
2.3.6 Preparation of caecum content 
After mice treated with vehicle, indomethacin, or indomethacin plus an EP4 agonist 
were culled, caecum content was immediately extracted, transferred into an 
eppendorf tube on dry ice and stored at -80 oC until required. Caecum matter was 
diluted in sterile PBS (100 mg/ml), vortexed vigorously, then spun at 10.0 x 1000 for 
2 minutes (Biofuge Benchtop Centrifuge). The solution was strained through a 0.22 




















2.4 Cell Purification 
Table 2: A list of antibodies used for flow cytometry and cell sorting staining. All items 
were purchased from eBioscience, Biolegend and Cell Signalling. 











eFluor670 670 (FITC) N/A 




IFNγ FITC RA3-6B2 








Ly6G APC 1A8-Ly6g 
CD103 FITC 2E7 
MHCII AF700 M5/114-15.2 
RORɣt PerCp-eF710 B2D 
Ki67 Bv605 16A8 










2.4.1  Purification of CD4+ splenocytes 
Spleens removed from Foxp3-YFP mice were processed as described in section 
2.3.1. CD4 microbeads (1:9) (Miltenyi Biotec) were added to the single cell 
suspension and incubated at 4 oC for 30 minutes. CD4+ cells were positively selected 
using the AutoMACS pro (Miltenyi Biotec) then re-suspended in PBS/2 % FCS before 
a sample was taken to be counted using the haemocytometer. The CD4+ isolated cell 
population was adjusted to 1 x 106 cells/ml in cell culture medium for initial in vitro 
experiments.  
In later experiments (as stated in the results section), CD4+ T cells were stained for 
30 minutes at 4 oC with antibodies for CD25 (fluorophores listed in table 2). After 
washes, cells were re-suspended in PBS/2 % FCS for sorting by the FACS Fusion 
(QMRI or SCRM) into live nTregs (CD4+, CD25+, Foxp3-YFP+) and live naïve T cells 
(CD4+, CD25-, Foxp3-YFP-). Cells were collected in tubes containing PBS/10 % FCS. 
2.4.2 Purification of dendritic and mononuclear phagocyte cells 
The mLN, BMDCs and colon single cell suspensions were stained for 30 minutes at 
4oC with antibodies for CD45, CD3/B220. CD11c, MHCII, CD11b and CD103 
(fluorophores listed in table 2). After two washes, cells were re-suspended in PBS/2 
% FCS for sorting by the FACS Fusion (QMRI or SCRM) into CD45+, CD3/B220-, 
CD11c+, MHCII+, CD11b+, and CD103+ or CD103- DCs and mononuclear phagocytes 
(MNPs). Cells were collected in tubes containing PBS/10 % FCS. 
 
2.5 In vitro Cell Culture 
2.5.1 iTreg and nTreg cell culture 
Anti-mouse CD3 (αCD3) and anti-mouse CD28 (αCD28) (both purchased from 
eBioscience) were diluted in PBS to 10 and 5 ng/ml respectively, and added to wells 
of a 96 well cell culture flat bottom plate (3595 Costar Corning). The plate was 
incubated at 37 oC for two hours, then washed three times with ice cold PBS before 
cells were plated. The sorted naïve T cell (CD4+CD25-Foxp3-YFP-) or nTreg 
(CD4+CD25+Foxp3-YFP+) cell population was adjusted to 1 x 105 cells/ml in cell 
culture medium. TGF-β was added to the required wells on day 0, then cells incubated 
at 37 °C, 5 % CO2 and 95 % humidity in a CO2 incubator. PGE2 and other compounds 
were added as specified in Table 1 on day 1. Cells were usually harvested on day 3 
(unless stated otherwise), to stain for Treg markers for flow cytometry analysis.  
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In vitro cell cultures were performed in triplicates and repeated three or more times 
as stated in the relevant results sections. 
2.5.2 Dendritic cell and naïve T cell co-culture 
Sorted mLN derived CD103+ and CD103- DCs were adjusted to 1 x 104 cells/well, and 
sorted splenic naïve T cells were adjusted to 0.5 x 104 cells/well on day 0, and plated 
in a 96 well cell culture round bottom plate (3595 Costar Corning). Soluble αCD3, 
TGF-β and IL-2 (details in table 1) were then added. Cells were incubated for 24 
hours at 37 °C, 5 % CO2 and 95 % humidity in a CO2 incubator before medium or 
caecal content addition. Cells were incubated for a further 48 hours at 37 oC before 
harvesting to stain for Treg markers for flow cytometry analysis. 
2.5.3 BMDC differentiation  
BMDCs sorted for CD45+, CD3/ B220-, CD11c+, MHCII+ and CD103- cells were re-
suspended at 1 x 106 cells/ml in culture medium, then sterile filtered caecal content, 
previously prepared as stated in section 2.3.5, was diluted 40X in culture medium 
prior to addition to the cells. BMDCs were stimulated with the caecum contents for 
either 2.5 or 6 hours at 37 oC with 5 % CO2, then washed twice with PBS/2 % FCS 
and re-suspended in buffer RLT and β-ME, and stored at -80 oC for future PCR work. 
The timings for this experiment were chosen due to previous experiments 
demonstrated in a paper by Nakahashi-Oda. C, et al [6]. 
 
2.6 Cell Staining and Flow Cytometry 
2.6.1 Processed tissue stain  
Tissues were processed to a single cell suspension as described in sections 2.3.1 - 
2.3.4, then plated in a 96 well cell culture round bottom plate (3595 Costar Corning). 
Total cells were counted using a NucleoCassette (Chemometec) counter. Plates were 
spun at 400 x g for 5 minutes, then cells stained with the live/dead marker Fixable 
Viability Dye eFluorTM 780. Cells were incubated for 30 minutes at 4 oC, then washed 
twice with PBS/2 % FCS. Cells were subsequently stained for either Treg or DC 
surface markers (antibody details in Table 2, markers described in results section) 
and incubated for 30 minutes at 4oC prior to washes with PBS/2 % FCS. Cells were 
spun down, re-suspended in fixation/permeabilization buffer (eBioscience) and 
incubated at 4 oC for two hours. Cells were washed with permeabilization buffer 
(eBioscience) prior to Treg or DC internal marker staining. 
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 Antibodies were diluted in permeabilization buffer (antibody details in Table 2, 
markers described in results section), and incubated for an hour at 4 oC. Cells were 
washed twice then re-suspended in permeabilization buffer, and transferred into 
FACS tubes before samples were run on the BD LSR 5 laser Fortessa (BD 
bioscience).  
To boost cytokine expression prior to staining for inflammatory cytokines such as IL-
17 or IFNɣ, phorbol 12-myristate 13-acetate (PMA), ionomycin and a Golgi Plug 
inhibitor were added to the single cell suspension re-suspended in culture medium, 
then incubated at 37 oC, 5 % CO2 for four hours. Cells were re-suspended and washed 
in PBS/2 % FCS before being stained with the live/dead marker diluted in PBS-only. 
Cells were incubated for 30 minutes at 4oC, then washed twice with PBS/2 % FCS. 
Cells were fixed with fixation/permeabilization buffer overnight, then washed with 
permeabilization buffer before staining for cytokines and other cellular markers 
(antibody details in Table 2, markers stated in results section) for one hour. Cells were 
washed twice then re-suspended in permeabilization buffer, transferred into FACS 
tubes and run on the BD LSR 5 laser Fortessa (BD bioscience). 
2.6.2 Cell culture stain  
On day 4 of the in vitro cell cultures, medium was aspirated from the wells and 
prestoblue cell viability reagent (Invitrogen) was added (diluted 1:10 in pre-warmed 
cell culture medium). Cells were incubated at 37 oC for 30 minutes before absorbance 
(570 nm) and fluorescence (528/20 nm, 590/20 nm) were detected by the computer 
programme Gen5 1.11 on the Synergy HT plate reader (Biotech). Cells were re-
suspended in PBS, transferred to a 96 round-bottom well plate and washed three 
times at 530 x g for five minutes. The live/dead marker was added to wells, and cells 
were incubated at 4 oC for 30 minutes before being washed with PBS. Surface staining 
antibodies were diluted in PBS and added to the cells preceding incubation at 4 oC 
for 30 minutes. After cells were washed and supernatant was removed, 
fixation/permeabilization buffer was added and cells incubated at 4 oC for two hours. 
Cells were subsequently washed with permeabilization buffer, then stained for internal 
markers for one hour. Cells were washed twice then re-suspended in permeabilization 






2.7 Detection of Gene Expression 
2.7.1 RNA purification and cDNA reverse transcription 
Colon tissues from mice treated with either vehicle (0.5 % ethanol) or indomethacin 
(5 mg/kg/day) were processed as discussed in section 2.3.3. Colonic MNPs were 
sorted for CD45+ CD3/B220- CD11c+ MHCII+ and CD103- or CD103+, then collected in 
tubes containing PBS/10 % FCS. Cells were washed with PBS/2 % FCS then re-
suspended in buffer RLT (QIAGEN) and beta-mercaptoethanol (β-ME) (Sigma-
Aldrich), and stored at -80oC for future work.   
nTreg and iTreg cells that had been cultured with either vehicle (0.04 % dimethyl 
sulfoxide (DMSO)) or PGE2 (100 nM) were also treated like this to detect Foxp3 gene 
expression. 
BMDCs that had been incubated with medium, or sterilely filtered vehicle, 
indomethacin or indomethacin plus an EP4 agonist caecum content, for either 2.5 or 
6 hours were washed then lysed in buffer RLT and β-ME. These samples were used 
to determine whether gene expression was altered between different culture 
conditions. 
A small section of colon tissue was excised after culling of treated mice prior to tissue 
processing and stored at -80 oC for subsequent PCR use to detect total gene 
expression. 
Ribonucleic acid (RNA) purification from lysed cell samples or tissue samples was 
performed using the Rneasy Mini Kit (Qiagen). 
2.7.1.1 Cell samples 
Lysed cell samples stored at -80 oC were thawed before addition of 70 % ethanol at a 
1:1 ratio. Samples were rapidly vortexed then transferred into the Rneasy mini-spin 
columns. Tubes were spun at 10,000 RPM for 30 seconds then supernatant removed. 
Buffer RW1 was added before spinning again prior to buffer RPE addition. After 
spinning at 10,000 revolutions per minute (RPM) for 3 seconds, supernatant was 
discarded. Buffer RPE was added and then tubes spun for 2 minutes at 10,000 RPM. 
After discarding the flow-through, tubes were centrifuged at 10,000 RPM for 1 minute 
to dry the membrane. The Rneasy mini-spin column was transferred into a new 
collection tube, before RNase-free water was added directly to the spin column 
membrane. Tubes were spun at 10,000 RPM for 1 minute to elute RNA.  
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2.7.1.2 Tissue samples 
A small section of frozen colon tissue was transferred into a labelled falcon tube and 
buffer RLT and β-ME was added in addition to two metal beads. The tubes were 
placed in a shaker rack and shaken for two minutes at 30 hertz. Tubes were then 
spun at 10,000 x g for 3 minutes and the processed tissue solution was transferred 
into a clean tube. The ensuing polymerase chain reaction (PCR) protocol was similar 
to the above steps for cell preparation (section 2.7.1.1), starting with the addition of 
70 % ethanol at a 1:1 ratio, until the addition of RNase-free water directly to the spin 
column membrane. Tubes were spun at 8,000 for 1 minute to elute RNA, then the 
NanoDrop was used to calculate the volume of sample required for the RNA 
concentration to be 1 ųg in 14 ųl, diluted in RNase-free water.  
2.7.1.3 cDNA reverse transcription 
Both the cell and tissue sample RNA was processed following the subsequent steps. 
Complementary deoxyribonucleic acid (cDNA) was synthesised by reverse 
transcription using the High-capacity cDNA Reverse Transcription Kits (ABI). The 
PCR reaction mixture consisted of: 10 X RT buffer, 25 X dNTP mix, 10 X RT random 
primers, MultiscribeTM Reverse Transcriptase and nuclease-free H2O. The PCR 
reaction mixture was added in a 1:1 ratio to the eluted RNA, then samples were run 
on the PCR machine (G-Storm) using the cDNA RT programme. Cycling conditions: 
lid heated to 100 oC; 25 oC for 30 minutes; 37 oC for two hours; 85 oC for five minutes; 
then samples held at 4 oC.  
The cDNA from cell samples was diluted 1:6 with deionised water, whereas cDNA 









2.7.2 Real-time PCR 
The cDNA reaction mix (GoTaq qPCR Master Mix, Promega) consisted of dH2O, 
SYBR premix (2x), Dye II (50 x), and primers for gene of interest (10 µM), made up in 
that order. The following primers were used (Table 3). 
Table 3: List of primers and their forward and reverse sequence. 
 Forward Reverse 





IFNα 5’-GGACTTTGGATTCCCGCAGGAGAAG -3’ 5’-GCTGCATCAGACAGCCTTGCAGGTC-3’ 
IFNβ 5’-AACCTCACCTACAGGGCGGACTTCA-3’ 5’-TCCCACGTCAATCTTTCCTCTTGCTTT-3’ 
IFNγ 5′-TGAACGCTACACACTGCATCTTGG-3′ 5′-CGACTCCTTTTCCGCTTCCTGAG-3′ 
ISG15 5’-TGACTGTGAGAGCAAGCAGC-3’ 5’-CCCCAGCATCTTCACCTTTA-3’ 
IRF7 5’-CCCCATCTTCGACTTCAGAG-3’ 5’-AAGGAAGCACTCGATGTCGT-3’ 
GAPDH 5’-ACAGTCCATGCCATCACTGCC-3’ 5’-GCCTGCTTCACCACCTTCTTG-3’ 
18S 5’- AAGTCCCTGCCCTTTGTACACA-3’ 5’-GATCCGAGGGCCTCACTAAAC-3’ 
 
Tubes were vortexed and kept on ice while preparing the Applied Biosystems 7900HT 
microAMP FAST 96-well reaction plate. The cDNA reaction mix was added in a 1:4 
ratio to the cDNA, and plate covered with a microAMP RT-PCR cover. The plate was 
spun for 30 seconds at 530 x g then run on the PCR machine (Applied Biosystems) 
using the SDS 2 programme. Cycling conditions: 95 oC for two minutes (stage 1); 95 
oC for one second and 60 oC for 20 seconds, 40 cycles (stage 2); 95 oC for 15 seconds, 
60 oC for 15 seconds and 95 oC for 15 seconds (dissociation step). Expression was 
normalised to mouse glyceraldehyde-3-phosphate dehydrogenase (GAPDH) or 18S 





2.8 In Vivo Management of PGE2 Signals and Depletion of Gut 
Microbiota  
2.8.1 Inhibition of endogenous prostaglandin expression 
To determine the effects of endogenous PGE2 in vivo, wild type (WT) C57Bl/6 or 
various transgenically-modified mice were treated with either vehicle (0.5 % ethanol), 
the non-steroidal anti-inflammatory drug (NSAID) indomethacin (5 mg/kg/day) to 
block endogenous PGE2 production, or indomethacin plus an EP4 agonist (10 ųg/day, 
i.p) to specifically activate a key PGE2 receptor for five to seven days. On day seven 
mice were culled and tissues removed for processing. Both vehicle and indomethacin 
were administered in the drinking water, whereas the EP4 agonist was injected 
intraperitoneally (i.p) daily. 
To see whether a lower dose of the NSAID indomethacin still influenced immune cell 
differentiation, a long-term treatment was performed. WT C57Bl/6 mice were treated 
with either vehicle (0.25 % ethanol) or indomethacin (2 or 1 mg/kg/day) for two or four 
weeks respectively before being culled and tissues removed for processing.   
The genetically modified MyD88/TRIF double knock-out (DKO) and interferon 
receptor deficient (IFNAR-/-) mice were treated with the same concentration of vehicle 
and indomethacin as the seven day treated WT mice, albeit only for five days before 
being culled due to concerns over bacterial translocation across the intestinal barrier 
potentially resulting in infection. 
Organs were collected, and processed as mentioned in sections 2.3.1 – 2.3.5.  
Caecum matter was extracted from the mice treated with the vehicle, indomethacin, 
or indomethacin plus an EP4 agonist and stored as stated in section 2.3.6. 
2.8.2 Depletion of gut microbiota 
Wild-type C57Bl/6 mice were treated with vehicle (0.5 % ethanol), or broad-spectrum 
antibiotics to deplete the gut microbiota (Table 4) in their drinking water a week prior 
to addition of vehicle (0.5 % ethanol) or indomethacin (5 mg/kg/day) in the drinking 
water for a further week. On day 14, mice were culled and organs extracted for 
processing as mentioned in sections 2.3.1 – 2.3.5. The antibiotic cocktail has been 















2.9 Disease Models 
2.9.1 Dextran sodium sulfate (DSS) colitis 
To determine the importance of PGE2 signalling in disease progression, LCKCre and 
EP4fl/fl (control) or LCKCreEP4fl/fl (T cell specific EP4 knockout) mice were given 2 % 
Dextran Sulfate Sodium Salt – colitis grade (DSS: MP Biomedicals) in drinking water 
on day 0, and disease severity was scored daily. After eight days, mice were culled 
and colons extracted and treated as stated in section 2.3.3.  
Another method to prevent PGE2 signalling is to use the NSAID indomethacin to inhibit 
prostaglandin production. Therefore, WT C57BL/6 mice were treated with either water 
only, 2 % DSS or 2 % DSS plus indomethacin for eight days and scored daily. On day 
8, mice were culled and processed for flow cytometry.  Duffin. R, et al (2016) have 
previously described severity scoring [112]. 
In brief, the scoring chart works out the cumulative score between stool appearance: 
0, normal; 1, soft; 2, soft and presence of dry blood; 3, loose with fresh blood; 4, sticks 
to fur. Detection of blood was scored on the following scale: 0, normal; 1, dark blood; 
2, fresh blood in stool; 3, blood around anus; 4, fresh blood. Weight loss was scored 
on percentage loss from initial weight: 0, 0 – 4 %; 1, 5 – 9; 2. 10 – 14; 3, 15-19; 4, 20 
– 24; 5, 25. General appearance was scored by these various parameters: 0, normal; 
1, piloerect; 2, piloerect and lethargic; 3, Ataxic, motionless and sunken eyes. A 
validated clinical disease activity index ranging from 0 to 17 was calculated using the 
following parameters: Stool consistency, presence of faecal blood, general 
appearance, and changes in body weight. If mice achieved a score of 11 or above, or 
their weight loss exceeded 25 % of their initial weight, then mice were culled.   
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2.9.2 T cell colitis 
T cell colitis was induced in RAG-/- mice. RAG-/- mice do not have any mature B or T 
lymphocytes, therefore any damage that is induced in these mice after T cell transfer 
is solely due to the donor cells initiation. Spleens were extracted from either WT or 
EP4 knockout mice and processed as stated in section 2.3.1. Naïve T cells 
(CD4+CD25-) were sorted on the FACS Aria Fusion (BD Biosciences) and washed 
five times with PBS-only to ensure that all serum was removed. These cells were used 
to determine whether preventing PGE2 signalling in naïve T cells had a protective 
effect when injected into RAG mice during induction of T cell colitis. Cells were re-
suspended at 2.5 x 106 cells/ml and 0.5 x 106 cells/ml were injected by i.p per mouse. 
Mice were scored weekly until clinical symptoms were observed then they were 
scored three times weekly. Mice were culled after six weeks, and colons prepared for 
histology, PCR and processed as stated in section 2.3.3 and stained for both Treg 
markers and cytokines to be detected using flow cytometry. 
Mice were clinically assessed using the following criteria: Weight loss was scored on 
percentage loss from initial weight: 0, 0 – 4 %; 1, 5 – 9; 2. 10 – 14; 3, 15-19; 4, 20 – 
24; 5, > 25. General appearance was scored by these various parameters: 0, normal; 
1, piloerect or lethargic; 2, piloerect and lethargic; 3, piloerect, lethargic and sickly 
appearance; 4, ataxic, motionless and sunken eyes. The ocular score was determined 
by the following symptoms: 0, normal; 1, puffy eyes; 2, puffy eyes, scratching, and 
skin inflammation. The scores are combined to provide a total colitis score for each 
mouse (ranging between 0 – 11). Mice were culled if their weight loss is greater than 
25 %, total score reaches nine or above for two consecutive days, general 
appearance is scored 4, or the ocular score 2 is noted for two consecutive scoring 










2.9.3 Faecal transplant and DSS colitis 
Figure 2.1: Experimental timeline for faecal transplant disease model. Eight groups of 
donor mice were treated with either indomethacin (5 mg/kg/day) or vehicle (0.5 % ethanol) for 
five days starting in a sequential manner. Mice were culled and caecum content removed 
under sterile conditions. Caecum content was diluted 1:10 with sterile PBS, then gavaged daily 
into recipient mice. Recipient mice were gavaged with fresh caecum content from day -2 until 
day 6, and treated with 2 % DSS colitis in drinking water from day 0 until day 6. 
To determine the effect of gut microbiota on immune cells and consequent disease 
development, C57BL/6 mice were treated with either indomethacin (5 mg/kg/day) or 
vehicle (0.5 % ethanol) for five days (donor mice) (Fig. 2.1). On day 5, donor mice 
from either the vehicle or indomethacin treated group were culled, and colon and 
caecum content removed. This content was weighed and diluted 1:10 in cold PBS, 
vortexed then gravity settled for two minutes prior to administration by gavage to 
another group of C57BL/6 mice (recipient mice) for eight days. On day 0 of the 
experimental protocol, DSS colitis was induced in the two groups of recipient mice 
(gavaged with caecum content from either indomethacin or vehicle treated mice) by 
2 % DSS in water, and disease severity was scored daily (scoring system same as 
stated above in section 2.9.1). Recipient mice were also weighed on day -2 in case 
faecal matter transfer influenced weight. On day 6, mice were culled, colons were 
processed as stated in section 2.3.3 and stained for both Treg markers and cytokines 
to be detected using flow cytometry. 
2.10 Statistical Analysis 
All data were expressed as mean ± SEM. Statistical significance between two groups 
was examined by the Mann-Whitney test, while the Kruskal-Wallis test with Dunn’s 
Multiple Comparison test for post-hoc comparison. was used to evaluate multiple 
groups. Statistical work was performed using Prism 6 software (GraphPad) and a p 
value of less than 0.05 was considered significant. 
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3  The Role of PGE2 on CD4+ T cells In Vitro 
3.1 Introduction 
Prostaglandins (PGs) are lipid mediators derived from arachidonic acid (AA), a 
product released from the phospholipid membrane by phospholipase A2 in response 
to harmful stimuli like infection and injury [87, 88]. The prostaglandin synthase 
produced by cells migrating to the site of damage result in the specific PG production.  
PGE2 exerts its actions by binding to its receptors termed eicosanoid prostanoid (EP)-
1, EP2, EP3 and EP4. While EP2 and EP4 activates cAMP-PKA and PI3K/Akt 
pathways, EP3 down-regulates cAMP signalling and EP1 initiates Ca2+ signalling. 
These receptors are expressed at different levels in various cells types and 
environments, and their differing sensitivities and abilities for desensitisation results 
in the ability to activate assorted signal pathways in response to similar signals [88]. 
EP2 and EP4 are similar in that they signal via the cAMP-PKA and PI3K-AKT 
pathways, and are both principally responsible for the anti-inflammatory and 
regulatory properties of PGE2 [88, 152].  
For decades it was believed that PGE2 suppresses the T cell responses due to 
downregulation of TCR signalling, as well as reducing IL-2 and IFNγ responsiveness 
and production, pushing naïve T cells away from a Th1 phenotype [109]. Sharma. S 
et al (2005), in agreement with other groups, saw increased levels of COX-2 and PGE2 
in non-small cell lung cancer (NSCLC) and saw in mice that this correlated with 
increased Tregs [153-155]. Similarly, Treg numbers were reduced by genetically 
inhibiting COX-2 [87]. Baratelli. F, et al (2005) observed an increase in Foxp3 
expression in human Tregs and naïve after a 24 hour culture with PGE2 [111]. 
Supporting Sharma’s work, they also saw an increase in Tregs after culturing naïve T 









However other groups have seen alternative results from PGE2. Ricciotti. E, et al 
(2011) saw that the rheumatoid synovium in murine collagen induced arthritis (CIA) 
produced high levels of PGE2 which correlated was implicated in the production of 
inflammatory cytokines IL-1 and IL-6 [83]. Mice deficient in EP4, preventing PGE2 
signalling, had reduced levels of these pro-inflammatory cytokines and fewer CIA 
symptoms [83]. This pro-inflammatory role of PGE2 was also supported by Sakata. D, 
et al (2010) who demonstrated that EAE severity was greatly reduced in both wild-
type and EP4 knock-out mice after use of an EP4 antagonist [156]. There was also 
reduced accumulation of Th1 and Th17 cells in lymph nodes, demonstrating the 
importance of PGE2 signalling in inflammatory responses [156]. Additionally, previous 
work has shown how PGE2, via the receptors EP2 and EP4, increases the 
differentiation of Th1 cells and enhances IL-23 production by APCs to enable Th17 
expansion [91, 102]. Therefore, PGE2 has been shown to effect both effector T cells 
during inflammation, and although some groups have shown it to boost Treg numbers, 
these conflicting results demonstrate that the function and role of PGE2 is still not fully 
understood. 
Further evidence for PGE2’s role in inflammation is that current treatment for 
autoimmune and chronic inflammatory conditions include non-steroidal anti-
inflammatory drugs (NSAIDs) which inhibit COX-1 and COX-2 activity, and 
subsequent prostanoid synthesis [157].  Considering that Tregs suppress T cell-
mediated inflammation, this raised the question whether PGE2 also influenced 
Treg cells. Additionally, the different responses that PGE2 can exert on cell types is 
due to the diversity and expression of the various EP receptors, likewise the varied 
sensitivities and ability for desensitisation of the receptors [87, 88]. It was then 
questioned how PGE2 affected Treg development in an in vitro cell culture.  
This subsequent chapter follows on from Dr Chengcan Yao’s preliminary work, which 
saw a reduction in Treg genes following a microarray of both human and murine cells 






3.2 Methodology  
To determine the role of PGE2 on T cell Foxp3 expression, spleens were removed 
from C57BL/6 mice then macerated between microscope slides to form a single cell 
suspension in ice cold PBS. Cells were filtered and red blood cells (RBCs) lysed by 
ACK lysing buffer, then incubated for 30 minutes with CD4 microbeads prior to 
positive selection using the AutoMACS pro.  In initial experiments, whole CD4+ T cell 
populations were used for in vitro culture (stated in specific results section). In later 
experiments, isolated CD4+ T cells from Foxp3-YFP mice were stained with antibodies 
for CD25 (APC), and sorted on the FACS Fusion into live nTregs (CD4+, CD25+, 
Foxp3-YFP+) and live naïve T cells (CD4+, CD25-, Foxp3-YFP-). 
Wells of a 96 well cell culture flat bottom plate were coated with αCD3 and αCD28, 
and incubated at 37 oC for two hours prior to washing with PBS and cell addition at 1 
x 105 cells/ml diluted in cell culture medium. Details of compounds added are 
described in more detail in the sections below but in brief, TGF-β was added to cells 
on day 0, then following 24 hours incubating in at 37 °C, 5 % CO2 and 95 % humidity 
in a CO2 incubator, PGE2 or the relevant compounds were added. On day 3 cells were 
harvested and stained for Treg markers using flow cytometry or PCR.    
 
3.2.1 Aims of chapter 
• To determine how PGE2 regulates TGF-β-induced Treg development in vitro. 












3.3.1 PGE2 negatively impacts the TGF-β response 
The role of PGE2 on regulatory T cells has been widely discussed, however there is 
no clear consensus on the effect on this compound on Tregs. Some groups have 
found that overexpression of cyclooxygenase 2 which correlates with PGE2  levels 
resulted in increased Foxp3 and Treg levels within the tumour microenvironment 
[158]. Whereas other groups have shown it to negatively affect Foxp3 expression, 
Chen, H. et al (2009), observed that mRNA levels of Foxp3 were increased in TGF-β 
only treated murine naïve T cells, however this was suppressed by PGE2 presence 
[159].  More recently, Yao. C, et al (2009, 2013) clearly observed both in vitro and in 
vivo that this lipid molecule enhanced differentiation and proliferation of Th1 and Th17 
cells, hence further evidence it would be expected to reduce levels of antithetical 
Tregs [91, 102].  
Preliminary work suggested that addition of PGE2 suppressed Foxp3 expression 
when naïve T cells were cultured with TGF-β. Therefore, to see whether PGE2 still 
affected the TGFβ response at increased concentration, CD4+ T cells were sorted 
from C57BL/6 mouse splenocytes using the AutoMACs, then stimulated with 
αCD3/αCD28 and TGF-β (0 – 10 ng/ml) on day 0. PGE2 at 100 nM) and vehicle (0.04 
% DMSO) were added to the cell culture on day 0. Cells were harvested and Foxp3 
expression detected by flow cytometry on day 3 (Fig. 3.1a). The gating strategy for 
analysis of CD25+Foxp3+ Tregs in live CD4+ T cells is demonstrated in figure 3.1b.    
TGF-β dose-dependently induced Foxp3 expression in CD4+ T cells, which was 
markedly suppressed by PGE2 at 100 nm, despite the higher TGFβ concentration 
(Fig. 3.1c). This dose of PGE2 also affected viable CD4+ cells (Fig. 3.1d).  However, 
the inhibitory effect on Foxp3 was observed most clearly at the highest levels of TGFβ 
stimulation (5, 10 ng/ml) (Fig. 3.1c, e). There was 55 % Foxp3 expression in cells 
cultured with TGF-β at 10 ng/ml and vehicle-only, whereas this expression was only 
16 % and for cells cultured with 100 ųM PGE2 respectably (Fig. 3.1d). Additionally, 
there was a steep increase in both percentage and number of Foxp3 expressing cells 
between those cultured with TGF-β at 1 ng/ml and 5 ng/ml, whereas this was not 
observed with cells additionally treated with PGE2 (Fig. 3.1c, d). These data suggest 
that PGE2 affects TGF-β’s induction of Foxp3 expression. (Fig. 3.1d, e). Therefore, 





Figure 3.1: Effect of PGE
2
 on the TGF-β response. (a) Experimental timeline for in vitro cell 
culture. Freshly isolated CD4+ T cells were stimulated with αCD3/αCD28 and indicated 
concentrations of TGF-β plus or minus PGE2 at 100 nM. On d 3, cells were harvested and 
intracellularly stained with anti-mouse CD25 and Foxp3. (b) Flow cytometry dot plot illustrates 
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the gating strategy for Foxp3 and CD25 expression in live CD4+ T cells. (c) Flow cytometry dot 
plots of CD25 and Foxp3 expression in live CD4+ T cells cultured with various concentrations 
of TGF-β in the absence or presence of PGE2 for three days. (d) Percentage of live CD4+ cells. 
(e) Percentages and number of Foxp3+ or CD25+Foxp3+ cells within total live CD4+ T cells 
under indicated conditions (mean ± standard error of the mean (SEM) of triplicates). Data 
represents one experiment. Representative of 3 independent experiments. 
 
3.3.2 PGE2 suppression of Foxp3 expression is independent of its inhibitory effects 
on T cell activation, proliferation and viability 
It was observed in figure 3.1 that there were fewer viable cells in the PGE2-treated 
group compared to the vehicle-treated group, indicating that the suppression of Foxp3 
expression may be secondary to its negative effect on cell viability. This is partially 
due to PGE2 being known to suppress TCR activation [87].  
To test whether delayed PGE2 addition would improve cell viability, but also still 
prevent Foxp3 induction, CD4+ T cells sorted from splenocytes using the AutoMACs, 
were stimulated with αCD3/αCD28 and TGF-β on day 0, and PGE2 (0 – 1000 nM) 
was added either on day 0 at the beginning of T cell activation, or day 1, 24 hours 
after TCR stimulation. Cells were harvested and Treg markers were detected by flow 
cytometry on day 3 (Fig. 3.2a).  
Postponed addition of PGE2 partially rescued T cell viability as well as T cell activation, 
assessed by expression of CD25 (Fig. 3.2b, c, d). However, PGE2 still dose-
dependently suppressed Foxp3 expression similarly despite its addition time (Fig. 
3.2b, c, d). This suggests that postponed addition of PGE2 does not rescue Foxp3 
expression, even though there is increased cell viability and activation.  
To see whether gene expression was also affected, naïve T cells were treated with 
either vehicle or PGE2 added on day 1. Cells were harvested and processed for PCR. 
It was observed that PGE2 similarly prevented Foxp3 gene expression in naïve sorted 
CD4+CD25-Foxp3-YFP- T cells compared to in vehicle-treated cells (Fig. 3.2e). 
Taken together, these results indicate that PGE2 suppression of Foxp3 induction is 





Figure 3.2: The effect of postponed PGE2 addition on Foxp3 expression. (a) Experimental 
timeline for an in vitro cell culture. Freshly isolated CD4+ T cells were simulated with 
αCD3/αCD28 and TGF-β in the absence or presence of indicated concentrations of PGE2 
added either on d 0 or d 1. On d 3, cells were harvested and intracellularly stained with anti-
mouse Foxp3. (b) Representative dot plots show Foxp3 expression gated on live CD4+ cells. 
(c) Percentages and numbers of live CD4+ T cells under indicated conditions. (d) Percentages 
and numbers of Foxp3+ cells within total live CD4+ T cells under indicated conditions. (e) 
Sorted naïve CD4+CD25-Foxp3-YFP- T cells cultured with vehicle or PGE2 (100 nM) added on 
day 1 were harvested day 3 and processed for PCR. Foxp3 expression was detected. (Mean 





3.3.3 PGE2 negatively affects natural Treg CD25+Foxp3+ expression 
Previous experiments had used AutoMACs sorted CD4+ cells, that may have included 
both naïve T cells and nTregs, therefore spleens from Foxp3-YFP mice were sorted 
for nTregs (CD4+CD25+Foxp3-YFP+). Cells were cultured with αCD3, αCD28 and 
TGF-β for 24 hours prior to addition of PGE2 on day 1. Day 3, cells were harvested 
and stained for Treg markers (Fig. 3.3a). Flow cytometry dot plots of CD25 and Foxp3 
expression in live nTregs cultured with vehicle or PGE2 (Fig. 3.3b). nTregs cultured 
with PGE2 saw a reduction in cells expressing both CD25 and Foxp3, whereas total 
Foxp3 was similar (Fig. 3.3c). Cells were also processed for PCR. Unlike in whole T 
cells (Fig. 3.2f), Foxp3 gene expression was largely unaffected in PGE2 cultured 
nTregs compared to the vehicle group (Fig. 3.3d). This suggests that PGE2 is 




Figure 3.3: The effect of PGE2 on nTreg Foxp3 expression. (a) Experimental timeline for 






 nTregs were simulated 
with αCD3/αCD28 and TGF-β in the absence or presence of indicated concentrations of PGE
2
 
on d 1. On d 3, cells were harvested and intracellularly stained with anti-mouse Foxp3. (b) 
Flow cytometry dot plot of CD25 and Foxp3 expression in live CD4+ T cells. (c) Percentage 
and number of CD25+Foxp3+ Tregs cultured with either vehicle or PGE2. (d) Foxp3 gene 
expression fold change between nTregs cultured with either vehicle or PGE2. (Mean ± SEM of 




3.3.4 PGE2 inhibits Foxp3 induction via EP2 and EP4 receptors 
PGE2 has four receptor subtype (EP1-4) which can each activate different 
downstream signalling pathways, and have varied affinities for PGE2 which was 
discussed in chapter 1. EP2 and EP4 have been shown to be involved in induction of 
Th1 and Th17, therefore the involvement of these EP receptors in suppressing Foxp3 
expression was examined.  
To detect this, freshly isolated CD4+ T cells were stimulated with αCD3/αCD28 and 
TGF-β on day 0, PGE2 analogues, EP agonists and antagonists were added 24 hours 
later. A PGE2 analogue (17-phenyl trinor PGE2) which preferably binds to EP1/EP3 
receptors, an EP2 and EP4 selective agonist and an EP2 or EP4 selective antagonist 
were used. Cells were harvested and Foxp3 expression was detected by flow 
cytometry on day 3 (Fig. 3.4a). 
It was observed that PGE2-induced Foxp3 suppression was overcome by the 
combined EP2 and EP4 antagonists (Fig. 3.4b, c, d). The EP4 antagonist alone could 
also partially rescue Foxp3 expression, but EP2 antagonist alone had no effect (Fig. 
3.4b, c, d). These data suggest that EP2 and EP4 receptors are vital in PGE2’s 









Figure 3.4: The role of EP2 and EP4 in suppression of Foxp3 expression in vitro. (a) 
Experimental timeline for in vitro cell culture. Freshly isolated CD4+ T cells were stimulated 
with αCD3/αCD28 and TGF-β on d 0. PGE2, EP agonists and EP antagonists were added 24 
hours after T cell activation. On d 3, cells were harvested and intracellularly stained with anti-
mouse Foxp3. (b) Flow cytometry dot plots of Foxp3 expression in live CD4+ T cells on d 3. 
(c) Number and percentage of live CD4+ cells under indicated conditions. (d) Number and 
percentages of Foxp3+ cells within total live CD4+ T cells under indicated conditions (mean ± 




3.3.5 The role of the cAMP pathway in suppression of Foxp3 expression 
It was observed that inhibition of EP2 and EP4 prevented PGE2’s suppression of 
Foxp3 expression, and this was largely dependent on the EP4 antagonist, illustrating 
the two key receptors for transmitting the PGE2 signal in the context of Foxp3 
inhibition.  Therefore, mechanisms for PGE2’s suppression of Foxp3 was examined 
through manipulation of various signal pathways. The main downstream signal 
activated by EP2 and EP4 receptors is the cAMP-PKA pathway, so this was the first 
route manipulated to see whether it was involved in Foxp3 expression.   
Freshly isolated CD4+ T cells were stimulated with αCD3/αCD28 and TGF-β on day 
0, then PGE2 and the following compounds; a cAMP analog, dibutyryl-cAMP (db-
cAMP), and a non-selective phosphodiesterase inhibitor, 3-isobutyl-1-methylxanthine 
(IBMX) were added 24 hours later. On day 3, cells were harvested and Foxp3 
expression was detected using flow cytometry (Fig. 3.5a).  
Similar to PGE2, db-cAMP dose dependently suppressed TGF-β-induced Foxp3 and 
expression (Fig. 3.5b, c). IBMX, which enhances intracellular cAMP by preventing 
degradation, also mimicked Foxp3 suppression (Fig. 3.5b, c). Protein kinase A (PKA) 
is downstream of cAMP, therefore an inhibitor H-89 was used to prevent further 
transition of this signal. PGE2 suppressed TGF-β-induced Foxp3 expression as 
observed previously, however notably this suppression could be partially rescued by 
blockade of PKA activity (Fig. 3.5d, e). These data indicated that PGE2 suppresses 









Figure 3.5: The effect of cAMP-PKA pathway on Foxp3 expression. (a) Experimental 
timeline for in vitro cell culture. Freshly isolated CD4+ T cells were stimulated with 
αCD3/αCD28 and TGF-β on d 0. Various concentrations of db-cAMP and IBMX (100 uM) were 
added 24 hours after T cell activation. On d 3, cells were harvested and intracellularly stained 
with anti-mouse Foxp3. (b) Expression of Foxp3 in live CD4+ T cells on d 3.  Representative 
dot plots were gated on live CD4+ cells. (c)  Bar graphs show percentages of live Foxp3+ cells 
within total live CD4+ T cells under indicated conditions. (d) Expression of CD25 and Foxp3 on 
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d 3 in live CD4+ T cells stimulated with TGF-β and in the absence or presence of PGE2 or H-
89. Representative dot plots were gated on live CD4+ cells. (e) Bar graphs show percentages 
of live Foxp3+ cells within total live CD4+ T cells under indicated conditions (mean ± SEM of 
triplicates). Representative of three independent experiments.  
 
3.3.6 LY294002, a PI3K inhibitor, could partially rescue PGE2-induced Foxp3 
suppression 
Besides the cAMP-PKA pathway, PI3K can similarly be activated by PGE2 signaling 
through EP2 and EP4 in T cells [87, 161]. It was then questioned whether PI3K is 
involved in PGE2-mediated suppression of Foxp3 through use of Ly294002, a PI3K 
inhibitor. To address this, T cells were stimulated with αCD3/αCD28 and TGF-β on 
day 0, and added PGE2 with or without LY294002, 24 hours later. Foxp3 expression 
was detected by flow cytometry on day 3 (Fig. 3.6a). 
While LY294002 itself did not affect TGFβ-induced Foxp3 expression or cell viability, 
it could partially rescue PGE2-dependent suppression of Foxp3 expression (Fig. 3.6b, 
c). These data suggest that PI3K may also be involved in PGE2 suppression of Foxp3 
induction, but more evidence should be obtained using other approaches, for example 







Figure 3.6: The effect of PI3K on Foxp3 expression.  (a) Experimental timeline for an in 
vitro cell culture. Freshly isolated CD4+ T cells were stimulated with αCD3/αCD28 and TGF-β 
on d 0. PGE2 and/or LY-294002 were added 24 hours after T cell activation. On d 3, cells were 
harvested and intracellularly stained with anti-mouse Foxp3. (b) Foxp3 expression in live CD4+ 
T cells on d 3. Representative dot plots were gated on live CD4+ cells. (c) Bar graphs show 
percentages of live CD4+ and Foxp3+ cells within total live CD4+ T cells under indicated 





3.4 Discussion  
In summary, these initial in vitro experiments demonstrated that PGE2 down-regulates 
the TGF-β response in CD4+ T cells thus preventing Foxp3+ expression and iTreg 
differentiation. This inhibitory effect of PGE2 on Foxp3 expression is mediated by the 
receptor subtypes EP2 and EP4 and their down-stream cAMP/PKA and PI3K 
pathway. PGE2 suppression of TGF-β-induced Foxp3 expression in T cells could be 
due to its disruption of TCR signalling and reduction of IL-2 production, evidenced as 
reduction of total cell viability [87]. This possibility was then excluded as postponed 
addition of PGE2 partially rescued PGE2’s negative influence on T cell viability and 
activation, but did not influence PGE2 suppression of Foxp3 expression.  
Figures 3.1 and 3.2 demonstrate that PGE2 addition markedly suppressed TGF-β-
induced Foxp3 expression in the murine CD4+ T cells. PGE2 acts via disruption of 
TCR signalling and reducing IL-2 expression, therefore it is not unexpected that 
addition of PGE2 reduced cell viability (Fig. 3.1) [87]. Postponed addition of PGE2 
could partially rescue PGE2’s negative influence on T cell viability and activation, but 
had no effect on PGE2 suppression of Foxp3 expression (Fig. 3.2). This excludes the 
possibility that PGE2 suppression of Foxp3 expression is a secondary effect from its 
suppression of T cell activation or survival.  
This is in contrast with other literature which suggests Foxp3 levels increase in the 
presence of PGE2, for example Dubinett’s group found increased Foxp3 expression 
when human T cells were stimulated with PGE2 [111]. Dubinett’s group used PGE2 at 
both 13 and 26 ųM which is higher than would be present physiologically, whereas 
we had shown the effect of PGE2 negatively influencing Treg development at 10, 100 
and 1000 nM which is more physiologically relevant [111]. This is especially important 
in in vitro cell cultures, where PGE2 is unlikely to be broken down quickly enough as 
it would be in vivo [88]. Additionally, Baratelli. F, et al (2012) stated that PGE2 induced 
Foxp3 expression after culturing human naïve T cells with supernatant from COX-2 
overexpressing lung cancer cells [111]. Although this supernatant will contain COX-






However, these findings were contrasted by work from Chen, H. et al (2009), who 
similarly observed dose-dependent suppression of mRNA Foxp3 expression in 
CD4+CD62L+ naïve murine T cells after treatment with PGE2 compared to TGFβ only 
[159]. Dr Yao has also done preliminary work on human cells, and a genomic 
microarray of these cells correlated with the murine work (data unpublished).   
It was observed that naïve T cells cultured with PGE2 had reduced Foxp3 gene 
expression, whereas the activation status (CD25 expression) of nTregs was affected 
but Foxp3 expression was unaffected (Fig. 3.3). The reason why there is a reduction 
in Foxp3 expression observed with flow cytometry however this is not seen with gene 
expression possibly because flow cytometry data is gated on ‘current’ live CD4+ T 
cells, whereas nTregs processed for PCR were initially sorted for live nTregs, however 
not re-sorted for live cells prior to observing gene expression. This is due to the low 
number of cells that would be recovered, thus potentially these cells are a mixture of 
live and dead Foxp3 expressing nTregs, additionally it does not show change of CD25 
(activation status) that the flow cytometry data also provides. Baratelli et al (2012) 
similarly observed a reduction in Treg CD25 expression when culturing cells with 
PGE2 [111]. This suggests that PGE2 affects Treg activation.  
Suppression of Foxp3 was mimicked by EP2 and EP4 agonists and this suppression 
was prevented by combination of EP2 and EP4 antagonists (Fig. 3.4). This suggests 
that both EP2 and EP4 are important for Foxp3 expression, relevant because these 
receptors have also been shown to enhance the proliferation and differentiation of 
Th1 and Th17 cells, the antithesis of Tregs [102, 103]. This is supported by work by 
Esaki, Y et al (2010), who demonstrated that use of an EP4 antagonist greatly 
reduced EAE symptoms in mice compared to the control group, and disease severity 
was further suppressed in EP2-/- mice treated with an EP4 antagonist, demonstrating 
the importance of these two key PGE2 receptors in induction of pro-inflammatory Th1 
and Th17 cells [137]. This may due to an increased number of Foxp3+ cells, 








The cAMP-PKA pathway has been implicated in induction of Foxp3 expression, 
increased levels of CREB activating the transcription factor ATF [30]. Upon Treg 
activation, cAMP levels are upregulated to prevent proliferation and IL-2 expression 
in inflammatory cells [162, 163]. However, it is known that PGE2 stimulation elevates 
intracellular cAMP via EP2 and EP4, therefore it was examined what effect addition 
of increased concentrations of a cAMP analog were added to naïve T cells to see 
whether this influenced Foxp3 expression [30, 91]. Interestingly, the cAMP analog 
dose-dependently suppressed TGF-β induced Foxp3 expression similar to what was 
observed with a dose-response of PGE2 in the in vitro cell culture. This was mirrored 
by Foxp3 expression levels observed after naïve T cells were incubated with IBMX, a 
competitive nonselective phosphodiesterase inhibitor which raises intracellular cAMP 
(Fig. 3.5). This is supported by recent data which suggests that activation of the cAMP 
pathway, inducing the transcription factor CREB, negatively effects Foxp3+ Tregs [33, 
34] .  
By contrast, inhibition of PKA, downstream of cAMP, by H-89 prevented PGE2 
suppression of Foxp3 (Fig. 3.5). Klein, M. et al (2012, 2016) demonstrated that cAMP 
inhibition should reduce Tregs suppressive ability, therefore testing the suppressive 
function of these cells under different conditions, such as increased db-cAMP, H-89, 
or with PGE2 merits further investigation [162, 163]. This work suggests that PGE2 
suppresses Foxp3 via the cAMP-PKA pathway, as with increased levels of the cAMP 
analogues, there is reduced Foxp3 expression, and use of H-89 was able to partially 












The PI3K/AKT pathway can also be activated by EP2 and EP4 stimulation. Yao, C. et 
al (2009) demonstrated that blockade of PI3K signalling could prevent PGE2’s 
stimulated IFNɣ production in Th1 cells [163]. PI3K signalling is known to inhibit Foxp3 
expression via activation of AKT which inhibits the transcription factor Foxo [30, 31, 
164, 165]. Novel inhibitors of which are being developed for anti-tumour immunity 
[165]. These results indicated that the PI3K inhibitor LY294002 did not affect TGF-β-
induced Foxp3 expression, but it did partially rescue PGE2-dependent suppression of 
Foxp3 (Fig. 3.6). These results suggest that PI3K mediates PGE2’s action in both Th1 
and Treg cells. 
 
3.5 Conclusion 
This work demonstrated that PGE2 reduced Foxp3 expression in TGF-β-induced in 
vitro Treg differentiation, and this involves the cAMP-PKA pathway. All this work was 
carried out in an in vitro situation; therefore it was vital to observe the effect of PGE2 













4 Endogenous PGE2 alters the Tissue Resident Treg 
Population 
4.1 Introduction 
In the following chapter, to see whether inhibition of PGE2 in vivo influenced immune 
cells and whether or not this was the same effect in different organs, cell populations 
within the colons, spleens and mesenteric lymph nodes (mLNs) were examined. 
These tissues were chosen because the spleen and mLNs are both important 
lymphoid organs for lymphocyte production and activation respectively and are 
therefore useful to determine the role of PGE2 in immune effector cell development. 
The colon was selected because it contains a greater number of immune cells than 
other tissues due to the continuous exposure to a plethora of dietary antigens and gut 
microbiota, which are involved in stimulating immune responses. Additionally, as 
PGE2 can be either protective or damaging depending on the cells affected, it was of 
interest to see what effect it had on Tregs within the gut [166].  
The intestines are a potentially inflammatory environment due to the microbes and 
food antigens amongst other factors that interact with the mucosa layer. Hence the 
co-evolution of the intestinal immune system alongside the commensal microbiota is 
important to prevent excessive inflammation. Within this environment, tTregs, or naïve 
T cells that migrate to the colonic environment prior to differentiation into pTregs, 
suppress pro-inflammatory cells via multiple mechanisms, such as antagonising pro-
inflammatory effector T cells, through contact-dependent mechanisms such as 
Cytotoxic T-Lymphocyte-Associated protein-4 (CTLA-4), and release of soluble 
cytokines such as IL-10 and TGF-β [3]. Sakaguchi. S, et al (1995) demonstrated that 
removal of these cells elicited an autoimmune response to certain self-antigens which 
confirmed their importance in maintaining tolerance [3, 13].  
Within the colonic pTreg population, approximately 40 – 60 % co-express RORγt, and 
the extent of co-expression correlates with microbial diversity [55].  These cells are 
more stable within an inflammatory environment due to significant demethylation at 
Treg signature genes, such as Foxp3 and CTLA-4, and also have a better flexibility 
to respond to signals due to the homing molecules CD62L and mTGFβ that are 




Previous work has shown how PGE2, via the receptors EP2 and EP4, increases the 
differentiation of Th1 cells and enhances IL-23 production by APCs to enable Th17 
expansion [91, 102]. However, the role that PGE2 plays on the induction of tissue 
resident regulatory T cells is less clear 
In chapter 3, it was demonstrated that in vitro addition of PGE2 to a Treg culture 
system resulted in reduced Foxp3 gene and protein expression, and this was largely 
dependent on the EP4 receptor. Therefore, to understand the effects of PGE2 on 
regulation of Tregs in vivo, endogenous PGE2 production was inhibited by a non-
selective COX inhibitor indomethacin (a NSAID) and Foxp3+ Treg cells were analysed 
in various organs. COX inhibitors inhibit the activity of the COX enzymes by binding 
to the active site, and block arachidonic acid from forming a complex therefore 
prevents further downstream prostaglandin products from being formed [4]. To further 
study the role of PGE2-EP4 signalling, an EP4 selective agonist (L-902,688) was also 
used [112]. 
 
4.2 Experimental methodology 
To determine the effect of inhibiting PGE2 in vivo on murine tissue Tregs, WT C57BL/6 
mice were treated with either vehicle (0.5 % ethanol) or a non-steroidal inflammatory 
drug (NSAIDS) indomethacin (5 mg/kg/day) to inhibit PGE2 production, or 
indomethacin plus an EP4 agonist (L-902,688) to specifically activate this key PGE2 
receptor. In addition to this, as indomethacin is known to potentially cause intestinal 
inflammation, a low dose (refer to section 2.8.1 in the methods chapter for doses) 
long-term treatment of indomethacin was employed to confirm that the results 
observed were due to PGE2 inhibition, not the treatment dose concentration.  
Spleen, mLNs and colons were removed from mice following treatment with vehicle 
or indomethacin, and processed into a single cell suspension (detailed protocols 
available in section 2, 2.31, 2.3.2, 2.3.3). RBCs were lysed then cells stained for 
tissue resident Tregs using the following panels for flow cytometry. Single cells were 
stained for live/dead (ef780), CD45 (APC-Cy7, efluor450), CD4 (PerCP-Cy5.5, PE), 





To boost cytokine expression prior to staining for effector cell types; phorbol 12-
myristate 13-acetate (PMA), ionomycin and a Golgi Plug inhibitor were added to the 
single cell suspension re-suspended in culture medium. Cells were incubated for four 
hours at 37oC, 5 % CO2. Cells were resuspended and washed twice with PBS/2 % 
FCS before being stained with the live/dead marker for 30 mins and incubated at 4oC. 
Cells were fixed and permeabilised overnight before staining for cytokines and other 
cellular markers for one hour. Cells were washed and prepared for flow cytometry.  
The panel to determine the effector cell type was; live/dead (ef780), CD45 (APC-Cy7, 
efluor450), CD4 (PerCP-Cy5.5, PE), CD3 (AF700, PE, APC), CD25 (APC, BV605, 
FITC), Foxp3 (FITC, PE) to determine the negative population, IFNɣ (FITC), IL-17a 
(PerCP-Cy5.5) and Ly6G (APC). Samples were all run on the BD LSR 5 laser 
Fortessa (BD bioscience). 
Treg levels were also examined in tissues from WT or EP4 T cell specific knockout 
mice under steady-state conditions, to see the effect of inhibition of EP4 signalling on 
endogenous Treg levels. Tissues were processed as previously described into a 
single cell suspension and stained using the previously described Treg staining panel 
for flow cytometry analysis. 
Mouse tissue extraction was performed in accordance to U.K. Home Office legislation. 
Mice were analysed individually and none were excluded from the analysis, with the 
exception of exclusions due to technical errors in preparation of intestinal lamina 
propria lymphocytes (LPLs). 
 
4.2.1 Aims of chapter 
• To determine the role of PGE2 on tissue resident Tregs. 










4.3.1 PGE2-EP4 signalling suppresses Foxp3+ Tregs in vivo. 
To study the effect of PGE2 on Tregs in vivo, WT C57BL/6 mice were treated for five 
days with vehicle (0.5 % ethanol), indomethacin (5 mg/kg/day), a NSAID to block 
endogenous PGE2 production, or indomethacin plus L-902,688 (an EP4 agonist), to 
specifically activate the PGE2 receptor EP4. On day 5, Tregs in various tissues were 
analysed by flow cytometry (Fig. 4.1a). The gating strategy for analysis of Foxp3+ 
Tregs among live CD4+ cells is shown in Fig. 4.1b.  
Supporting previous in vitro work presented in chapter 3, inhibition of endogenous PG 
production resulted in a greater number and proportion of Foxp3+ Tregs compared to 
the vehicle treated group within the colonic lamina propria (p ≤ 0.0001), spleen (p ≤ 
0.001) and mLNs (p ≤ 0.001) (Fig. 4.1c - f). The increase in Foxp3 expression induced 
by indomethacin was prevented by co-treatment with an EP4 agonist, suggesting that 
activation of the PGE2-EP4 signalling pathway suppressed Foxp3+ Treg induction at 
the steady state (Fig. 4.1c - f).  The indomethacin treated mice had a significantly 
greater number of colonic Foxp3+ Tregs compared to mice treated with vehicle, or 
indomethacin plus an EP4 agonist (p ≤ 0.05).  This was not as clear within the mLNs 
or spleen, suggesting that PGE2 - EP4 signalling selectively suppresses Tregs in the 
colonic environment (Fig. 4.1f). The number of T conventional cells (CD4+Foxp3- 
cells) were unaffected by treatment in the various organs (Fig. 4.1g). This data 














Figure 4.1: Effect of PGE2 on tissue resident Foxp3
+ Tregs in vivo. (a) Experimental 
timeline for in vivo inhibition of endogenous PGE2. WT C57BL/6 mice were treated with either 
vehicle, or indomethacin in drinking water for 7 days, or indomethacin plus an EP4 agonist, 
delivered by i.p injection daily. Mice were culled on d 7, tissues removed and processed to a 
single cell suspension by macerating the spleen, mLNs and digesting colonic tissue. Cells 
were stained with anti-CD45, anti-CD3, anti-CD4, anti-CD25, anti-Foxp3 antibody. (b) Flow 
cytometry plot illustrates the gating strategy for Foxp3 and CD25 expression in live CD4+ T 
cells from colonic tissue. (c) Expression of CD25 and Foxp3 in live CD4+ T cells in the spleen, 
mLNs and colons of mice treated with either vehicle, indomethacin, or indomethacin plus an 
EP4 agonist. Representative dot plots were gated on live CD4+ cells. (d) Percentages of 
Foxp3+ Tregs within total live CD4+ cells in spleens, mLNs and colons of mice treated under 
different conditions. (e) Percentages of Foxp3- Tconvs within total live CD4+ cells in spleens, 
mLNs and colons of mice treated under different conditions. (f) Total number of Foxp3+ cells 
within total live CD4+ cells in spleens, mLNs and colons of mice treated under different 
conditions. (g) Total number of Foxp3- cells within total live CD4+ cells in spleens, mLNs and 
colons of mice treated under three different conditions. Data shown as means ± SEM (error 
bars) are pooled from two independent experiments. (n = 8) * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 















4.3.2 PGE2-EP4 signalling inhibits colonic RORγt+Foxp3+ Tregs at a steady state 
Within the intestine, there are a subpopulation of Foxp3+ pTregs (40 – 60 %) that also 
express the Th17 transcription factor RORγt which is not largely expressed within the 
tTregs population [55]. These RORγt expressing Tregs are thought to be essential 
within a pro-inflammatory environment such as the colon, which is constantly in 
contact with potentially inflammatory factors such as the commensal microbiota [55]. 
This subset of cells is highly stable and unlikely to have their phenotype switched to 
a more pro-inflammatory type in the presence of highly inflammatory cytokines, their 
suppressive ability is greater due to the homing molecules CD62L and mTGFβ they 
express [55, 167].  
Inhibition of endogenous PGE2 in vivo resulted in significantly enhanced colonic 
Foxp3+ Tregs, I thus wondered whether PGE2 also affected the RORγt+ Treg subset. 
Flow cytometry dot plot of RORγt expression within a Foxp3+ Treg or Foxp3- Tconv 
cell population is shown in Figure 4.2a. Indeed indomethacin increased 
RORγt+Foxp3+ Tregs by within the colonic tissue (p ≤ 0.0001), and this increase was 
prevented by activation of the EP4 receptor (p ≤ 0.0001) (Fig. 4.2b). In contrast, a 
smaller proportion of Tregs expressed RORγt in the mLNs and spleens, and these 
were not influenced by indomethacin or an EP4 agonist treatment (Fig. 4.2b). 
However, RORγt+Foxp3- T conventional cells, which are expected to be the pro-
inflammatory Th17 cells, within these organs including the colon were not affected by 
indomethacin, or the EP4 agonist (Fig. 4.2c). There was similarly an increase in 
RORɣt+ Treg numbers in colons (p ≤ 0.001) and mLNs (p ≤ 0.01) of mice treated with 
indomethacin, compared to vehicle-treated mice, prevented by EP4 agonist addition, 
however this was not observed within the spleen (Fig. 4.2d). There was no increase 
in RORɣt+ Tconv cell numbers within the tissue with either indomethacin or 
indomethacin plus EP4 agonist treated mice (Fig. 4.2e).  These data suggests that 
the PGE2-EP4 signalling pathway critically controls the development of the RORγt+ 









Figure 4.2: Effect of PGE2 on intestinal RORɣt
+ Tregs in vivo. (a) RORɣt expression was 
measured in Foxp3+ Tregs from section 4.1. Flow cytometry dot plot of RORγt and Foxp3 in 
CD25+Foxp3+ Tregs or Foxp3- Tconv cells in the spleen, mLNs and colons of mice treated 
with vehicle, indomethacin or indomethacin plus an EP4 agonist. (b) Percentages of RORγt 
within CD25+Foxp3+T cells with spleens, mLNs and colons of mice treated under three 
different conditions. (c) Graphs show percentages of RORγt within Foxp3- Tconv cells with 
spleens, mLNs and colons of mice treated under three different conditions. (d) Total number 
of RORɣt+Foxp3+ Tregs in spleens, mLNs and colons of mice treated under different 
conditions. (e) Total number of RORγt+ Tconv cells in the spleens, mLNs and colons of mice 
treated under three different conditions. Data shown as means ± SEM (error bars) are pooled 
from two independent experiments. (n = 8) * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001 
by Kruskal-Wallis test, Dunn’s Multiple Comparison test used for post-hoc comparison. 
 
4.3.3 PGE2-EP4 signalling also inhibits small intestine Foxp3+ Tregs at a steady 
state 
It had been shown that only within the colon, an increase in Foxp3+ Tregs, especially 
the RORɣt+Foxp3+ subpopulation, was observed after inhibition of PGE2 production. 
It was then wondered whether Foxp3+ Tregs were similarly regulated within the small 
intestine. This is because differences occur between them due to the changing 
environment along their length, although the small intestine and colon are part of the 
digestive tract and have similar morphological features, such as both are involved with 
the digestion of food. For example, the small intestine is more acidic compared to the 
colon and therefore has a reduced commensal microbiota diversity compared to the 
more diverse colon microbial community [51, 55].  
As described in section 4.3.1, WT C57BL/6 mice were treated with either vehicle (0.5 
% ethanol) or indomethacin (5 mg/kg/day) five days in this experiment. Mice were 
culled on day 5 and Tregs were analysed within the small intestine by flow cytometry 
(Fig. 4.3a). The flow cytometry dot plot of Foxp3 and RORγt expression in live CD4+ 
T cells is demonstrated in figure 4.3b. There was increased Foxp3+ and 
RORγt+Foxp3+ expression in the small intestine of mice treated with indomethacin, 
compared to those treated with vehicle (Fig. 4.3c, d). There was also a slight increase 
in RORγt+Foxp3- T conventional cells within the small intestine from the indomethacin-
treated mouse (Fig. 4.3e). These results indicated a similar mechanism for regulation 




Figure 4.3: Effect of in vivo inhibition of endogenous PGE2 on small intestine 
RORγt+Foxp3+ Treg production. (a) Experimental timeline for in vivo inhibition of 
endogenous PGE2. WT C57BL/6 mice were treated with either vehicle, or indomethacin in 
drinking water for 5 days. Mice were culled on d 5, tissues removed and processed. (b) 
Expression of Foxp3 and RORγt in live CD4+ T cells in the small intestines of mice treated with 
either vehicle or indomethacin. Representative dot plots were gated on live CD45+CD3+CD4+ 
cells. (c) Percentages of Foxp3+ cells within total live CD4+ cells in small intestines of mice 
treated under different conditions. (d) RORɣt expression within total live Foxp3+CD4+ cells in 
the small intestine of mice treated under different conditions. (e) Total proportion of RORɣt+ 
cells within Foxp3- Tconv cells in the small intestine of mice treated under different conditions. 






4.3.4 Inhibition of PGE2 signalling can result in an increased inflammatory 
environment within the colon 
It is clear that use of NSAIDs, such as indomethacin can increase the proportion of 
RORɣt+ Tregs within the intestinal environment (Fig 4.2d, Fig. 4.3c). Although there 
was no significant increase in any pro-inflammatory RORɣt+Foxp3- T conventional 
cells, it has been thought that long-term NSAID use can exacerbate colonic 
inflammation [168]. Flow cytometry was used to detect pro-inflammatory cytokines 
within the colonic tissue.  
As before, WT C57BL/6 mice were treated with either vehicle (0.5 % ethanol) or 
indomethacin (5 mg/kg/day) for one week, colons extracted and a single cell 
suspension was formed. Cells were cultured for five hours with ionomycin, Golgi plug 
and PMA to stimulate cytokine production prior to staining for T cell and inflammatory 
cytokine markers (Fig. 4.4a). Cells were gated on live CD45+CD3+CD4+ T cells, and 
the gating strategy for the inflammatory markers IL-17 and IFNɣ are demonstrated in 
figure 4.4b. There is a slight increase in the number of IL-17 expressing cells in the 
colon of indomethacin-treated mice, and this is mirrored by the mean fluorescence 
intensity (MFI) (p = 0.07) (Fig. 4.4c). This is similarly observed with both the number 
(p = 0.07) and MFI of IFNɣ expressing cells (Fig. 4.4d).  
Inhibition of the COX enzymes by NSAIDs affects the arachidonic acid (AA) 
metabolism pathways [89]. AA is pushed towards leukotriene formation, and these 
compounds recruit neutrophils to the site of production. Therefore, to see whether use 
of indomethacin likewise enhanced neutrophil infiltration, CD45+CD3-CD11b+CD11c+ 
cells were also stained for lymphocyte antigen 6 complex locus G6D (Ly6G), a 
neutrophil marker, and gating strategy is demonstrated in figure 4.4e. As expected, 
there was a significantly greater proportion (p ≤ 0.01), and number of neutrophils (p ≤ 
0.05) in the indomethacin-treated mice colons compared to those treated with vehicle 








Figure 4.4: The effect on colonic inflammatory markers after inhibition of PGE2. (a) 
Experimental timeline for in vivo inhibition of endogenous PGE2. WT C57BL/6 mice were 
treated with either vehicle, or indomethacin in drinking water for 7 days. Mice were culled on 
d 7, colons removed and processed. Cells were incubated for four hours with PMA, ionomycin 
and Golgi plug, prior to staining of intra-cellular cytokines, or with anti-Ly6G antibody as a 
neutrophil marker. (b) Flow cytometry plot illustrates the gating strategy for IL-17 and IFNɣ in 
live CD4+ T cells from colonic tissue. (c) Graphs show percentage, number and MFI of IL-17+ 
expressing cells within total live CD4+ cells in colons of mice treated under different conditions. 
(d) Graphs show percentage, number and MFI of IFNɣ+ expressing cells within total live CD4+ 
cells in colons of mice treated under different conditions. (e) Flow cytometry plot illustrates the 
gating strategy for Ly6G, a neutrophil marker, in live CD11b+CD11c+ cells within colonic tissue. 
(f) Graphs show percentage and total number of Ly6G+ cells within total live CD11b+CD11c+ 
cells within the colons of mice treated under different conditions. Experiment repeated twice. 
Data shown as means ± SEM (error bars) (n = 2 - 5) * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001 by 






















4.3.5 Long-term low dose indomethacin treatment does not result in colonic 
inflammation      
It is widely known that use of NSAIDs is associated with negative effects in the lower 
section of the G.I tract [168]. The adverse effects include; colonic ulceration and 
reduced mucosal hydrophobicity, which create an ineffective barrier allowing 
commensal microbiota to potentially cross the epithelial barrier and enter peripheral 
sites causing inflammation [98, 168, 169]. A lower dose of indomethacin was used to 
block endogenous PGE2 production over a longer period to see whether this had a 
similar effect of the higher dose over a short period.  
WT C57BL/6 mice were treated with either vehicle (0.25 % ethanol) or indomethacin 
at 2 mg/kg/day for two or 1 mg/kg/day for four weeks, before colons were extracted 
and processed for flow cytometry (Fig. 4.5a). Flow cytometry dot plot of Foxp3 and 
RORγt expression in live CD4+ T cells from mice treated with vehicle or indomethacin 
at 2 mg/kg/day for two weeks is demonstrated in Figure 4.5b. There was a 
significantly greater proportion of Foxp3+ Tregs in colons treated with low dose 
indomethacin (2 mg/kg/day) for two weeks compared to the vehicle group (p ≤ 0.01), 
whereas there was no increase in the pro-inflammatory RORγt+ Tconv cells (Fig. 
4.5b). Flow cytometry dot plot of Foxp3 and RORγt expression in live CD4+ T cells 
from mice treated with vehicle or indomethacin at 1 mg/kg/day for four weeks is 
demonstrated in figure 4.5c. There was also a significantly greater number (p ≤ 0.05) 
of Foxp3+ Tregs in colons treated with low dose indomethacin (1 mg/kg/day) for four 
weeks compared to the vehicle group, whereas there was no increase in the pro-
inflammatory RORγt+ Tconv cells, similar to what was observed with 2 mg/kg/day 
indomethacin over two weeks (Fig. 4.5c). These data demonstrates that low dose of 








Figure 4.5: The effect of low dose indomethacin treatment on colonic Tregs. (a) 
Experimental timeline for in vivo inhibition of endogenous PGE2. WT C57BL/6 mice were 
treated with either vehicle, or indomethacin at 1 mg/kg/day or 2 mg/kg/day in drinking water 
for 28 days or 14 days respectively. Mice were culled on day 14 or day 28, colons extracted 
and processed for flow cytometry. (b) Flow cytometry dot plots for RORγt and Foxp3 
expression within live CD45+CD3+CD4+ T cells in colons from mice treated with 2 mg/kg/day 
indomethacin or vehicle for two weeks. Proportion of colonic Foxp3+ Tregs and RORγt+ Tconv 
cells from mice treated with 2 mg/kg/day indomethacin or vehicle for two weeks. (c) Flow 
cytometry dot plots for RORγt and Foxp3 expression within live CD45+CD3+CD4+ T cells in 
colons from mice treated with 1 mg/kg/day indomethacin or vehicle for four weeks. Graphs to 
show number of colonic Foxp3+ Tregs and RORγt+ Tconv cells from mice treated with 1 
mg/kg/day indomethacin or vehicle for four weeks. Data shown as means ± SEM (error bars) 





4.3.6 EP4 signalling in T cells does not affect colonic Tregs at a steady state 
Loss-of-function (e.g. through indomethacin use) and gain-of-function (e.g. using the 
EP4 agonist) studies showed an inhibitory effect of PGE2-EP4 signalling on intestinal 
Tregs. To further investigate whether PGE2 regulates intestinal Tregs through direct 
action on T cells, or indirectly via other cells, I used mice with specific deletion of the 
EP4 receptor in T cells. LCKcreEP4fl/fl mice were used to determine the effect of the 
EP4 receptor on endogenous Treg expression.  
To examine whether the cell populations were different in vivo compared to WT 
C57BL/6 mice under steady-state conditions, EP4fl/fl (control) or LCKcreEP4fl/fl (KO) 
mice were culled and tissues processed. Flow cytometry dot plots showing CD25, 
Foxp3 and RORγt expression in CD4+ T cells are shown in figure 4.6a. There was a 
similar proportion and number of CD25+Foxp3+ cells between the tissues from the 
EP4 KO and control mice (Fig. 4.6b). However inhibition of T cell PGE2 signalling in 
EP4 KO mice resulted in a greater proportion of RORγt+ Tregs in the colonic lamina 
propria (p ≤ 0.05), albeit total numbers were not affected. This suggests that inhibition 
of RORɣt+ Tregs is only partially due to T cell involvement (Fig. 4.6b - e). This was 
also mirrored by an increase in RORγt MFI in colons of KO mice compared to control 





















Figure 4.6: Effect of EP4 signalling in T cells at a steady state. (a) Expression of RORγt 
and Foxp3 in CD25+ T cells from the colons of naïve mice at a steady state. Representative 
dot plots were gated on live CD45+CD3+CD4+ cells. (b) Graphs show percentages of Foxp3+ 
T cells within live CD4+ T cells in spleens, mLNs and colons of EP4 KO or control mice. (c) 
Graphs show number of Foxp3+ T cells within live CD4+ T cells in spleens, mLNs and colons 
of EP4 KO or control mice. (d) Graphs show percentages of RORγt+Foxp3+ Tregs within live 
CD4+ T cells in spleens, mLNs and colons of EP4 KO or control mice. (e) Graphs show number 
of RORγt+Foxp3+ Tregs within live CD4+ T cells in spleens, mLNs and colons of EP4 KO or 
WT mice. (f) Graphs show RORγt+ MFI among RORγt+ Tregs. Data shown as means ± SEM 
(error bars) are pooled from two independent experiments. (n = 4 - 6) * p ≤ 0.05, ** p ≤ 0.01, 






















Data presented in this chapter suggest that PGE2 suppresses intestinal Foxp3+ Tregs, 
especially the RORγt+Foxp3+ Tregs, through its receptor EP4 which is consistent with 
my previous in vitro work.  
The in vivo role of PGE2 on tissue resident Tregs was determined by treating mice 
with a vehicle, indomethacin to inhibit PGE2 production, or indomethacin plus an EP4 
agonist to specifically activate this pathway. Addition of the EP4 agonist to specifically 
activate this PGE2 signalling pathway prevented an increase in Foxp3+ Tregs within 
each tissue that had been observed with mice treated with indomethacin only (Fig. 
4.1). This difference was detected most significantly within the colonic tissue, which 
is why the subsequent work focused on this organ. Within this environment, there are 
a subtype of Foxp3+ Tregs that express RORγt (40 – 60 %) that are vital in 
suppressing pro-inflammatory cells, therefore this marker was measured by flow 
cytometry to determine whether this subtype of Tregs were similarly influenced by 
inhibition of endogenous PGE2. As expected, it was only within the colonic 
environment that the proportion of RORγt+Foxp3+ Tregs were affected by 
indomethacin treatment (Fig. 4.2). There was also a greater number of these cells 
detected in the mLNs of indomethacin treated mice (no significant difference in 
percentage) that was not observed in the spleen. This suggests that there is increased 
migration of these highly suppressive RORγt+ Tregs from the colon to the mLNs (Fig 
4.2).  
The increase of RORγt+ Tregs was likewise observed with the SI (Fig. 4.3). The SI 
and colon are similar organs in that they are both key components of the 
gastrointestinal tract and experience a variety of food antigens from diet and 
commensal microbiota along its surface, however they are also greatly different due 
to the pH gradient that is present along the tract. The colon is a less acidic 
environment compared to the SI and therefore has a greater commensal diversity 
which in turn can influence immune cells within the environment as previously 
discussed [170]. This suggests there are similar factors between the colon and SI that 





Initially it was thought that intestinal Tregs may have been enhanced after 
indomethacin treatment due to inflammation, evidenced by slight increases in 
inflammatory cytokines (IFN-γ, IL-17), compared to the vehicle group (Fig. 4.4) [168]. 
Duffin’s (2016) finding which showed mice with reduced PGE2 synthesis developed 
systemic inflammation associated with gut microbiota infiltration, however they 
showed this to be due to reduced ILC3 proliferation and IL-22 production 
consequently affecting the gut barrier integrity [112]. NSAIDs are commonly used for 
treatment of inflammatory diseases, however they have been shown to be ineffective 
at treating patients with systemic inflammation due to damage to intestinal barriers 
and bacterial infiltration, worsening symptoms  [112]. In this model of PGE2 inhibition 
there was no increase in T conventional cells in the colons of indomethacin treated 
mice, albeit a slightly greater proportion of inflammatory cytokines, such as IL-17 (Fig. 
4.1, 4.4).  
RORγt+ Tregs are vitally important within the colonic environment to suppress 
inflammation, and have a greater flexibility to respond to signals due to the homing 
molecules CD62L and mTGFβ [167]. It has been demonstrated that RORɣt+Foxp3+ 
Tregs are better at protecting against colitis induction compared to RORɣt-Foxp3+ 
Tregs, which demonstrates the importance of understanding the mechanism for 
induction [55]. 
To ensure the increase in Tregs was not due to initiation of an inflammatory phenotype 
within the colonic environment, mice were treated with a lower dose of indomethacin 
1 mg/kg/day for 4 weeks or 2 mg/kg/day for 2 weeks, prior to measuring the levels of 
RORγt and Foxp3 expression in colonic cells. At both 2 and 4 weeks, vehicle-treated 
mice had a significantly reduced number of Foxp3+ Tregs compared to mice treated 
with the low dose indomethacin (Fig. 4.5). Whereas there was no increase in Tconv 
cells, or RORγt+ Tconv cells (Fig. 4.5) suggesting that the increase in RORγt+ Tregs 







It was shown in figure 4.2 that stimulation of EP4, the key PGE2 receptor, prevented 
an increase of colonic RORγt+Foxp3+ Tregs in indomethacin treated mice. To further 
confirm the importance of this receptor, Tregs were measured in T cell specific EP4 
KO mice under steady-state conditions. Contrary to expectations, there was no 
difference in Foxp3+ Tregs within the tissues (Fig. 4.6), however there was a 
significantly greater proportion of RORɣt+ Tregs in the colon (Fig. 4.6), demonstrating 
that inhibition of Tregs was only partially due to T cell involvement. Additionally, both 
EP4 KO and WT mice will have a similar level of basal nTregs present in the colon 
which may be why similar levels of Foxp3 were detected, whereas colonic pTreg 
differentiation will be affected in the EP4 KO mice, and as mentioned before, 
approximately 40 – 60 % of this population co-express RORγt [55].  
T cell specific EP4 KO mice only saw an increase in colonic RORγt+ Tregs, Foxp3 
levels were unaffected by disrupting PGE2 signalling in T cells, contradictory to what 
was observed in the in vitro results (chapter 1, section 3.3.1 – 3.3.4). These findings 
suggested that there are other factors involved in PGE2’s suppression of colonic Tregs 
in vivo.  
Previous work has demonstrated that an increased commensal microbiota correlates 
with augmented colonic Tregs, and also the number of antibiotics prescribed during 
childhood is associated with an escalated risk of IBD [51, 55, 171]. Since the 
microbiome has been shown to be so important to the induction and regulation of the 
immune system, it was then thought that possibly the microbiota were involved in 
PGE2’s suppression of colonic Tregs. In the following chapter, antibiotics were used 
to deplete gut microbiota, to determine whether these were involved in PGE2’s 
modulation of colonic Tregs, and specific genetically modified mice were used to 
determine the pathways involved in this. 
4.5 Conclusion 
It has been demonstrated that the PGE2-EP4 T cell signalling pathway was only 
partially involved in suppressing colonic lamina propria Foxp3+ Tregs. Therefore, the 
next questions that were asked were; are commensal microbiota involved in PGE2’s 
suppression of colonic Tregs, and are there any other cell types involved? 
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5 Mechanisms for PGE2 Suppression of Intestinal Tregs 
5.1 Introduction 
In the previous chapter it was demonstrated that inhibition of endogenous PGE2 
enhanced colonic Foxp3+ Tregs, especially the RORγt+Foxp3+ Tregs. In this chapter, 
the mechanism for RORγt+ Treg induction within this environment was then examined.  
The human gut contains more than 100 trillion microbes, of which a large number play 
an important role in disease and health [172]. Microbiota can breakdown indigestible 
carbohydrates providing energy for both itself and the host. The resulting products 
such as short-chain fatty acids (SCFAs) can benefit the immune system through 
induction of Tregs [49, 172]. These products of a fibrous diet can lower the intestinal 
pH and consequently influence the population of gut microbiota which inhabit this 
environment [57]. SCFAs such as butyrate, boost pTreg differentiation within the gut, 
however they have no effect on tTregs. The importance of gut microbiota in 
influencing intestinal products, and also their influence on the intestinal immune 
response was shown by Smith. P, et al (2013) [70]. They demonstrated that germ-
free (GF) mice had a reduced concentration of important SCFAs such as butyrate, 
and lower number of colonic Tregs compared to wild type (WT) mice [70]. Tregs are 
required to prevent excessive expansion of Th cells due to signals via the microbiota 
and also enables survival [172].  Intestinal Tregs (and dendritic cells (DCs)) have the 
highest expression of the SCFA receptor GPR43 compared to those in the spleen and 
mesenteric lymph nodes (mLNs) which demonstrates the importance of microbial 
products on intestinal immune cell development [70]. SCFAs signal via this receptor 
to stabilise Treg Foxp3 expression through acting as a histone deacetylase (HDAC) 
inhibitor, and boosting Treg function through increased IL-10 expression and 
suppressive ability [70].   
The gut microbiota influences intestinal Treg development, for example Clostridia can 
colonise the mucosal layer, and exert influence on the intraepithelial cells to produce 
TGFβ and Indoleamine 2,3-dioxygenase (IDO), both which are important  in 







The gut microbiota influences intestinal Treg development, therefore it was 
questioned whether the intestinal DC subsets, which convert naïve T cells into their 
various subsets partially through processing bacterial peptides, were also affected by 
suppression of PGE2. Ohnmacht. C, et al (2015) demonstrated that not only do 
RORγt+ Tregs require gut microbiota for development, but they are also dependent 
on MHCII+ DCs [167]. DCs process proteins and display antigens on the surface, and 
depending on whether they have encountered a pro- or anti-inflammatory stimulus at 
the site of conversion, this determines the cytokines produced which influences 
differentiation of naïve T cells into either effector or regulatory T cells. Feng. T, et al 
(2010) showed in vitro that MyD88 knockout (KO) DCs induced less FOXP3 
expression in naïve T cells, compared to WT DCs indicating that signalling via this 
receptor is important for Treg induction and optimal TGF-β production [173]. BMDCs 
express aldehyde dehydrogenases (ALDH)1 and ALDH2, and provide retinoic acid to 
DC precursors in the intestinal environment [173]. Retinoic acid can enhance 
expression of the gut homing molecule CCR9 on both DCs and Tregs. 
CD103+ DCs are thought to be vital in generating Tregs via TGF-β and retinoic acid, 
a vitamin A metabolite but also critical for mucosal Th17 cell differentiation [6, 68, 69].  
Likewise, CD103- DCs have recently been shown to be important in generating Tregs 
[6, 37]. CD103- DCs are able to maintain intestinal homeostasis in mechanisms which 
involves the gut microbiota, while CD103+ DCs acts independently of the microbiome 
[6, 37]. It was demonstrated that CD11b+CD103- DCs produced IFNβ after stimulation 
by gut microbiota, and subsequently enhanced proliferation of Foxp3+ Tregs [6]. 
IFNβ is already used as a vital treatment for Multiple Sclerosis (MS) [174, 175]. IFNβ 
treatment not only increases the production of Tregs to suppress the pro-inflammatory 
response, but also reduces T cell IL-6R expression, and subsequently enables 
effector T cells to be more responsive to the suppressive activity of Tregs [174, 175]. 
The aetiology of MS is still not known; however, it is likely to be a combination of 
environmental and genetic factors. It has also been suggested that MS could be 






Berer, K. et al (2011) used mice genetically altered to express myelin basic protein 
(MBP) to demonstrate that commensal microbiota were required for the development 
of spontaneous experimental autoimmune encephalomyelitis (EAE), an animal model 
of human MS [175, 176]. Germ-free mice were protected from spontaneous EAE 
induction, whereas specific-pathogen-free mice did develop disease highlighting the 
involvement of gut microbiota in the immune system  [175, 176].  
After production of IFNβ, it binds to the IFN receptor resulting in phosphorylation of 
STAT-1 and STAT-2 by JAK and TYK2 [167]. The consequent phosphorylated 
products form a complex with IRF7 to translocate into the nucleus and bind to the 
interferon-stimulated response element (ISRE) to further enhance transcription of 
interferon-related genes [167]. IFNβ is important in maintaining Foxp3 expression, 
Treg suppressive function and has been shown more recently to enhance Treg 
proliferation [74, 167]. Lee, E. E, et al (2012) demonstrated the importance of 
interferon signalling using a T cell colitis disease model [74]. RAG mice had worse 
symptoms when IFNAR KO Tregs were injected compared to the mice injected with 
WT Tregs [74].  
It was described in chapter 3 and 4 that in vivo inhibition of PGE2 increased colonic 
RORγt+Foxp3+ Tregs, and this was prevented by addition of an EP4 agonist. In T cell 
specific EP4 knock-out mice, there was no difference in Foxp3 expression, however 
there was significantly greater RORγt expression, suggesting that PGE2 signalling via 
T cell EP4 receptors were only partially involved in suppression of RORγt+ Tregs. The 
effect of PGE2 on colonic Treg development was of most interest after initial 
experiments, hence broad-spectrum antibiotics were also utilised later to deplete 
intestinal microbiota, to determine whether these were involved in PGE2‘s modulation 









5.2 Experimental methodology 
To determine the involvement of gut microbiota in PGE2’s modulation of colonic Treg 
number, broad-spectrum antibiotics (details in chapter 2, section 2.8.2) were used 
to deplete intestinal microbiota. The combination and concentration of broad-
spectrum of antibiotics have been previously used by multiple groups to deplete the 
gut microbiota [112, 151, 177]. The importance of the gut microbiota was aslso 
confirmed by the use of MyD88/TRIF double knockout mice, which are deficient in the 
downstream TLR adapter molecules MyD88 and TRIF, which would prevent gut 
microbial signalling via the immune cells.   
Another important subset of immune cells that are involved in naïve T cell 
differentiation are colonic lamina propria mononuclear phagocytes (cLP MNPs). cLP 
MNPs are important for processing microbial peptides and signalling for naïve T cells 
to be converted to either pro- or anti-inflammatory T cells, therefore these were 
examined to see whether inhibiting PGE2 affected the cLP MNP subsets activated 
within colon tissue. As before, mice were treated with vehicle (0.5 % ethanol) or 
indomethacin (5 mg/kg/day) to block endogenous PGE2, plus or minus broad-
spectrum antibiotics to deplete commensal microbiota, then colons were removed and 
stained for markers for measuring on the flow cytometer.   
To also confirm the involvement of the gut microbiota, MyD88/TRIF DKO mice were 
treated with vehicle or indomethacin, and colons removed for staining for cLP MNP 
markers, then measured by flow cytometry. Different MNP subsets have been 
described as having varied abilities to transform naïve T cells into either a more 
effector or regulatory cell type, therefore subsets of MNPs will be sorted from mLNs 
and spleens of WT mice, and co-cultured with naïve T cells sorted from spleens of 
Foxp3-YFP mice, to confirm previous work that has shown MNP subsets influencing 
naïve T cell differentiation, and to see if the subset that is increased in colons of 








As previously discussed, recently Nakahashi-Oda. C, et al (2016) demonstrated that 
CD103-CD11b+ DCs were able to express IFNβ which enabled colonic Treg 
proliferation [6]. Therefore, using PCR, type 1 interferon genes were measured in 
CD103-CD11b+ MNPs from both vehicle- and indomethacin-treated mice. 
Phosphorylated STAT-1 was detected within Treg and MNP cells using flow cytometry 
as another method to measure the involvement of interferon signalling. In addition to 
this, IFNAR mice were also treated with vehicle or indomethacin, to confirm the 
involvement of interferon signalling in colonic Treg and MNP differentiation. 
As commensal microbiota were shown to mediate PGE2’s suppression of Tregs in 
vivo, caecum content from vehicle or indomethacin treated mice was extracted and 
sterilely filtered so only metabolites remained, to see whether metabolites also 
affected naïve T cell conversion in vitro. This solution was added to a naïve T cells – 
DC co-culture to see whether the metabolites had been altered between the two 
different treated groups, and whether this would alter Treg differentiation.   
 
5.2.1 Aims of chapter 
• To determine the involvement of gut microbiota in PGE2’s suppression in intestinal 
Tregs. 
• To determine the involvement of DCs in intestinal Treg induction. 











5.3.1 Gut microbiota mediate PGE2 suppression of colonic Tregs 
Inhibition of colonic RORγt+ Tregs by PGE2 was only partially due to PGE2-EP4 
signalling in T cells, suggesting the involvement of other mechanisms through PGE2’s 
indirect action on T cells. Gut microbiota are important for colonic RORγt+ Tregs 
development, as germ-free (GF) mice have significantly fewer colonic RORγt+ Tregs 
compared to WT mice, and levels were restored after recolonization by the microbes 
which demonstrate their importance [55].  
To determine whether microbiota were involved in the inhibition of RORγt+ Tregs by 
PGE2, WT mice were treated with broad-spectrum antibiotics (chapter 2, table 4) for 
two weeks to deplete commensal bacteria and indomethacin (5 mg/kg/day) or vehicle 
(0.5 % ethanol) for the second week. On day 14, mice were culled, tissues removed 
and cells stained for Treg markers which were detected by flow cytometric analysis 
(Fig. 5.1a). Flow cytometry dot plots for Foxp3 and RORγt expression in live CD4+ 
cells are demonstrated in Fig. 5.1b. As observed in chapter 4, inhibition of PGE2 
resulted in a significantly greater proportion (p ≤  0.01) and number of colonic Foxp3+ 
Tregs (p < 0.01) compared to the vehicle group. Whereas co-treatment with broad-
spectrum antibiotics prevented the increase of Foxp3+ Tregs (p ≤ 0.01) (Fig. 5.1c). 
This was similarly observed with the proportion and number of RORγt+ expressing 
colonic Tregs, in which co-treatment of antibiotics resulted in levels analogous to the 
vehicle-treated group (Fig. 5.1d). This indicates that PGE2 is influencing the gut 










Figure 5.1: The involvement of gut microbiota in PGE2 regulation of intestinal Tregs. (a) 
Experimental timeline for depletion of gut microbiota and in vivo inhibition of endogenous 
PGE2. WT C57BL/6 mice were treated with either vehicle, or broad-spectrum antibiotics for 
seven days before also given either vehicle or indomethacin for a further week in drinking 
water. Mice were culled on d 14, tissues removed and processed. Cells were stained with anti-
Foxp3 and anti-RORγt antibody. (b) Flow cytometry plot of Foxp3 and RORγt expression in 
live CD4+ T cells from colonic tissue. (c) Total number and proportion of Foxp3+ cells within 
total live CD4+ cells in colons of mice treated under four different conditions. (d) Total number 
and proportion of RORγt+ cells within total live Foxp3+ Tregs cells in colons of mice treated 
under four different conditions. Data shown as means ± SEM (error bars) are pooled from two 
independent experiments. (n = 5 - 7) * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001 by 
Kruskal-Wallis test, Dunn’s Multiple Comparison test used for post-hoc comparison. 
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5.3.2 Inhibition of endogenous PGE2 is unable to influence colonic RORɣt+ Tregs 
due to TLR adapter molecule knock-out 
It was clear from figure 5.1, that the gut microbiota are significantly involved in PGE2’s 
suppression of colonic RORγt+ Tregs. As discussed in chapter 1, the intestine is in 
constant contact with potentially pro-inflammatory products such as; microbiota, 
viruses, or food antigens. The gut microbiota influences the intestinal immune system 
via production of microbial metabolites which can be detected by toll-like receptors 
(TLRs) present on a variety of cells. This prevents an over-reactive immune response 
during steady-state conditions, maintaining intestinal homeostasis [178]. TLRs, 
alongside inflammatory markers known as pathogen associated molecular patterns 
(PAMPs), such as bacterial lipopolysaccharides (LPS), are vital to induce DC 
migration to peripheral lymphoid organs to either prime effector T cells, or regulatory 
T cells if there is an absence of pro-inflammatory signals to induce tolerance. Follicle-
associated epithelial cells within the intestine aid transmission of bacterial metabolites 
to intraepithelial immune cells such as DCs, which can then present the peptide to 
lymphocytes [178]. MyD88 and TRIF are signal adapter molecules required to 
transmit signals from TLRs through to induction of nuclear factor-kappa-beta (NFκβ), 
which can influence gene expression, such as the regulatory cytokine IL-10, important 
in a hypo-responsive situation [179].  
To confirm that inhibition of endogenous PGE2 was affecting microbiota and their 
metabolites, which consequently affected intestinal RORγt+ Treg development, 
MyD88-TRIF double knockout (DKO) mice were used to determine the effect of 
inhibiting microbiota signal transduction within cells. MyD88-TRIF DKO mice or WT 
C57BL/6 mice were treated for five days with vehicle (0.5 % ethanol) or indomethacin 
(5 mg/ kg/day) in drinking water. On day 5, mice were culled, colons collected and 
tissues processed for flow cytometry (Fig. 5.2a). Dot plots for CD25, Foxp3 and 
RORγt expression in CD4+ T cells, from either WT or MyD88/TRIF double knockout 
mice treated with either vehicle or indomethacin, is demonstrated in figure 5.2b.  As 
expected, indomethacin treated WT mice had a greater proportion of colonic 
CD25+Foxp3+ Tregs (p ≤ 0.05) and RORγt+Foxp3+ Tregs (p ≤ 0.01) compared to the 
vehicle WT mice, however there was no difference observed between the vehicle or 
indomethacin-treated MyD88-TRIF DKO mice Foxp3+ or RORγt+ Treg cell population 
(Fig. 5.2c). This confirms the involvement of gut microbiota in PGE2’s suppression of 




Figure 5.2: The involvement of toll-like receptor signalling in PGE2 regulation of 
intestinal Tregs. (a) Experimental timeline for in vivo inhibition of endogenous PGE2. 
MyD88/TRIF DKO or WT C57Bl/6 mice were treated with either vehicle, or indomethacin in 
drinking water for 5 days. Mice were culled on d 5, colons removed and processed. Cells were 
stained with Treg antibodies. (b) Flow cytometry gating strategy for Foxp3+ and RORɣt+ Tregs 
within live colonic CD45+CD3+CD4+ T cells. (c) Graphs show number of Foxp3+ and RORɣt+ 
Tregs within colons of treated mice normalised to the WT vehicle mice. Data shown as means 
± SEM (error bars) are pooled from two independent experiments. (n = 5 – 6) *p ≤ 0.05, **p ≤ 






5.3.3 PGE2 regulates CD103-CD11b+ cLP MNPs via gut microbiota 
There are multiple mechanisms for Treg induction within the gut, as described in more 
detail in chapter 1. For example, there are direct approaches due to SCFA production 
by gut microbiota that can directly act on the SCFA receptor GPR109a, which both 
enhances proliferation of these Tregs and also stabilises gene expression [70]. 
Indirect methods are via gut metabolites activating DCs, and inducing Treg 
differentiation through retinoic acid and TGF-β production [70]. As MNPs are vital in 
processing these microbial peptides, and in Fig. 5.2, it was observed that 
MyD88/TRIF DKO mice did not have an increase in RORγt+ Tregs when treated with 
indomethacin, the different MNPs subsets were measured to examine whether they 
were also influenced by the inhibition of PGE2.  
Mice were treated as previously stated in 5.3.1, then colons were processed and 
stained for cLP MNP markers (Fig. 5.3a). The gating strategy for cLP MNP markers 
is demonstrated in figure 5.3b. There was a significantly greater number of colonic 
CD103-CD11b+ cLP MNPs in the indomethacin-treated compared to mice treated with 
vehicle only (p ≤ 0.001) (Fig. 5.3c, d). Co-treatment with broad-spectrum antibiotics 
prevented the increase in CD103-CD11b+ MNPs (Fig. 5.3c, d). The CD103+ and 
CD103-CD11b- MNPs did not appear to be affected by indomethacin or antibiotic 
treatment (Fig. 5.3c, d). These data suggests that PGE2 negatively affects colonic 
CD103-CD11b+ MNP accumulation through modulation of the microbiota which may 




Figure 5.3: The involvement of gut microbiota in PGE2 regulation of intestinal MPNs. (a) 
Experimental timeline for depletion of gut microbiota and in vivo inhibition of endogenous 
PGE2. WT C57BL/6 mice were treated with either vehicle, or broad-spectrum antibiotics for 
seven days before also given either vehicle or indomethacin for a further week in drinking 
water. Mice were culled on d 14, tissues removed and processed. (b) Flow cytometry plots 
illustrates the gating strategy for CD103+ or CD103- MNPs. (c, d) Total number and percentage 
of CD103+ and CD103-  MNPs within live colonic CD45+CD3-B220-CD11c+MHCII+CD11b+ 
cells. Data shown as means ± SEM (error bars) are pooled from two independent experiments. 
(n = 5 - 7) * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001 by Kruskal-Wallis test, Dunn’s Multiple 
Comparison test used for post-hoc comparison. 
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5.3.4 Inhibition of endogenous PGE2 is unable to influence CD103- cLP MNPs due 
to MyD88/TRIF DKO 
PGE2 has been shown to influence colonic CD103-CD11b+ MNPs via the microbiota 
(Fig. 5.3c, d), and this was still observed after inhibiting PGE2 using low dose 
indomethacin over a longer period (data not shown), hence the population increase 
was thought not to be due to inflammation. To confirm the involvement of the 
microbiota in influencing the CD103-CD11b+ MNP subpopulation, MyD88/TRIF DKO 
mice were used to see the effect of inhibiting microbiota signal transduction within 
cells. 
As previously described in section 5.3.2, WT or MyD88/TRIF DKO mice were treated 
with vehicle (0.5 % ethanol) or indomethacin (5 mg/kg/day) for four days, culled and 
colons extracted. Tissues were processed and cLP MNPs were analysed by flow 
cytometry (Fig. 5.4a). As expected, indomethacin-treated WT mice had a significantly 
greater proportion of CD103-CD11b+ MNPs compared to vehicle-treated WT mice (p 
≤ 0.01) (Fig. 5.4b, c).  It was also significantly greater than the CD103-CD11b+ MNPs 
population from the indomethacin-treated DKO mice (p ≤ 0.05) (Fig. 5.4b, c). 
Indomethacin and antibiotic treatment had no effect on CD103+ and CD103-CD11b- 
MNPs in both WT and DKO mice. These results support the earlier findings indicating 
that PGE2 alters microbial metabolite production, hence inhibition of signal 











Figure 5.4: The involvement of TLR signalling in PGE2 regulation of intestinal MNPs. (a) 
Flow cytometry gating strategy for CD103- or CD103+ MNPs within live colonic CD45+CD3-
B220-CD11c+MHCII+ cells. (b) Graphs show number of CD103- or CD103+ CD11b- or CD11b- 
MNPs within colons of MyD88/TRIF DKO and WT mice. Data shown as means ± SEM (error 
bars) are pooled from two independent experiments. (n=5-6) *p ≤ 0.05, **p ≤ 0.01 by Kruskal-
Wallis test, Dunn’s test used for post-hoc test.  
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5.3.5  cLP CD103- MNPs enhance RORγt+Foxp3+ Tregs in vitro 
It was observed in vivo that PGE2 specifically repressed colonic CD103-CD11b+ MNPs 
dependently of gut microbiota, while CD103+ MNPs were unaffected. A recent paper 
by Nakahashi-Oda. C, et al (2016) has suggested that CD103- MNPs are also able to 
boost proliferation of Foxp3+ Tregs within the intestine, ability of which is suppressed 
by markers on dying epithelial cells [6].  
Therefore, to determine whether these MNPs subtypes had a similar effect on iTreg 
induction in vitro, on day 0, naïve T cells (CD4+CD25-Foxp3-YFP-) were sorted from 
Foxp3-YFP mice splenocytes, and MNPs (CD45+CD3-CD11c+MHCII+CD11b+ and 
CD103+ or CD103-) from either WT or Foxp3-YFP mice mLNs. CD103- and CD103+ 
MNPs were co-cultured in a 1:2 ratio with naïve T cells plus TGFβ, IL-2 and soluble 
aCD3 until day 5, then cells were stained for Treg markers (Fig. 5.5a). Figure 5.5b 
demonstrates the gating strategy for CD25, Foxp3 and RORγt in live CD3+CD11c- 
cells.  
As expected, there was a greater proportion of Foxp3+ Tregs in the co-culture with 
CD103+ MNPs, however surprisingly within this population there was lower RORγt 
expression compared to what was observed with the naïve T cells co-cultured with 
CD103- MNPs (Fig. 5.5c). This suggests that the increased proportion of CD103-
CD11b+ MNPs within the colon of indomethacin-treated mice are important for 









Figure 5.5: Effect of MNPs on Treg induction in vitro. (a) Experimental timeline for sorting 
naïve T cells from the spleens of Foxp3-YFP mice, and CD103+ or CD103- MNPs from mLNs. 
MNPs cultured in a 2:1 ratio to naïve T cells, with TGF-β, soluble αCD3, IL-2 on d 0. Cells 
were stained with anti-Foxp3 and anti-RORγt antibody and analysed on d 5. (b) Flow cytometry 
plot illustrating the gating strategy for Foxp3 and RORγt in live CD3+CD11c-CD25+ cells 
cultured with either CD103+ or CD103- MNPs. (c) Graphs show proportion of Foxp3+ and 
RORγt+Foxp3+ cells within live CD3+CD11c-CD25+ cells. (Mean ± SEM of triplicates.) Data 




5.3.6 Caecum content from indomethacin-treated mice enhance CD103- MNPs 
induction of RORγt+Foxp3+ Tregs 
It was observed in vivo that PGE2 specifically repressed colonic CD103- MNPs 
dependently of gut microbiota, while CD103+ MNPs were unaffected (Fig 5.3c, d). 
Therefore, to determine whether the metabolites produced by gut microbiota affected 
the CD103-CD11b+ MNPs ability to induce RORγt+Foxp3+ iTregs, naïve T cells 
(CD4+CD25-Foxp3-YFP-) were sorted from Foxp3-YFP mouse splenocytes, and 
CD103- MNPs from mLNs. MNPs and naïve T cells were co-cultured for five days with 
TGFβ, soluble αCD3 and IL-2. On day 1, sterilely filtered caecum matter from vehicle- 
or indomethacin-treated mice was added. Day 5, cells were stained for Treg markers 
(Fig. 5.6a). Flow cytometry dot plot Foxp3 and RORγt expression is demonstrated in 
figure 5.6b. The indomethacin-treated mice sterilely filtered caecum content did not 
affect Foxp3 expression within the CD103- MNPs co-culture, however there was an 
increase in the RORγt expression within this Foxp3+ population (Fig. 5.6c). These 
data suggest that indomethacin-treated mice sterilely filtered caecum can further 






Figure 5.6: Effects of caecum content on a sorted CD103- MNP-naïve T cell co-culture. 
(a) Experimental timeline for sorting of naïve T cells from the spleens of Foxp3-YFP mice, and 
CD103- MNPs from mLNs. MNPs cultured in a 2:1 ratio to naïve T cells, with TGF-β, soluble 
αCD3, IL-2 on d 0, and sterilely filtered caecum matter from vehicle or indomethacin-treated 
mice was added on d 1. Cells were stained with anti-Foxp3 and anti-RORγt antibody and 
analysed on d 5. (b) Flow cytometry plot illustrating the gating strategy for Foxp3 and RORγt 
in live CD3+CD11c-CD25+ cells cultured with CD103- MNPs with sterilely filtered caecum 
content from mice treated with either vehicle or indomethacin. (c) Graphs show proportion of 
Foxp3+ and RORγt+Foxp3+ cells within live CD3+CD11c-CD25+cells. (Mean ± SEM of 






5.3.7 Colonic CD103- MNPs from indomethacin-treated mice express higher levels 
of IFN-β related genes than vehicle-treated mice 
Multiple groups have suggested that CD103- DCs can induce Tregs via retinoic acid 
and TGFβ production, similar to the mechanism CD103+ DCs use [6, 180-182]. As 
previously shown in figure 5.3c, d indomethacin-treated mice had a greater 
proportion of CD103- cLP MNPs within the colonic tissue compared to the vehicle 
group, and co-culturing CD103- cLP MNPs with naïve T cells resulted in a greater 
proportion of RORγt+Foxp3+ Tregs compared to the cells cultured with CD103+ cLP 
MNPs (Fig. 5.5c). 
To examine whether the cLP MNP subset which was enhanced in the colons of 
indomethacin-treated mice were also expressing IFN-β, which is known to enhance 
proliferation of Tregs, WT C57BL/6 mice were treated with vehicle (0.5 % ethanol) or 
indomethacin (5 mg/kg/day) for 4 days, colons extracted and cells isolated. cLP cells 
were sorted for CD45+CD3- CD11+MHCII+CD103- mNPs, then processed for PCR 
(Fig. 5.7a). The mNP sorting gating strategy is demonstrated in Fig. 5.7b. 
The PCR results showed that CD103- MNPs extracted from colons of indomethacin-
treated mice have both a two-fold increase of Ifn-b and Ifn-a compared to the vehicle-
treated group, and also a larger increase in Irf7 (5.5X) (Fig. 5.7c). IFN-β can act in 
both an autocrine and paracrine manner, resulting in a positive feedback loop. Irf7 is 
downstream of the interferon receptor and forms a complex with p-STAT-1 and p-
STAT-2 after receptor activation. IRF7 is largely restricted to lymphoid tissue and 
activates viral-inducible cellular genes such as Ifn-b, hence an increase in one gene 
suggests that there will be an increase in the other.  
The p-STAT-1/p-STAT-2 and IRF7 complex translocates to the nucleus, and 
upregulates the interferon-stimulated gene (Isg)15, levels of which were 4x greater in 
the CD103- cLP MNPs from the indomethacin-treated mice colons, compared to the 
vehicle group (Fig. 5.7c). ISG15 conjugates to intracellular target proteins after 
activation by signal proteins such as IFN-β or IFN-α transmitting the downstream 
effect (Fig. 5.7c) [74]. These data demonstrates that inhibition of PGE2 enhances 






Figure 5.7: Type 1 interferon gene expression in colonic CD103- MNPs. (a) Experimental 
timeline for sorting CD103
-
 MNPs from colons of C57BL/6 mice treated with either vehicle (0.5 
% ethanol) or indomethacin (5 mg/kg/day). (b) Flow cytometry plot illustrating the gating 
strategy for sorting CD103
- 
MNPs from colon tissues. (c) Graphs to show the fold change of 
various IFN-β-related genes compared to the housekeeping gene, GAPDH in colonic CD103
-
 
MNPs. Data shown as means ± SEM (error bars), samples pooled from 3-4 mice. Data 





5.3.8 Sterile filtered caecum content from indomethacin-treated mice induces type 
1 interferon gene expression in BMDCs 
Microbial products from indomethacin treated mice had a greater ability to enhance 
RORɣt+ expression in Tregs compared to vehicle treated microbial products, thus it 
was thought that culturing BMDCs with caecum from indomethacin-treated mice 
would result in tolerogenic BMDCs.  Therefore, BM cells were extracted from WT mice 
and cultured for three days with GM-CSF, media refreshed every three days until day 
9. Cells were sorted for CD45+CD3-MHCII+CD103- BMDCs, then cultured for 2.5 or 6 
hours with either media, or sterilely filtered caecum content from vehicle, 
indomethacin, or indomethacin plus an EP4 agonist, treated mice. Cells were washed 
three times in PBS/2 % FCs, then re-suspended in β-ME and buffer RLT and stored 
at -80 oC for future use (Fig. 5.8a). Cells were lysed and cDNA produced prior to PCR 
to detect various genes; Ifn-β, Irf-7 and Isg-15. Culturing BMDCs with sterilely filtered 
caecum content resulted in a greater proportion of gene expression compared to the 
BMDCs cultured with media only (Fig. 5.8b, c). After both 2.5 and 6 hours culturing 
BMDCs with sterilely filtered caecum content from vehicle or indomethacin treated 
mice, there was an increase in type 1 interferon genes, whereas this was not observed 
with the cells cultured with the filtrates from indomethacin plus an EP4 agonist treated 









Figure 5.8: The effect of sterile filtered caecum content on BMDC differentiation. (a) 
Experimental timeline for BMDC differentiation. Femurs were removed from mice on d 0, and 
bone marrow cells were cultured with media plus GM-CSF for nine days. BMDCs were sorted 
for CD103- DCs and cultured with either media, or sterilely filtered caecum content from mice 
treated with vehicle, indomethacin or indomethacin plus an EP4 agonist, for 2.5 or 6 hours, 
cells washed then sorted for PCR. (b) Type 1 interferon gene fold change compared to the 
housekeeping gene GAPDH after culturing CD103- DCs for 2.5 hours with media, or sterilely 
filtered caecum content from vehicle, indomethacin or indomethacin plus an EP4 agonist 
treated mice. (c) Type 1 interferon gene fold change compared to the housekeeping gene 
GAPDH after culturing CD103- DCs for 6 hours with media, or sterilely filtered caecum content 
from vehicle, indomethacin or indomethacin plus an EP4 agonist treated mice. Data shown as 
means ± SEM (error bars), n = 4-8, samples from two independent experiments. 
131 
 
5.3.9 Inhibition of endogenous PGE2 increases STAT-1 phosphorylation in both 
colonic Tregs and MNPs 
Colonic CD103- MNPs from indomethacin-treated mice had an increase in both IFN-
β and type 1 interferon genes detected by PCR (Fig. 5.7c). To confirm that there was 
also increased interferon signalling, not just an increase in gene expression, 
phosphorylation of STAT-1, downstream of the interferon receptor was measured via 
flow cytometry in both Tregs and cLP MNPs.   
Mice were treated as before for seven days with either vehicle (0.5 % ethanol) or 
indomethacin (5 mg/kg/day) then colons processed and stained for both Treg and 
MNPs markers and p-STAT-1 and 2, then ran on the flow cytometer (Fig. 5.9a). The 
flow cytometry dot plots for CD25, Foxp3 expression and p-STAT-1 is demonstrated 
in figure 5.9b. As observed previously, there was a greater number of Foxp3+ Tregs 
within the colon of indomethacin treated mice, compared to mice treated with vehicle 
only (p ≤ 0.01) (Fig. 5.9b). Within this Foxp3+ population, there was likewise a 
significantly higher number of p-STAT-1 positive cells (p ≤ 0.01) (Fig. 5.9c). This 
suggested that there was increased type 1 interferon signalling within the colon Tregs 
of the indomethacin treated mice, either stabilising gene expression, or boosting 
proliferation [6].  
STAT phosphorylation was also detected within the cLP MNP population. The gating 
strategy for CD11b+ and consequent p-STAT-1 expression within live CD45+CD3-
CD11c+ MNPs is demonstrated in figure 5.9d. There was a greater number of CD11b+ 
MNPs within the colons of indomethacin treated mice (Fig. 5.9d), and within this 
population there was a significantly greater number of p-STAT-1 positive cells (p ≤ 
0.05) (Fig. 5.9e). This supports the previous data that there was increased IFN-β and 
type 1 interferon-related genes within the colons of indomethacin treated mice, as 
there was also increased down-stream signalling from the receptor, measured via 
STAT-1 phosphorylation. Type 1 IFN related proteins signal in a positive feedback 
loop, indicating that a trigger to begin IFN-β production can then maintain its 





Figure 5.9: Detection of type 1 interferon signalling in colonic MNPs and Tregs. (a) 
Experimental timeline for in vivo inhibition of endogenous PGE2. WT C57Bl/6 mice were 
treated with either vehicle, or indomethacin in drinking water for 7 days. Mice were culled on 
d 7, colons removed and processed. Cells were stained with antibodies for phosphorylated 
STAT-1 within MNPs or Treg cell populations. (b) Gating strategy for Foxp3+ Tregs and 
phosphorylation of STAT-1 within this population. (c) Proportion and number of p-STAT-1 
positive Foxp3+ colonic Tregs from indomethacin or vehicle treated mice. (d) Gating strategy 
for CD11b+ MNPs and phosphorylation of STAT-1 within this population. (e) Proportion and 
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number of p-STAT-1 positive CD11b+ MNPs from indomethacin or vehicle treated mice. Data 
shown as means ± SEM (error bars) are pooled from two independent experiments. (n = 6 - 
8) *P ≤ 0.05, **P ≤ 0.01 ***P ≤ 0.001 by Mann-Whitney U. 
 
5.3.10 IFNAR knockout prevents an increase in colonic RORɣt+ Tregs after inhibition 
of endogenous PGE2 
Previous data showed that there were increased type 1 interferon related genes, and 
subsequent STAT signalling in colonic tissue of indomethacin treated mice, compared 
to mice treated with vehicle only. Therefore, to confirm that PGE2 was influencing 
interferon signalling to affect colonic Treg induction, WT C57BL/6 or IFNAR knock-
out mice were treated with vehicle (0.5 % ethanol) or indomethacin (5 mg/kg/day) in 
drinking water for five days, then culled and colons processed for flow cytometry (Fig. 
5.10a). The flow cytometry dot plot for CD25, Foxp3 and RORγt expression in live 
CD45+CD3+CD4+ cells is demonstrated in figure 5.10b. As previously observed, in 
WT C57BL/6 mice, inhibiting PGE2 production via indomethacin resulted in a 
significantly greater proportion and number of Foxp3 expressing cells (p ≤ 0.01) There 
was no difference observed between the colons of the IFNAR knock-out indomethacin 
or vehicle treated mice (Fig. 5.10c). This was similarly observed with RORγt 
expression. Within the Foxp3+ population, there was a significantly greater proportion 
RORγt expressing cells in the indomethacin treated mice colons, compared to the 
vehicle treated group (p ≤ 0.01) There was no difference observed between the 








Figure 5.10: Confirmation of the IFN pathway in Treg induction. (a) Experimental timeline 
for in vivo inhibition of endogenous PGE2. IFNAR knock-out or WT C57Bl/6 mice were treated 
with either vehicle, or indomethacin in drinking water for 4 days. Mice were culled on d 4, 
colons removed and processed. Cells were stained with Treg antibodies. (b) Flow cytometry 
gating strategy for Foxp3+ and RORɣt+ Tregs within live colonic CD45+CD3+CD4+ T cells. (c) 
Graphs show percentage and number of Foxp3+ Tregs within colons of treated mice. (d) 
Graphs show percentage and number of RORɣt+ Tregs within colons of treated mice. Data 
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shown as means ± SEM (error bars) are pooled from two independent experiments. (n = 4 - 
7) *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001 by Kruskal-Wallis test, Dunn’s test used for post-hoc test. 
 
 
5.3.11 Inhibition of endogenous PGE2 is unable to influence CD103- cLP MNPs due 
to IFNAR KO 
It was shown that there was an increase in type 1 interferon genes in the CD103-
CD11b+ MNPs within the colons of indomethacin treated mice compared to the vehicle 
treated mice, and this was the only subset that was affected by inhibition of PGE2. It 
was also observed that RORγt+Foxp3+ Tregs were unaffected by PGE2 inhibition 
when the interferon signalling pathway was inhibited. Therefore, to see whether the 
CD103-CD11b+ cLP MNP population was similarly affected by inhibition of interferon 
signalling, as before WT C57BL/6 or IFNAR knockout mice were treated with vehicle 
(0.5 % ethanol) or indomethacin (5 mg/kg/day) in the drinking water for five days. Mice 
were culled and colons processed for flow cytometry (Fig. 5.11a). Flow cytometry dot 
plot for CD103 and CD11b expression in live CD45+CD3-CD11c+MHCII+ cells is 
demonstrated in figure 5.11b. As observed before, there was an increase in CD103-
CD11b+ MNPs in the colons of WT mice treated with indomethacin compared to WT 
mice treated with vehicle (p ≤ 0.001). There was no difference observed between the 
CD103-CD11b+ MNP subpopulation of the IFNAR knockout mice treated with either 













Figure 5.11: Confirmation of the IFN pathway in cLP MNP subsets. (a) Experimental 
timeline for in vivo inhibition of endogenous PGE2. IFNAR knock-out or WT C57Bl/6 mice were 
treated with either vehicle, or indomethacin in drinking water for 4 days. Mice were culled on 
d 4, colons removed and processed. Cells were stained with Treg antibodies. (b)  Flow 
cytometry gating strategy for CD103+/- cLP MNPs within live colonic CD45+CD3-B220-
CD11c+MHCII+ cells. (c) Graphs show number of CD103+ or CD103-- MNPs within colons of 
IFNAR KO and WT mice. Data shown as means ± SEM (error bars) are pooled from two 
independent experiments. (n=5-7) *p ≤ 0.05, **p ≤ 0.01, *** p ≤ 0.001, ****p ≤ 0.0001 by 
Kruskal-Wallis test, Dunn’s test used for post-hoc test. 
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5.3.12 Indomethacin does not affect iTreg differentiation 
A question was raised about whether indomethacin remained within the caecum of 
mice after treatment, and this influenced Treg induction, rather than due to the 
resulting products from inhibition of prostaglandins. Therefore, naïve T cells were 
sorted from the spleens of a Foxp3-YFP+ mouse, and cultured for 24 hours before 
addition of media, vehicle, PGE2 or indomethacin. On day 4 cells were stained and 
analysed for Foxp3 expression and samples ran on the flow cytometer (Fig. 5.12a). 
Gating strategy for Foxp3 expression is demonstrated in figure 5.12b. Graphs show 
the proportion and number of Foxp3+ expressing cells cultured with media vehicle, 
PGE2 or indomethacin (Fig. 5.12c). Addition of indomethacin does not influence 
Foxp3 expression within the cell culture, there was no difference observed between 
the cells cultured with media or vehicle, however as expected, PGE2 inhibited Foxp3 
expression (Fig. 5.12c). This confirms that indomethacin is not directly affecting naïve 

















Figure 5.12: The effect of indomethacin on naïve T cell differentiation. (a) Experimental 
timeline of sorted naïve T cells cultured with PGE2 and indomethacin added on d 1. Cells 
stained for anti-mouse Foxp3, and samples run on the Fortessa on d 4. (b) Flow cytometry 
plot illustrating the gating strategy for CD25, Foxp3 and Ki67 in live CD4+ T cells. (c) Proportion 
and number of Foxp3+ Tregs from naïve T cells cultured with media, vehicle, PGE2 or 
indomethacin. Data shown as means ± SEM (error bars). Data represents one experiment. 











At this point, I have shown that colonic RORγt+ Tregs were significantly increased 
after inhibition of endogenous PGE2, and this involved the gut microbiota. Additionally, 
colonic CD11b+CD103- MNPs are enhanced through inhibition of endogenous PGE2 
and this is also influenced by gut microbiota, as it can be inhibited by antibiotic 
treatment and was not observed in MyD88/TRIF DKO mice. The colonic 
CD11b+CD103- MNPs from indomethacin treated mice express a greater proportion 
of type 1 interferon genes, which correlates with increased phosphorylation of STAT-
1 in both Tregs and MNPs. Interferon signalling is important for the induction of both 
colonic Tregs and CD11b+CD103- MNPs, as there was no increase in these cell types 
in indomethacin treated IFNAR KO mice. 
Numbers of colonic RORγt+ Tregs were increased in T cell specific EP4 conditional 
KO mice, whereas Foxp3 levels were unaffected by the disruption of PGE2 signalling 
in T cells, contradictory to what was observed in the in vitro results (chapter 3, figure 
3.4). These findings suggested that there are other factors involved in PGE2’s 
suppression of colonic Tregs in vivo. Previous work has demonstrated that an 
increased commensal microbiota correlates with augmented colonic Tregs [51, 55, 
171]. Since the microbiome has been shown to be so important to the induction and 
regulation of the immune system, it was then thought that possibly the microbiota was 
involved in PGE2’s suppression of colonic Tregs. Suppression of endogenous PGE2 
did not affect colonic Tregs in mice with depleted gut microbiota, suggesting that the 
microbiota mediates PGE2 suppression of RORγt+ Tregs (Fig. 5.1). It has been 
suggested that antibiotic treatment can affect the ability to metabolise indomethacin, 
largely due to reduction in β-glucuronidase activity which results in increased levels 
of prostanoids in the blood, compared to indomethacin-only treated mice [183]. 
However, as previously mentioned, the antibiotic-only treated group had similar levels 
of Tregs compared to the vehicle-only treated group, so if there had been an increase 
in PGE2, this did not result in any further suppression of colonic Tregs (Fig. 5.1). It is 
trusted that the dose and length of time that the antibiotics were used are enough to 
significantly deplete gut microbiota. The antibiotic combination and length of treatment 
has been used by multiple groups. Fukisaka. S. et al (2016), saw a significant 
reduction of bacterial DNA in the faeces, suggesting that the fortnight of treatment will 
be enough to significantly reduce the intestinal bacterial burden [54, 112]. 
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In addition to this, inhibition of COX pushes arachidonic acid down the leukotriene 
pathway via lipoxygenase [184]. Leukotrienes attract neutrophils, which also express 
β-glucuronidase, to aid in indomethacin metabolism. There was an increased number 
of neutrophils detected in the colons of the indomethacin treated mice, suggesting 
that the compound is still effectively metabolised and suppressing COX activity (Fig. 
5.1) [184].  
To further confirm the hypothesis that PGE2 modulates the commensal microbiota to 
influence colonic RORɣt+Foxp3+ Treg development, MyD88/TRIF DKO mice were 
used. MyD88 and TRIF are signal adapter molecules for TLRs, which are important 
components of APCs to recognise bacterial signature markers and induce a relevant 
immune response [185]. Indomethacin-treated WT mice had a greater number of 
colonic RORɣt+ Tregs compared to vehicle-treated WT mice, however this difference 
was not observed between MyD88/TRIF DKO mice (Fig. 5.2). This supports the idea 
that colonic RORɣt+Foxp3+ Tregs are affected by PGE2’s modulation of gut microbiota 
and subsequent metabolites. These data confirm that PGE2 regulates colonic RORγt+ 
Tregs via the gut microbiota.  
There are two main subsets of colonic MNPs, CD103+ MNPs which are considered to 
typically enhance Foxp3+ Treg differentiation through production of retinoic acid and 
TGFβ, and CD103- MNPs which have been thought to push a more pro-inflammatory 
phenotype [68, 173]. However recently, Nakahashi-Oda, C. et al (2016), 
demonstrated that gut microbiota stimulated colonic CD11b+CD103- DCs production 
of IFN-β which enhanced proliferation of Tregs [6]. MNPs are vital for detecting 
microbial metabolites and inducing immune cells, therefore it was examined whether 
subsets were also affected by inhibition of endogenous PGE2. PGE2 inhibition 
enhanced CD11b+CD103- cLP MNPs compared to vehicle treated mice and this was 
dependent on microbiota. Co-treatment of antibiotics and indomethacin prevented an 
increase in this cLP MNP subset (Fig 5.3). The involvement of microbiota is supported 
by Nakahashi-Oda, C. et al (2016) who saw that faecal matter stimulated BMDC IFNβ 






To further confirm that PGE2’s inhibition of CD11b+CD103- cLP MNPs was influenced 
by the microbiota, MyD88/TRIF DKO mice were used. As previously observed in 
figure 5.3, inhibition of endogenous PGE2 in WT mice resulted in a significantly 
greater number of CD11b+CD103- cLP MNPs compared to indomethacin-treated 
MyD88/TRIF DKO mice, supporting the idea that PGE2 influences microbial 
metabolite production consequently affecting CD11b+CD103- cLP MNPs development 
(Fig. 5.4). There was no difference observed between the CD103+ or CD103-CD11b- 
cLP MNP groups. 
Inhibition of endogenous PGE2 had the greatest effect on colonic CD103- MNP levels, 
so wanted to determine whether this affected naïve T cell differentiation differently to 
CD103+ MNPs. Initial results confirmed previous literature, CD103+ DCs induced the 
greatest proportion of Foxp3 in naïve T cells, however within this Foxp3+ population, 
the cells cultured with CD103- DCs had higher RORγt+ expression (Fig. 5.5). CD103- 
DCs Treg induction is dependent on microbiota, so it is logical that PGE2’s influence 
on the microbiota and metabolite composition will have a greater effect on this subset 
[186].  
In figure 5.5, it was shown that although naïve T cells cultured with CD103- MNPs 
expressed less Foxp3 than cells cultured with CD103+ MNPs, they expressed more 
RORγt. In vivo this involved the gut microbiota therefore it was questioned whether 
addition of sterilely filtered caecum content from indomethacin treated mice could 
further enhance CD103- MNPs ability to induce RORγt+ Tregs. The CD103- MNP co-
culture with sterilely filtered caecum content from indomethacin-treated mice had a 
greater proportion of RORγt+Foxp3+ Tregs, compared to the co-culture with sterilely 
filtered vehicle caecum content, suggesting that the metabolites present in the 
caecum content of mice treated with indomethacin enhanced the regulatory ability of 








Nakahashi-Oda, C. et al (2016) demonstrated that colonic CD103- DCs produced IFN-
β and this was shown to increase Treg proliferation, therefore IFN-β and IFN-β-related 
genes were measured in CD103- MNPs sorted from colons of vehicle- or 
indomethacin-treated mice. There was a greater fold change of type 1 interferon 
genes such as; Ifn-β, Ifn-α, Irf-7 and Isg-15, in the indomethacin-treated mice 
compared to vehicle-treated mice (Fig. 5.7). This is supported by earlier data showing 
that indomethacin-treated MyD88/TRIF DKO mice, deficient in TLR adapter 
molecules, had similar levels of colonic Tregs compared to vehicle mice, whereas 
indomethacin treated WT mice had a significantly greater number of both colonic 
Foxp3+ and RORγt+ Tregs compared to vehicle treated mice (Fig. 5.2). Similarly, there 
was no increase in colonic Tregs within the colons of antibiotic and indomethacin co-
treated mice, compared to mice treated with indomethacin only. This may be due to 
the inability for LPS to signal via TLR4, or deficiency of microbiota, to induce IFNβ 
production.         
Nakahashi-Oda. C, et al (2016) had demonstrated that culturing BMDCs with faecal 
content enhanced type 1 interferon genes significantly [6]. This demonstrated the 
importance of the gut microbiota in stimulating DCs to enhance proliferation of Tregs. 
It was already observed that the sterilely filtered caecum contents boosted RORγt+ 
Tregs in a culture with CD103- MNPs (Fig. 5.6). Therefore, it was thought that 
potentially the sterilely filtered caecum content from indomethacin treated mice could 
increase type 1 interferon genes in BMDCs, and consequently boost Tregs within a 
co-culture. This could then potentially be used as DC immunotherapy. BMDCs were 
generated, sorted for CD103- DCs, then cultured with media, or sterilely filtered 
caecum contents from vehicle, indomethacin or indomethacin plus an EP4 agonist 
treated mice, and gene fold change measured by PCR. Interestingly there appeared 
to be a greater fold change of type 1 interferon genes in the BMDCs co-cultured with 
the sterilely filtered indomethacin caecum, compared to the media or, indomethacin 
plus an EP4 agonist filtrate, which suggested that the metabolites within this filtrate 







Inhibition of endogenous PGE2 expression resulted in increased colonic type 1 
interferon gene expression, therefore to examine whether there was also increased 
signalling, phosphorylation of a downstream molecule STAT-1 was measured. As 
observed previously, indomethacin-treated mice had a greater proportion of colonic 
Foxp3+ Tregs, and within this population, there was a significant increase in 
phosphorylated STAT-1 which was expected due to increased type 1 interferon 
signalling (Fig. 5.9). In addition to this, indomethacin treated mice had a greater 
proportion of colonic CD11b+ cLP MNPs, and within this population there was also 
significantly greater phosphorylation of STAT-1, compared to vehicle treated mice. 
Type 1 interferons can act in either a paracrine or autocrine manner, hence can act 
on itself to continue to boost transcription of these genes [175].     
It is evident that IFNβ production is increased when endogenous PGE2 production is 
inhibited and this correlates with both colonic Foxp3 Treg numbers and CD103- cLP 
MNPs. Therefore, to finally confirm the importance of IFN signalling in Treg induction, 
IFNAR KO mice were used. WT indomethacin treated mice had a greater number of 
Foxp3+ and RORγt+ Tregs compared to indomethacin treated IFNAR mice (Fig. 5.10). 
This was similarly observed with CD11b+CD103- cLP MNPs. Levels in the IFNAR KO 
mice were comparable to the vehicle group, impressing the importance of interferon 
signalling on CD11b+CD103- MNPs (Fig. 5.11).  
MyD88/TRIF DKO mice are resistant to transmitting TLR signals from bacterial 
products such as LPS and peptidoglycans, however they are still able to produce IFN-
β which suggest there are MyD88 independent pathways to induce this [187]. There 
was not a significant increase in Tregs between the indomethacin and vehicle treated 
MyD88/TRIF DKO mice, but there was still a slight increase, which suggests that the 
microbial products signalling via TLR are important in induction of the RORγt+ Tregs, 
but suggests that IFN-β signalling is also active and has a role (Fig. 5.2). This was 
similarly observed with the IFNAR KO mice, there was still a slight increase in RORγt+ 
Tregs in the indomethacin treated IFNAR KO mice compared to the vehicle treated 
mice, demonstrating the importance of MyD88/TRIF signalling in combination with 
IFNAR signalling for induction of Tregs (Fig. 5.11). To potentially confirm that it is 
these two signalling pathways that are involved, MyD88/TRIF DKO mice could be 
treated with αIFNβ antibodies to block IFNβ signalling. After treating these mice with 
vehicle or indomethacin, Treg markers could be examined in colons to see whether 
there was still an increase in Tregs compared to vehicle-treated mice.   
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To confirm that indomethacin did not directly affect naïve T cell differentiation in the 
intestine, and that it was the inhibition of PGE2 and resulting bacterial metabolites that 
affect Treg induction, naïve T cells were cultured with indomethacin. The 
indomethacin-treated cells had little reduction in Foxp3 expression compared to the 
media or vehicle treated group, whereas as observed in chapter 1, PGE2 greatly 
reduced Foxp3 expression (Fig. 5.12). Indomethacin is readily absorbed 2 hours from 
when the drug was administered, and approximately 90 % of the dose is absorbed 
within 4 hours [188]. Therefore these data suggests that indomethacin does not 
directly affect naïve T cells, and the increased Tregs are due to inhibition of PGE2 and 
resulting microbiota [188]. Additionally, indomethacin treatment has been shown to 
increase microbiota diversity, so there may an increased variety of metabolites that 
can potentially affect immune cell differentiation [183, 189].  
5.5 Conclusion 
These data suggested that type 1 interferon signalling via CD103- cLP MNPs also 
influenced PGE2’s suppression of Tregs, which involved the gut microbiota. The next 
question was whether this knowledge could be used to reduce disease symptoms in 















6 The Role of PGE2 on Intestinal Disease Models  
6.1 Introduction 
In chapter 4, figure 4.6, it was demonstrated that T cell specific EP4 receptor deletion 
did not affect the intestinal Foxp3 expressing Tregs, however there was a greater 
proportion of RORγt+ expressing Tregs. RORγt+ expressing Tregs are highly 
suppressive against pro-inflammatory cells such as Th1 and Th17 cells that may be 
present within the intestinal environment. Data from our group (unpublished) 
observed that caecum content from indomethacin treated mice had a positive effect 
on Foxp3 expression after being cultured with naïve T cells and I also demonstrated 
that it could influence CD103- mNP induction of Tregs (Chapter 5, Fig. 5.6). It is 
known that intestinal microbiota can induce tolerogenic DCs, which can then induce 
Treg proliferation, therefore it would be useful to be able harness this by enhancing 
our understanding of how to influence gut microbiota to induce regulatory cells [67].  
Disease models are important in research to confirm research hypothesises prior to 
further investigations and development of potential drugs for human use. They can 
also can confirm validity of previous research. Work discussed in the previous 
chapters demonstrated that an increase in colonic Tregs after inhibition of PGE2 was 
prevented by use of broad-spectrum antibiotics, suggesting that the gut microbiota 
was involved in this process. Therefore, intestinal disease models were used to 
examine the role of PGE2 in Tregs and colonic inflammation.  
Boschetti, et al (2017) found that non-specific colonic inflammation enhanced 
lymphoid organ Treg differentiation and their suppressive ability, but negatively 
affected colonic DCs ability to convert naïve CD4+ T cells into Tregs [190].  
Inflammatory bowel diseases are T cell mediated disorders, involving both the innate 
and adaptive immune system. Thus, demonstrating the importance of understanding 
the role of the immune modulator prostaglandin E2 within this system, its effect on 
both colonic Tregs and MNPs, and the potential protective role in colonic inflammation 






Animal models of intestinal inflammation provide a multitude of information about the 
mucosal environment [191]. Dextran sulphate sodium (DSS) colitis is a severe, acute 
disease model which involves a sulphated polysaccharide disrupting the intestinal 
membrane after epithelial damage, enabling bacterial and intestinal antigens entry 
into the mucosal layer [191, 192]. This consequently stimulates a ‘chronic’ or ‘acute’ 
immune response. Research groups have historically used this disease model due to 
its low cost, simplicity to induce, and inducing an acute, chronic or relapsing model 
can be easily managed by changing the concentration of DSS administered [193]. 
Additionally, in the chronic stage of DSS colitis, the intestinal cell dysplasia observed 
is similar to what is observed in ulcerative colitis (UC) [192, 193].  
Another intestinal disease that is used to examine intestinal inflammation is adoptive 
transfer colitis. Injection of naïve T cells can induce intestinal inflammation five to ten 
weeks from treatment, due to expansion of mature T cells [191]. Co-treatment with 
Tregs can be used to see the suppressive effect of these cells on pro-inflammatory T 
cell expansion.  This is a milder disease model than DSS colitis as there is no chemical 
disruption to the intestinal membrane, therefore easier to see a smaller difference 
between treatment types. Fiona Powrie and her group led vital research into this, 
examining the role of Tregs in preventing T cell colitis development [190]. However 
the role Tregs have on in suppressing non-T cell mediated colitis is much less well 
known [190]. tTregs are developed to recognise and suppress a response to self-
antigen, whereas pTregs suppress responses against both self-antigen, but also food 
and mucosal antigens [190]. pTregs are of highest importance within the mucosal 
environment, as deficiencies in pTregs result in intestinal inflammation. Naïve T cells 
were used in the T cell colitis disease model, as these could either convert to effector 









Multiple groups have looked at the mechanisms for intestinal Treg induction and the 
benefits of microbial metabolites [45, 46, 52, 53, 190]. These are important due to the 
link between the intestinal microbiota and the immune system. Arpaia, et al (2013) 
demonstrated that administering SCFAs after antibiotic treatment resulted in a greater 
proportion of stable intestinal Tregs compared to mice treated with vehicle [194]. 
Additionally, other groups have found that various microbes such as Clostridia and 
Bacteroides fragilis can enhance intestinal Tregs and regulatory intestinal 
macrophages. Colonisation of the intestine by these regulatory cell inducing 
commensal microbiota were found to prevent DSS-induced colitis [38]. This 
demonstrates the great interest in this field, and how new information can benefit 
multiple groups. 
Faecal transfer experiments are an exciting new field of research that can be used to 
determine the influence of gut microbiota on disease progression, which can then be 
utilised for development of treatment of intestinal inflammatory disorders. The work 
which I have previously discussed demonstrated that microbiota were involved in 
PGE2’s suppression of intestinal Tregs and this was affected by antibiotic treatment. 
Xiao. et al (2017) demonstrated that just two days of treatment with the COX inhibitor 
indomethacin, altered the gut microbiota and there was a reduced proportion of 
Bacteroidetes and increased Firmicutes [195]. A transfer of faeces from these mice 
protected WT mice from indomethacin-induced injury and this was specifically 
dependent on the altered microbiota, as the sterile filtered solution did not protect 
against injury, and both COX and PGE2 levels were similarly reduced in both groups 
treated with a high dose of indomethacin [195]. This is important, because current 
treatment for intestinal disease is maintaining remission by anti-inflammatory drugs, 
colectomy, or immunosuppressive drugs response [196, 197]. All which have 
potentially harmful side-effects, whereas altering the gut microbiota by faecal 
transplant or pre- or pro-biotics are cheaper, lower-risk and a more efficient way to 
enhance the ‘good’ gut microbiota that can likewise influence the anti-inflammatory 
response [196, 197]. It is also currently a successful method for treating Clostridium 
difficile infection [196]. Tian. Z, et al (2016) demonstrated the importance of faecal 
matter transplants by reducing disease activity in DSS-induced ulcerative colitis mice 
compared to those untreated by transferring via intra-rectal injection faeces from 





To determine the role of PGE2 signalling in disease induction, T cell specific EP4 KO 
(LCKcreEP4fl/fl) mice or control mice (EP4fl/fl) were treated with 2 % DSS in drinking 
water for eight days, and disease severity scored daily (refer to chapter 2, Section 
2.9.1 for full details of scoring system). Mice were culled on day 8, colons removed 
and processed for flow cytometry to measure Foxp3 and IL-17 expression in live 
CD45+CD3+CD4+ T cells. Data was analysed using Prism 6 software (GraphPad).  
Additionally, to see whether inhibition of endogenous prostaglandin in WT mice would 
affect disease induction, WT (C57BL/6) mice were either treated with water only, 2 % 
DSS or 2 % DSS plus indomethacin in drinking water for 8 days. Disease severity and 
weight change was scored daily (refer to chapter 2, Section 2.9.1 for full details of 
scoring system). Mice were culled on day 8, colons removed and processed for flow 
cytometry to measure Foxp3 expression in live CD45+CD3+CD4+ T cells. Foxp3, IL-
10 and pro-inflammatory genes such as IFNɣ and IL-17 were also measured using 
rtPCR from stored colon tissue.  
To determine how EP4 KO T cells, preventing PGE2 signalling, acted in vivo, naïve T 
cells (live CD4+CD25- cells) were sorted from spleens either from LCKcreEP4fl/fl or WT 
C57BL/6 mice then injected i.p. into RAG-/- mice to induce T cell colitis. Mice were 
monitored weekly until disease symptoms were observed, then monitored three times 
weekly (refer to chapter 2, Section 2.9.2 for full details of scoring system). Mice were 
culled, colons extracted and stained for Treg markers and pro-inflammatory markers 
such as IL-17 and IFNɣ, then run on the LSR Fortessa.  
It was thought that inhibition of PGE2 not only affected colonic Tregs, but also involved 
the gut microbiota. Therefore, to examine whether indomethacin treatment affected 
the gut microbiota and resulted in a more protective phenotype, eight groups of donor 
mice were treated for five days with indomethacin (5 mg/kg/day) or vehicle (0.5 % 
ethanol), starting sequentially after each other. On day 5 of their individual treatment, 
the donor mice were culled, and caecum removed within a sterile hood. Caecum 







The solution was vortexed and then diluted 1:10 in sterile PBS and left at 4 oC for the 
sediment to settle. This was done daily for fresh caecum content to be available for 
the recipient mice from day -2 to day 5, recipient mice were gavaged with the top layer 
of solution from the caecum content mixture. Recipient mice were given 2 % DSS 
colitis in their drinking water between day 0 and day 6, and monitored daily (refer to 
chapter 2, Section 2.9.1 for full details of scoring system). On day 6, mice were culled 
and colons processed for flow cytometry.  
 
6.2.1 Aims of chapter 
• To determine whether inhibition of T cell specific PGE2-EP4 signalling reduced 
disease severity in a DSS or T cell colitis disease model. 
• To investigate whether inhibition of endogenous PGE2 production reduced 
disease severity in a DSS-induced colitis disease model.  
• To determine whether manipulation of the host gut microbiota by a caecum 
content transplant from COX inhibitor treated mice protected against a colitis 
















6.3.1 EP4 signalling in T cells is dispensable in DSS-induced colitis 
It was demonstrated in chapter 4, figure 4.6, that steady-state LCKcreEP4fl/fl mice had 
a similar level of colonic Foxp3 Tregs compared to control mice, however expressed 
a greater proportion of RORγt+. To see whether the LCKcreEP4fl/fl mice were better at 
suppressing inflammatory disease than control mice, mice were treated for eight days 
with 2 % DSS in drinking water to induce DSS-colitis. Mice were culled, colons 
removed and Tregs were analysed on day eight (Fig. 6.1a). Disease severity was 
scored daily and mice were culled if severity reached 11 or above, or they lost more 
than 25 % of their initial body weight (Fig. 6.1b). The disease score was comparable 
between both groups of mice during the experimental period (Fig. 6.1b). Histograms 
demonstrating Foxp3 expression and flow cytometry dot plots of IL-17 expression in 
live CD45+CD3+CD4+ cells from colons of EP4fl/fl and LCKCreEP4fl/fl mice induced with 
colitis are demonstrated in Figure 6.1c. There is no difference between colon lengths 
between the groups (Fig. 6.1d), and there was a similar percentage of Foxp3 and IL-
17 detected too (Fig. 6.1e, f). In conclusion, LCKcreEP4fl/fl mice were not better 





Figure 6.1: The effect of T cell EP4 receptor deficiency on DSS-colitis: (a) Experimental 
timeline for inducing DSS-colitis in LCKcreEP4fl/fl or WT mice. Mice were given 2 % DSS in 
drinking water for eight days. Day eight, mice were culled and tissues extracted and processed 
for staining. (b) Disease severity and percentage weight loss from starting weight was 
measured daily during the experiment. (c) Histograms demonstrate Foxp3 expression in live 
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CD45+CD4+CD3+ colonic lamina propria cells, and flow cytometry dot plot demonstrating IL-
17 expression in live CD45+CD4+CD3+ colonic lamina propria cells. (d) After mice were culled, 
colons were extracted and measured, there was no difference between the average lengths 
of the colon between the two groups. (e) Graphs showing the percentage of Foxp3+ and IL-
17+ T cells within live CD4+ T cells in the colons of LCKcreEP4fl/fl or WT (EP4fl/fl) mice after DSS-
colitis induction. (f) Graphs showing the percentage of Foxp3+ and IL-17+ T cells within live 
CD4+ T cells in the mLNs of LCKcreEP4fl/fl or WT (EP4fl/fl) mice after DSS-colitis induction. Data 
shown as means ± SEM (error bars) n = 4 - 8. * p ≤ 0.05 by Mann-Whitney U test.      
 
6.3.2 Indomethacin treatment enhances both pro- and anti-inflammatory gene 
expression in DSS colitis mice 
Figure 6.1 demonstrated that inhibition of the PGE2-T cell signalling pathway was not 
enough to protect mice from colitis induction, and in the previous chapter it was shown 
that the gut microbiota and CD103-CD11b+ DCs were also involved in Treg induction 
after inhibition of endogenous PGE2. Therefore, DSS colitis was induced in C57BL/6 
mice, and one group treated with indomethacin to inhibit endogenous PGE2 
production. One group was treated with water only as a control. Mice were culled on 
day eight and tissues processed for flow cytometry (Fig. 6.2a).   
Figure 6.2b shows the flow cytometry dot plot of CD25 and Foxp3 expression in live 
colonic CD45+CD4+CD3+ T cells. Mice induced with DSS colitis had a greater number 
and proportion of colonic Foxp3+ Tregs, compared to control mice (p ≤  0.05) (Fig. 
6.2c). However, levels were significantly enhanced when mice were also treated with 
indomethacin (p ≤ 0.05) (Fig. 6.2c). Foxp3 gene expression was likewise increased 
in mice treated with 2 % DSS compared to control mice (p ≤  0.01), and further 
enhanced in mice co-treated with indomethacin (p ≤   0.05) (Fig. 6.2d). This similarly 
correlated with levels of the Treg associated gene il-10 (p ≤  0.05), and the pro-
inflammatory cytokine Ifn-γ (p ≤  0.05), supporting the disease severity score which 
suggests that the increased number of Tregs within the colitis mice treated with 
indomethacin, are not completely protective against disease induction. Additionally, 
inhibition of PGE2 only increased Foxp3 gene expression, it had little effect of Il-10, 
Ifn-ɣ or IL-17 gene expression within the whole colon tissue (Fig. 6.2c, d). Treatment 
with indomethacin in combination with DSS did not reduce disease severity, 
suggesting that directly inhibiting endogenous PGE2, although enhances colonic 
RORγt+ Tregs, also has negative effects on other cells such as ILCs which negates 




Figure 6.2: The effect of endogenous PGE2 inhibition on DSS induction of Foxp3
+ Tregs. 
(a) C57BL/6 mice were treated with water, 2 % DSS or 2 % DSS plus indomethacin in their 
drinking water for 8 days. On day 8, mice were culled and colons removed to be processed 
for flow cytometry. (b) Flow cytometry gating strategy for Foxp3 expression in live colonic 
CD45+CD4+CD3+ cells. (c) Percentage and number of Foxp3 expressing T cells in colons of 
mice treated with water (control), DSS or DSS plus indomethacin. (d) Foxp3, Il-10, Ifn-ɣ and 
Il-17 gene expression from colons of mice treated with water (control), 2 % DSS and 2 % DSS 
plus indomethacin. Data shown as means ± SEM (error bars) n = 5-10. * p ≤ 0.05, ** p ≤ 0.01, 





6.3.3 T cell colitis disease severity was reduced in mice injected with T cell specific 
EP4 KO cells  
Inhibition of endogenous PGE2 as a protective mechanism for a disease model is 
problematic because PGE2 can also have a protective effect on other cell types such 
as ILC3s, therefore complete suppression of PGE2 can damage the intestinal barrier, 
counteracting the positive effect of increased Tregs (as previously demonstrated). In 
chapter 4, figure 4.6, it was demonstrated that T cell specific EP4 KO mice had a 
greater proportion of colonic RORɣt+ Tregs compared to control mice. Therefore, a T 
cell colitis disease model was induced by i.p injection of CD4+CD25- T cells sorted 
from spleens of either WT mice or LCKcreEP4fl/fl (EP4 KO) mice in RAG-/- mice on day 
0 (Fig. 6.3a). This was to see whether disease severity would be reduced using EP4 
KO T cells due to potentially a greater number of those cells converting to Tregs due 
to inhibition of PGE2 signalling.  
Mice injected with EP4 KO naïve T cells gained weight more easily until day 39, 
compared to mice injected with WT naïve T cells (Fig. 6.3b). In addition to this, only 
the mice injected with WT naïve T cells developed any mild disease symptoms (itchy 
eyes) during the experimental period (Fig. 6.3b). However, the colon length is similar 
between both groups (Fig. 6.3c). The flow cytometry plots for CD25, Foxp3 
expression, and IL-17 and IFN-γ expression in Foxp3- T cells are demonstrated in 
Figure 6.3d. There are a significantly greater proportion of Foxp3+ Tregs in the colons 
of RAG-/- mice administered with EP4 KO naïve T cells (p ≤ 0.01), whereas those 
injected with WT naïve T cells had a higher proportion and number of Tconv cells (p 
≤ 0.01) (Fig. 6.3e, f). Mice injected with WT naïve T cells also had a greater number 
of IFNɣ+ Tconv cells (thought to potentially be Th1 cells) (p ≤ 0.05) (Fig. 6.3g). 
However, they had did have a smaller proportion of IL-17+ Tconv cells (thought to 
potentially be Th17 cells) (Fig. 6.3h). These data suggest that RAG-/-  mice injected 
with EP4 receptor KO live CD4+CD25- T cells had reduced disease symptoms, and 












Figure 6.3: The effect of T cell specific EP4 KO on T cell colitis induction. (a) RAG-/- mice 
were injected with sorted CD4+CD25- T cells from either WT or EP4 KO mouse spleens on 
day 0. Weight and disease severity was scored weekly until disease symptoms were apparent, 
then mice were scored three times a week until day 42. On day 42, mice were culled, colons 
removed and tissues processed for flow cytometry. (b) Percentage weight change from original 
weight and disease score over 42 days. (c) Colon length of colons from mice injected with 
either WT or EP4 KO T cells. (d) Flow cytometry plots of Foxp3 expression in live colonic 
CD45+CD4+CD3+ cells from mice injected with WT or EP4 KO T cells, and pro-inflammatory 
cytokines IFNɣ and IL-17 expression in live colonic CD45+CD4+CD3+Foxp3-  cells. (e) 
Percentage and number of Foxp3 expressing colonic Tregs in mice injected with naïve T cells 
from WT or EP4 KO mice. (f) Percentage and number of Foxp3- expressing colonic Tconv 
cells in mice injected with naïve T cells from WT or EP4 KO mice. (g) Percentage and number 
of IFNɣ+ expressing colonic Tconv cells in mice injected with naïve T cells from WT or EP4 KO 
mice. (h) Percentage and number of IL-17+ expressing colonic Tconv cells in mice injected 
with naïve T cells from WT or EP4 KO mice. Data shown as means ± SEM (error bars) n = 6. 



















6.3.4 PGE2 exacerbates intestinal inflammation through driving microbial shifts. 
It was observed that inhibition of PGE2 resulted in increased colonic lamina propria 
Tregs, which are known to suppress inflammatory markers and co-treatment with 
antibiotics prevented this, suggesting that gut microbiota are involved in PGE2’s 
modulation of Tregs. Therefore, a DSS colitis model was carried out using faecal 
transplants from either vehicle- or indomethacin-treated mice, to see whether 
microbes and metabolites from treated mice could influence disease progression.  
Eight groups of donor mice were treated with indomethacin (5 mg/kg/day) or vehicle 
(0.5 % ethanol) for five days sequentially. On day 5 of the respective group’s 
treatment, donor mice were culled, caecum extracted and contents removed under 
sterile conditions and diluted 10 X in sterile PBS. Contents were vortexed, left for the 
solid particles to settle before the solution was gavaged into recipient mice from day 
-2 to day 5. Recipient mice were given 2 % DSS in drinking water from day 0 until day 
6, and scored and weighed daily (Fig. 6.4a).  Recipient mice gavaged for eight days 
with fresh and sterile caecum solution from indomethacin-treated mice were better 
protected against DSS colitis induction compared to mice gavaged with filtrate from 
vehicle-treated mice (Fig. 6.4b). They had less severe weight loss, and a better 
disease score over the seven-day colitis disease period (Fig. 6.4b). Colon length was 
similar between the two groups (Fig. 6.4c). Flow cytometry dot plots of CD4 and 
Foxp3 expression in live colonic lamina propria CD45+CD3+ T cells, and IL-17 and 
IFNɣ expression in live colonic lamina propria CD45+CD4+CD3+Foxp3-  Tconv cells is 
demonstrated in figure 6.4d. Recipient mice gavaged with caecum solution from 
indomethacin-treated mice had a greater proportion of colonic Foxp3 expressing T 
cells (p ≤ 0.01), and likewise had smaller proportion of Foxp3- Tconv cells (p ≤ 0.01) 
(Fig. 6.4d, e). These mice also had a reduced number of colonic IFNɣ expressing 

















Figure 6.4: The effect of an altered gut microbiota on colitis development. (a) Eight 
groups of donor mice were treated with either indomethacin (5 mg/kg/day) or vehicle (0.5 % 
ethanol) for five days starting in a sequential manner. Mice were culled and caecum content 
removed under sterile conditions. Caecum content was diluted 1:10 with sterile PBC, then 
gavaged daily into recipient mice. Recipient mice were gavaged with fresh caecum content 
from day -2 until day 6, and treated with 2 % DSS colitis in drinking water from day 0 until day 
6. (b) Percentage weight change from original weight and disease score over an eight day 
experimental period. (c) Colon length of DSS colitis mice gavaged with caecum content from 
indomethacin or vehicle treated mice. (d) Flow cytometry dot plots of Foxp3 expression in 
colonic live CD45+CD4+CD3+ cells and pro-inflammatory cytokines IFNɣ and IL-17 expression 
in live colonic CD45+CD4+CD3+Foxp3-  cells from DSS colitis mice gavaged with caecum 
content from indomethacin or vehicle treated mice. (e) Percentage and number of Foxp3 
expressing colonic Tregs in mice injected with naïve T cells from WT or EP4 KO mice. (f) 
Percentage and number of Foxp3- expressing colonic Tconv cells in mice injected with naïve 
T cells from WT or EP4 KO mice. (g) Percentage and number of IL-17+ expressing colonic 
Tconv cells in mice injected with naïve T cells from WT or EP4 KO mice. (h) Percentage and 
number of IFNɣ+ expressing colonic Tconv cells in mice injected with naïve T cells from WT or 
EP4 KO mice. Data shown as means ± SEM (error bars) n = 5-6. * p ≤ 0.05, ** p ≤ 0.01 by 















At this point, I have shown that EP4 KO T cells induce less severe colitis in RAG mice 
compared to WT T cells, and pre-treating mice with caecum content from 
indomethacin-treated mice was more protective against DSS colitis induction 
compared to mice pre-treated with caecum content from vehicle-treated mice.  
It was demonstrated in chapter 4, figure 4.6, that T cell specific EP4 conditional KO 
mice had a similar number of Foxp3 expressing colonic cells compared to WT mice, 
however within this population there was a greater number of RORɣt+ Tregs. These 
Tregs are known to be highly suppressive within the potentially inflammatory 
environment of the colon due to increased levels of mTGFβ and colonic homing 
markers CD62L, therefore to determine whether these mice were more protected from 
disease, DSS colitis was induced in either WT or EP4 KO mice [46]. WT mice had 
greater weight loss and disease activity score compared to EP4 KO mice over the first 
few days, however at the end of the disease progression, there was no difference 
between the two groups with regard to weight change, disease score, regulatory 
Foxp3+ Tregs or pro-inflammatory IL-17 Tconv cells (Fig. 6.1). Blocking PGE2 
signalling via inhibition of EP4 signalling was not enough to protect mice from colitis 
induction, therefore colitis induction was repeated again with additional indomethacin 
treatment which was previously shown to enhance colonic RORɣt+Foxp3+ Tregs in 
chapters 4 and chapter 5.  
Mice treated with indomethacin in addition to colitis induction had a greater number 
and proportion of Foxp3+ Tregs compared to vehicle and DSS-colitis only mice (Fig. 
6.2). However, these increased Tregs did not provide increased protection again 
disease (data unpublished), because indomethacin and DSS co-treated mice had a 
more severe disease phenotype than even DSS-alone. This is due to indomethacin 
having a negative effect on the colonic environment due to gastrointestinal damage 
[35, 198-200]. This is confirmed by the PCR results which demonstrated that although 
colonic tissue from indomethacin-treated colitis mice had a greater fold change of 
Foxp3 and Il-10 expression, there was also an increase in the pro-inflammatory 





NSAIDs are known to have long-term benefits, such as reducing the risk of certain 
diseases such as Alzheimer’s, however side-effects are also associated with their use 
such as gastrointestinal damage and increasing severity of IBD [35, 137, 157, 201]. 
Similarly using specific prostaglandin synthase inhibitors are totally inefficient, as AA 
can be redirected to another prostaglandin, resulting in other adverse effects [83]. 
Therefore, if the complex role of PGE2 cannot be fully understood or harnessed 
directly, then the role that it has on microbiota and benefits of this can be used more 
efficiently to regulate the colonic immune system. 
Due to our previous work in chapter 4, figure 4.6, demonstrating the increased 
number of colonic RORɣt+ Tregs T cell specific EP4 KO mice had compared to control 
mice, a T cell colitis model using naïve T cell from these two genotypes of mice was 
used to see the effect of these cells on disease induction. Some groups suggest that 
DSS colitis cannot be directly compared to human IBD as DSS colitis is a result of 
massive immediate damage to the epithelial layer and is a result of mixed pro-
inflammatory T cell involvement, whereas IBD normally involves polarised T cells and 
slower disease development therefore a milder disease course using T cell colitis was 
also observed [191]. It was demonstrated that inhibition of PGE2 increased type 1 
interferon signalling in Tregs and DCs, similar to the increased levels of RORɣt 
expression that was observed in the Foxp3+ Tregs. 
It was  noted that mice injected with naïve T cells from T cell specific EP4 KO mice 
gained more weight during the disease period compared to the WT mice, and similarly 
there were a greater number of colonic Foxp3 Tregs and fewer IFNɣ+ Tconv cells 
(thought to be a Th1 phenotype) (Fig. 6.3). However, there are a greater number of 
IL-17+ Tconv cells (thought to have a Th17 phenotype). The intestine favours pTreg 
generation, of which 40 – 60 % RORɣt, therefore as EP4 KO mice at a steady-state 
condition had a greater proportion of colonic RORɣt+ Tregs compared to WT mice a 
greater proportion of these naïve T cells may have converted to the anti-inflammatory 
Tregs within the colonic environment and consequently allowed better weight gain 






Yang et al (2016), demonstrated the importance of RORɣt+ Tregs by an adoptive 
transfer of a suboptimal ratio of Foxp3+ or RORɣT+Foxp3+ Tregs to naïve T cells in 
mice, to observe the difference in suppressive ability [55]. Mice given RORɣt+Foxp3+ 
Tregs had better protection compared to RORɣt-Foxp3+ Tregs [55]. The increased 
type 1 interferon signalling also enhanced Treg suppressive ability, potentially 
reducing the T cell colitis disease severity that was observed [76]. Additionally, 
interferon-STAT-1 signalling is known to enhance Treg differentiation which was 
shown to be enhanced in colonic Tregs and DCs, whereas interferon-STAT-4 
signalling enhanced Th1 cell induction, demonstrating the importance of the signalling 
pathway. Future work should examine STAT molecules within the stored colonic 
tissue and cells to see whether STAT-4 is similarly altered in intestinal inflammation 
[76]. This correlates with what was observed with our T cell colitis model, where naïve 
T cells from EP4 KO mice were expected to have a greater level of RORɣt expression. 
This is also potentially why there was a greater number of IL-17 expressing cells within 
the colon, as well as Foxp3 Tregs as Foxp3+RORɣt+ T cells have been described as 
intermediate cells which can further differentiate into mature Foxp3+ Tregs or RORɣt+ 
T conv cells. This experiment should be repeated while also weighing WT mice as 
controls during the experimental process to compare natural weight gain. However, 
this initial preliminary experiment demonstrated that T cells unable to transmit the 
PGE2 signal via EP4, resulted in a better disease course and were more protective 
than WT T cells, and this correlated with colonic Treg numbers. 
As demonstrated in chapter 5, figure 5.6, and data from our group (unpublished), 
sterile filtered caecum content from indomethacin-treated mice enhanced Tregs and 
boost CD103- MNPs ability to induce Tregs in vitro. Additionally Xiao, X. et al (2017), 
saw that indomethacin treatment altered murine gut microbiota, which resulted in an 
increase in Firmicutes whereas there is a reduction in Bacteroidetes [195]. The 
importance of the gut microbiota was evident because both PGE2 and COX levels 
were similarly reduced in indomethacin-injury induced mice, thus suggesting that 
inhibition of PGE2 in the donor mice resulted in more protective microbiota, and also 






Use of indomethacin altered the gut microbiota resulting in a more protective 
phenotype, therefore I wanted to determine whether this protected mice against DSS 
colitis induction. Caecum content from donor indomethacin-treated mice was 
transferred two days prior to colitis induction until day 7 to potentially alter the gut 
microbiota of recipient mice and protect against disease. Xiao et al (2017), saw mice 
treated with caecum content from indomethacin treated mice had better protection 
against indomethacin-induced disease, and similarly were protected from DSS colitis 
disease progression [195]. They did not observe any protective benefit when the 
caecum content was filtered so only microbial metabolites remained, therefore in the 
DSS colitis disease model, caecum content was not filtered, yet for ease of gavage 
the solid particles were allowed to settle before drawing up the clear solution. 
However, our group has previously observed that sterilely filtered caecum content 
from indomethacin-treated mice were able to enhance Foxp3 expression in naïve T 
cells (data unpublished) and also in a naïve T cell-CD103- DC co-culture (chapter 5, 
figure 5.6).  
Similar to what was observed with the T cell colitis disease model, colitis mice 
gavaged with the caecum contents from indomethacin-treated mice lost weight at a 
slower rate than mice gavaged with caecum content from vehicle-treated mice (Fig. 
6.4). Similarly, they also had a greater proportion of Foxp3+ Tregs, and IFNɣ+ Tconv 
cells compared to vehicle-caecum content treated mice, whereas the vehicle-caecum 
treated mice had a greater number of pro-inflammatory Foxp3- Tconv, and IL-17+ 
Tconv cells. A comparable result was seen in Xiao’s paper, where vehicle-treated 
mice had a greater proportion of inflammatory markers such as IFN-β and TNF-α 
[195]. However Tian, Z, et al (2016) observed an improvement in disease activity 
score in DSS-induced ulcerative colitis BALB/c mice after faecal matter transfer 
compared to those not given faecal matter transfer, however they still saw a significant 
weight loss in C57BL/6 mice after a faecal matter transfer similar those without 
treatment suggesting that mouse background or housing facilities could influence this 
[196]. However, I saw an improvement in disease activity scores in C57BL/6 mice 
given a faecal matter transfer from indomethacin treated mice, compared to transfer 
from vehicle treated mice. Foxp3+ Tregs have been shown to enhance divergence of 
gut microbiota, and regulation of IgA production, all which is important for intestinal 




Multiple groups have demonstrated that commensal microbiota are important in 
maintaining type 1 interferon expression in the mucosal tissue, which regulates the 
immune response for various challenges [76]. And conversely, deficiency in Ifnar1 
affected the commensal microbiota diversity, demonstrating the importance of 
interferon signalling in the intestinal immune response [76]. Thus, suggesting that 
altering the gut microbiota of the DSS colitis mice with caecum content from 
indomethacin-treated mice could boost interferon signalling and consequently 
enhance intestinal Tregs to protect from colitis.   
This indicates that other methods to boost intestinal Tregs, rather than directly 
inhibiting PGE2, could be used even more efficiently through understanding of the 
mechanism of PGE2 suppression of Tregs.  
It should be considered further whether inhibition of PGE2 is directly affecting Tregs 
which can consequently affect the gut microbiota, or whether it affects the gut 
microbiota which can consequently influence Treg expression [167].   
6.5 Conclusion 
The caecum contents from indomethacin-treated mice had a protective effect on DSS 
colitis mice, which was expected from previous results. Additionally, EP4 KO T cells 
induced a milder version of T cell colitis, potentially due to the increased colonic Tregs 










7 Discussion  
7.1 Rationale for study 
Prostaglandin E2 (PGE2) is a ubiquitously expressed molecule that is implicated in 
multiple biological processes such as fertility, gastric mucosal integrity, and the 
immune response. PGE2 is involved in the key signs of inflammation; rubor (redness), 
calor (heat), tumor (swelling) and dolor (pain), and recent work has demonstrated that 
it can have both pro- and anti-inflammatory properties depending on the EP receptors 
activated and concentrations of PGE2 present at the site [83].  
Self-reactive T helper cells (Th) cells (i.e. Th1 and Th17) can induce autoimmune and 
autoinflammation. These inflammatory cells can be suppressed by regulatory T cells 
(Tregs), which express the transcription factor Foxp3. The equilibrium between 
Th1/Th17 cells and Tregs is important to not only prevent the development of 
autoimmunity, but also the induction of cancer for example, due to Tregs preventing 
T helper cells in recognition and aiding destruction of damaged cells.  It has been 
demonstrated that PGE2 aids Th1 and Th17 cell induction and proliferation and 
therefore supports inflammation development. However, the role of PGE2 in Treg 
development and function is not as clear [91, 102]. The work presented here aimed 
to test the hypothesis that PGE2 signalling regulates Treg Foxp3 expression, which 
consequently affects development and function, facilitating intestinal inflammation. 
7.2 In vitro work – direct actions of PGE2 on Tregs 
PGE2, acting via the EP2 and EP4 receptors, has previously been indicated to 
increase Th1 cell differentiation and expand the Th17 population [102, 156]. As helper 
T cells are controlled by regulatory T (Treg) cells, I wondered whether PGE2 promotes 
inflammatory response by also affecting Tregs. I found that in an in vitro culture 
system, PGE2 negatively affects Foxp3 expression in Tregs, and this is mediated by 
the receptor subtypes EP2 and EP4 (chapter 3, Fig. 3.1, 3.4). EP2 and EP4 have 
previously been shown as key PGE2 receptors in regard to effector Th1 cell 
differentiation, and Th17 cell expansion [91, 102]. Using agonists and antagonists to 
examine the signalling pathways involved, I further found that this was due to their 
cAMP/PKA and PI3K pathways (chapter 3. Fig. 3.4, 3.5). These findings were in 
agreement with previous reports that discuss the transcription factor CREB as an 
important molecule in balancing effector Th17 cells and regulatory Tregs, negatively 
influencing Foxp3+ Treg survival [33, 34, 159].  
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The cAMP response element binding protein (CREB) transcription factor, a member 
of the basic leucine zipper superfamily, has previously been thought to bind to the 
promoter and conserved non-coding sequence 2 (CNS 2) within the Foxp3 gene, and 
increase expression of this gene [34]. Moreover, a recent paper showed that 
activation of CREB promoted Th17 differentiation both in vitro and in vivo, and 
reduced survival and expansion of Foxp3+ Tregs [33, 34]. cAMP-responsive element 
modulator (CREM) is also a member of the basic leucine zipper superfamily, and the 
alpha isoform was found to enhance IL-17 protein (a Th17 family cytokine) production 
through binding of the gene promoter region [33, 34]. Wang. X, et al (2017) used a T 
cell colitis model to determine the importance of CREB, activated after PGE2 – EP4 
signalling, and observed reduced inflammatory cytokine production from CREB 
deficient CD4+ T cells and a better disease activity score, compared to WT CD4+ T 
cells [34]. These findings together suggest that the reduction in Foxp3+ Tregs is due 
to PGE2 activating the EP2 and EP4 receptors, and signalling via the cAMP-CREB 
pathway.  
Although some groups have shown a positive link between PGE2 and Foxp3+ Tregs, 
Baratelli, F. et al (2005) detected an upregulation in Foxp3 expression in human 
CD4+CD25+ Tregs and CD4+CD25- T cells after culturing cells with supernatant from 
COX-2 overexpressing tumour supernatant [202]. However, they did observe a 
reduction in CD25 levels, similar to the data presented in this thesis (chapter 3, Fig. 
3.1, Fig. 3.3).  Sharma, S. et al (2005) also observed that PGE2 enhanced Treg Foxp3 
levels in COX-2 overexpressing tumour environments, and inhibition of COX-2 
prevented this [153]. The EP4 receptor was shown to be vital in this process, and 
deficiency in this receptor reduced Treg Foxp3 expression, and was completely 
prevented by co-suppression of the EP2 receptor. The importance of these receptors 
was observed in my studies (chapter 3, Fig. 3.4). Increased Foxp3 expression has 
been detected in tumour microenvironments when the enzyme COX-2 is 
overexpressed [129, 158, 203]. However within tumour tissues, cells may be secreting 
various other molecules such as chemokines like CCL28, which can recruit Tregs via 
stimulation of the chemokine receptor CCR10, also expression of other tumour 
derived factors can cause Treg expansion, such as TGF-β [204]. Therefore, these 







Gene microarrays carried out by our group (unpublished data) suggested that PGE2 
disrupted the TGF-β signalling pathway through suppression of Tgfbr1 and increasing 
expression of Smad6 and Smad7, both of which have an inhibitory effect of TGF-β 
signalling (data not shown). Additionally, there was reduced phosphorylated SMAD2 
and phosphorylated SMAD3 levels, downstream of the TGF-β receptor, in Tregs 
present within the PGE2 treated cell population compared to vehicle cultured cells. 
This suggests that PGE2 is negatively affecting the TGF-β signalling pathway. This 
can also influence Foxp3 expression through disrupting the TGF-β signalling pathway. 
This in vitro work provided useful evidence supporting the hypothesis that PGE2 
negatively effects Foxp3 expression at a range of TGF-β concentrations, and addition 
to the cell culture 24 hours after initial plating removed any effect due to cell viability. 
However, it was necessary to also confirm this in vivo prior to further investigations 
into PGE2’s mechanism of action on Foxp3+ Tregs. 
7.3  In vivo studies 
I also investigated the roles of endogenous PGE2 on tissue resident Tregs in vivo, and 
found that PGE2 suppresses intestinal Foxp3+ Tregs, especially RORɣt+Foxp3+ Tregs 
via the EP4 receptor. Further supporting the role of PGE2 in this response, an increase 
in RORɣt+ Tregs was also observed in colons of T cell specific EP4 knock-out mice 
compared to WT mice, demonstrating that suppressing the PGE2 signalling pathway 
influences RORɣt expression in Foxp3 expressing intestinal Tregs (chapter 4, Fig. 
4.6). Data obtained from in vitro experiments demonstrated that Foxp3 expression 
was affected in iTreg cell cultures treated with PGE2, whereas nTreg activation status 
was affected (CD25+Foxp3+) however total Foxp3 gene expression was unaffected 
(chapter 3, Fig. 3.3). Inhibition of PGE2 production by NSAID treatment resulted in 
increased Foxp3 expression in Tregs present within the mesenteric lymph nodes, 
spleen and colon, however the proportion and number of Foxp3- Tconv cells were 
unaffected, suggesting that the increase in Tregs was not due to inflammation 
(chapter 4, Fig. 4.1). Use of NSAIDs is known to increase the risk of colonic 
inflammation, due to deleterious changes in mucosal hydrophobicity and epithelial 





Wang. X, et al (2017) used CREB knock-out mice to observe the effect of inhibition of 
the PGE2 – EP4 signalling pathway on Th17 and Foxp3+ Treg development in vivo 
[34]. They observed that preventing CREB signalling resulted in increased intestinal 
Foxp3+ Tregs while reducing Th17 cell numbers, and was protective in a colitis 
disease model [34]. Thus, suggesting that PGE2 signalling via EP4 within the intestine, 
inducing CREB signalling via cAMP, negatively effects Foxp3+ Treg levels, as 
inhibition of PGE2 using a NSAID resulted in increased intestinal Tregs.  
Within the colonic Foxp3+ Tregs, inhibition of PGE2 also resulted in an increased 
proportion and number of RORɣt+ expressing Tregs, whereas RORɣt+Foxp3- Tconv 
cells were unaffected (chapter 4, Fig. 4.2). However, there was no similar increase 
observed within Tregs from spleens or mLNs. Intestinal RORɣt+Foxp3+ Tregs are a 
sub-population of peripheral derived Tregs (pTregs) which represent approximately 
50 % of this population, vitally important within this environment due to their stable 
suppressive ability within an inflammatory environment and due to significant 
demethylation at Treg signature genes, such as Foxp3 and Ctla-4  [55, 62, 167]. High 
levels of membrane-bound TGF-β (mTGF-β) and CD62L result in this Treg subset 
having a better ability to respond to inflammatory signals [55, 167]. The importance of 
this Treg subtype is well known, and Yang et al (2016), demonstrated their ability to 
suppress inflammation by injecting suboptimal numbers of either RORɣt+ or RORɣt- 
Tregs alongside naïve T cells to determine their effect [55]. RORɣt+Foxp3+ Tregs had 
an increased suppressive compared to RORɣt-Foxp3+ Tregs in a T cell colitis model 
[55, 62]. 
IL-6 and TGF-β signalling are both involved in induction of RORɣt expression, which 
can activate molecules essential for Th17 differentiation [205].  It was thought that 
cells co-expressing Foxp3 and RORɣt can become inflammatory due to the balance 
of TGF-β and inflammatory cytokines, and produce the Th17 associated cytokine IL-
17 after IL-6 treatment due to ‘plasticity’ of the Tregs, which was considered after fate-
mapping in mice indicated that a number of effector T cells come from a Treg lineage 
[62, 205]. However, it was more recently demonstrated that the Foxp3+RORɣt+ co-
expressing Tregs have a stable lineage, because although Foxp3+RORɣt+ Tregs 
express both Treg and Th17 signature genes, transcriptomic and epigenetic profiling 
detected that their similarity was closer to Foxp3+RORɣt- Tregs rather than Foxp3-





Foxp3+ Tregs co-expression of Th1/ Th2/ Th17 transcription factors; T-bet, GATA-3 
and RORɣt, is beneficial for the cells as it boosts the Tregs suppressive ability against 
the respective T effector cells  [25]. It is thought that the shared receptor expression 
increases the efficiency of homing to the inflammatory environment, and helps 
maintain Treg functionality during a specific effector T cell inflammatory response [25, 
180]. An adoptive transfer model was used to determine the in vivo stability of these 
cell populations [62]. Approximately 90 % of Foxp3+ Tregs maintained Foxp3 
expression after transfer, and around 80 % of Foxp3+RORɣt+ co-expressing Tregs 
maintained Foxp3 expression, and RORɣt expression was unaffected, however this 
was in the intestine, in other organs, such as the spleen, RORɣt levels were reduced 
[62]. Additionally, colonic Foxp3+ Tregs significantly enhanced RORɣt expression 
when re-isolated from colonic tissue, however adoptively transferred RORɣt+ T 
effector cells saw only a slight increase in Foxp3 expression, demonstrating that the 
dual RORɣt and Foxp3 expressing cells developed from FoxP3+ Tregs [62]   This 
demonstrated the stability of this regulatory cell lineage which can be maintained 
within the intestine, thus understanding the mechanisms behind the induction and 
maintenance of this cell population could potentially be beneficial for further research 
into inflammatory intestinal conditions.    
For future work, it would be useful to use an antibody against PGE2 for further 
confirmation of the direct role of PGE2. As previously mentioned, NSAIDs and COX 
inhibitors can have mixed results as treatment for inflammation, especially within the 
colon, therefore it may be more important to understand the mechanism by which 
PGE2 suppresses intestinal RORɣt+ Tregs. Manipulation of this mechanism could then 










7.4 Intestinal immunity  
The intestine is a highly variable environment with a large interface. In human adults, 
the small intestine is on average 6 metres long, while the large intestine is 
approximately 1.5 metres long [206]. This ensures that the immune system and gut 
microbiota are in close contact, thus maintaining homeostasis is key to prevent 
unnecessary colonic inflammation. Aberrant expression of the COX enzymes, notably 
COX-2 which is greatly upregulated in an inflammatory environment, increases PGE2 
expression within tissues, potentially resulting in cancer development [84, 129]. This 
demonstrates the potential harmful effect that overexpression of PGE2 has within this 
environment, and the importance of understanding the effect of suppressing levels of 
this molecule. 
Increased levels of prostaglandins have been observed in various conditions such as 
pre-malignant and malignant colorectal tumours, demonstrating the importance in 
understanding both the benefits and issues with suppression of this molecule [84, 
129].  Loughry, R. W (1983); Chan, A. T (2007); Levin, B (2006); Chan, A. T (2014); 
Sørensen. H, T (2015); are just a few examples of the growing number of groups that 
have observed a link between long-term aspirin use and a reduced risk of colorectal 
cancer [122-126]. Groups have shown that hydroxyprostaglandin dehydrogenase 15 
(15-PGDH) is vital in the antagonism of prostaglandin-endoperoxide synthase 2 
(PTGS2), encoding COX-2, during cancer development [125]. 
COX enzymes and their consequent prostaglandin products were first implicated in 
colorectal tumorigenesis back in 1983 when Gardner’s syndrome patients, who 
develop multiple colon polyps, had a reduced adenoma burden after NSAID treatment 
[123, 129]. This increase in PGE2 is due to aberrant expression of the cyclooxygenase 
(COX) enzymes COX-1 and COX-2.  Deng, Z. et al (2015) demonstrated that within 
the intestine, PGE2 expression was elevated due to enteropathogenic bacteria-
secreted particles stimulating the epithelium [207]. It is thought that increased 
intestinal PGE2 enhances epithelium production of the chemokine ligand CCL2,  and 
these molecules work together to recruit pro-inflammatory Th17 cells and stimulate 





This has been demonstrated in animal disease models, but is also comparable to 
what is observed in human colorectal patients, which confirms the importance of the 
role and mechanism of action of PGE2 on immune cells within organs. Additionally, 
this demonstrates the role that the gut microbiota can play, affecting PGE2 expression 
within the intestinal environment, which can consequently modulate the immune 
response. 
Long-term use of non-steroidal anti-inflammatory drugs (NSAIDs), which can 
suppress PGE2 expression through inhibition of COX-1 and COX-2, can have long-
term benefits such as reducing the risk of developing diseases such as Alzheimer’s 
and colorectal tumours as previously discussed [157]. One NSAID is even included 
on the World Health Organisation (WHO) Model List of Essential Medicine (2015), 
and widely used by people due to ease of purchase over-the-counter. Nevertheless, 
for some patients with inflammatory conditions such as inflammatory bowel disease 
(IBD), administration of COX inhibitors could worsen symptoms, rather than reduce 
the pro-inflammatory activity within this environment [47, 207].  
It was thought that NSAID use, inhibiting both COX enzymes non-specifically, resulted 
in intestinal inflammation due to reduced levels of COX-1 in the intestine. COX-1 is 
vital for expression of house-keeping levels of prostaglandins, some of which are 
important for maintenance of the intestinal barrier as aforementioned. COX-2 specific 
inhibitors have been designed, as this enzyme is mainly involved in inflammation and 
pain, also to reduce the risk of gastrointestinal complications because COX-1 is an 
important in maintaining house-keeping levels of prostaglandins, however, the risk of 
myocardial infarctions and strokes were increased [208, 209]. This is largely due to 
suppression of PGI2 that normally induces thrombomodulin production, which reduces 
the risk of blood coagulation by converting thrombin into an anti-coagulant enzyme 
[208]. This risk was reduced by use of non-specific NSAIDs, suggesting that use of 
specific inhibitors to suppress PGE2 production within the intestine had variable 
results, while non-specific NSAIDs can damage the intestine, leading to a conundrum 
about treatment options [209]. Additionally, suppression of COX-2 can reduce resolvin 
production, which could worsen symptoms, although some can be produced by 
leukotrienes [210]. This may be why an increase in neutrophil markers was also 
detected in colons of indomethacin-treated mice, due to leukotriene induced 
recruitment (chapter 4, Fig. 4.4).  
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Specific prostaglandin synthase inhibitors are thought not to be a suitable alternative, 
as PGH2 can be re-diverted towards another synthase, resulting in other adverse 
effects [124, 137]. Blocking further up at phospholipase 2 is also not advised, as it is 
a very diverse enzyme so very tough to develop drugs against, and additionally it 
would inhibit the production of multiple products vital for housekeeping roles if 
blocked, therefore more receptor or organ specific treatment is required. 
Indomethacin was used as the NSAID to inhibit prostaglandin E2 synthesis for the 
majority of experiments, due to its ease of administration and its use previously by our 
group and others as an efficient way of inhibiting prostaglandin synthesis [112, 120, 
211, 212]. It can inhibit both COX-1 and COX-2, important within the intestine as COX-
1 is present for housekeeping prostaglandin production, however inflammation 
significantly upregulates COX-2 expression, thus an inhibitor of both isoforms can 
demonstrate the importance of inhibition of PGE2 synthesis. An EP4 agonist was used 
to confirm that the results observed were due to inhibition of PGE2. Celecoxib, another 
NSAID which is a specific COX-2 inhibitor, was used by our group to determine 
whether other NSAIDs had a similar effect on intestinal Tregs (data unpublished). As 
observed in mice treated with indomethacin, celecoxib treatment also resulted in an 
increased proportion of intestinal Foxp3+ Tregs, and additionally there was increased 
RORɣt expression within this Foxp3 expressing population. Celecoxib has similarly 
been shown in a double-blind study to reduce colorectal adenomatous polyps due to 
suppression of the overexpressed COX-2 observed in human colorectal cancer and 
adenomatous polyps [122, 129].  Similarly, an EP4 agonist prevented this increase.  
 
7.5 The role of gut microbiota and PGE2 on intestinal Tregs 
The gastrointestinal epithelium is constantly exposed to potentially pathogenic stimuli 
such as the gut microbiota, of which there are approximately ten times more microbial 
cells in the human intestine than there are cells making up the body and the 
microbiome contains more than 100 times more genomic material than consists within 
the human genome, therefore regulatory mechanisms are vital to prevent an 
unnecessary immune response to a harmless signal [89]. The microbiome does have 
some benefits for the host, including; regulating the immune system, protection 
against harmful pathogens, production of energy through fermentation of undigested 




Gut microbiota dysbiosis, a microbial imbalance, can result in negative effects, such 
as allowing pathogenic bacteria to adhere to intestinal epithelium, and altering 
microbial metabolite products which normally enhance regulatory cell development, 
thus inflammatory symptoms as observed by IBD patients can develop [214].   
The understanding of the importance of gut microbiota has been rapidly increased 
within the last few years, within both the scientific and general community. IBD 
patients treated with prebiotics, non-digestible substances that help support growth of 
the beneficial gut microbiota, and fermented products such as butyrate to provide an 
energy source for the intestinal epithelium, resulted in reduced IBD symptoms [214]. 
This demonstrates the importance and ‘ease’ of modulating the immune system via 
delivery of dietary supplements which are less severe than current IBD treatments, 
such as immunosuppression [214]. Probiotic treatments, delivery of live 
microorganisms to fill a niche and reduce inflammation within the intestine, have been 
trialled, however due to differences in lengths of therapy and great variety of 
heterogeneity of microbial specifies,  and various patient disease states, have 
resulted in varying results from trials [214].   
It has recently been published that there is evidence that certain gut microbiota can 
boost cancer therapy, and modulate susceptibility to harmful side-effects [215-219], 
its importance in regulating blood pressure [220] and involvement in diabetes and 
obesity [221]. More specific examples are the method of curing H. pylori infections 
with the aim to reduce symptoms of peptic ulcers, and faecal transplants have been 
used for curing C. difficile infections,  [222].  These products can signal via APC toll-
like receptors, acting via MyD88 and TRIF signal adapters to influence the immune 
response. Suppression of PGE2 did not affect colonic Treg levels in mice treated with 
broad-spectrum antibiotics, demonstrating the importance of the gut microbiota 
facilitates PGE2 mediated inhibition of Foxp3+ Tregs (chapter 5, Fig. 5.1). 
Additionally, MyD88 and TRIF double knock-out mice did not detect an increase in 
colonic Foxp3+ Tregs following PGE2 inhibition (chapter 5, Fig. 5.2). All this just 
further demonstrates the importance of the intestinal microbiota in development of the 







The importance of the gut microbiota and its diversity is clear from birth, and various 
practices can influence it during the whole lifetime. Studies have indicated that 
numerous prescribed antibiotics, are unnecessarily  [51].  This both increases the risk 
of developing strains of antibiotic-resistant bacteria, but intestinal microbial dysbiosis 
can also occur. Microbial dysbiosis is implicated in conditions such as Ulcerative 
colitis  [51, 52, 55, 171]. A greater microbial diversity correlates with a greater 
population of intestinal Tregs, and this is consequently more protective for the host 
[55].  More recently, in 2017 a paper was released describing the role that intestinal 
microbiota plays on cancer patients responses to immunotherapy [223, 224].  
Therefore, due to the close link between the microbiota and immune cells, it was 
considered whether the microbiota also influences PGE2’s suppression of intestinal 
Tregs.  
 
7.6 The involvement of mononuclear phagocytes in intestinal immune 
homeostasis 
My data demonstrated that gut microbiota was involved in PGE2’s suppression of 
intestinal Tregs, and this was demonstrated via use of broad-spectrum antibiotics and 
toll-like receptor adapter molecule MyD88/TRIF double knock-out mice.  Multiple cell 
types, such as dendritic cells (DCs), a mononuclear phagocyte (MNP) subtype, are 
required within the intestine to process microbial peptides and regulate the immune 
system. CD103+ DCs are known to enhance intestinal Tregs via retinoic acid (RA) 
and TGFβ production, therefore it was questioned whether inhibition of PGE2 also 
influenced colonic MNP subtypes. PGE2 is known to suppress differentiation of retinal 
dehydrogenase, the enzyme responsible for RA synthesis [110]. It was interesting 
that PGE2 inhibition resulted in increased CD11b+CD103- cLP MNPs compared to 
vehicle treated mice, whereas CD11b+CD103+ cLP MNPs were unaffected (chapter 
5, Fig. 5.3).  
The importance of these cells within this environment and the link between the gut 
microbiota was supported by Nakahashi-Oda, C. et al (2016) [40]. This group 
demonstrated that gut microbiota signalling via CD103- DCs induced IFNβ signalling 
and consequently enhanced Foxp3+ Treg proliferation [40].  
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There was an increased expression of type 1 interferon genes, such as Ifn-β, in 
colonic CD11b+CD103- cLP MNPs sorted from indomethacin-treated mice compared 
to vehicle-treated mice (chapter 5, Fig. 5.7). This increased IFN-β expression is 
thought to enhance colonic Treg proliferation. Nakahashi-Oda. C, et al (2016) 
suggested that CD300a, expressed on CD103- DCs, is activated by 
phosphatidylserine (PS), a marker expressed on dying epithelial cells and 
consequently prevents IFNβ production [112]. CD300a is important for preventing 
Treg proliferation, important within a site of self-renewing epithelial cells which need 
to be cleared by a variety of phagocytic immune cells. This suggests that the 
increased type 1 interferon gene expression that was detected is not due to any 
potential intestinal damage that could result from indomethacin treatment. A greater 
number of dying epithelial cells would have increased PS expression, and 
consequently suppressed IFNβ production. The gut microbiota can initiate IFNβ 
production due to TLR4 activation, which may be why no increase in RORɣt+ Tregs 
are observed in antibiotic-treated or MyD88/TRIF double knock-out mice (Chapter 5, 
Fig. 5.1, 5.2) [6, 50]. 
 
7.7 The use of disease models to confirm my hypothesis 
I have demonstrated the role of PGE2 on intestinal RORɣt+ Treg levels and the 
influence of CD11b+CD103- cLP MNPs and microbiota. Thus, to illustrate the potential 
pathological importance of the in vitro and in vivo results, intestinal disease models 
were used.  
In chapter 4, Fig. 4.6, it was demonstrated that Foxp3 levels were unaffected in T 
cell specific EP4 KO mice, although they did have an increased level of RORɣt within 
the Foxp3 positive population. Thus, a DSS colitis disease model was used to see 
whether the EP KO were more protected from disease induction. Chemical methods 
of colitis induction, such as DSS and 2,4,6-trinitro benzene sulfonic acid (TNBS) are 
frequently used by groups to help further understand the mechanisms of cells involved 






In my DSS colitis disease model, both EP4 KO and WT mice had similar disease 
scores and inflammatory markers at the end of the experimental period which 
suggested that the increase in RORɣt expression within the intestinal Foxp3 
expressing cell population was not enough to protect from disease induction. This 
also may have been due to the harshness of the treatment damaging the intestine, 
therefore an increase in Tregs would not be enough to prevent the damage and 
inflammatory cell infiltration. If future treatments are wanting to target EP4 receptors, 
it is necessary to be careful from translation from mouse to human, as PGE2 signalling 
via EP4 within the colon, can induce production of gastrointestinal bicarbonate to 
neutralise gastric acid to maintain a balanced pH within the protective mucosal layer 
of the stomach and duodenum, however in mice the PGE2 receptor EP3 is also able 
to do this [85]. Thus inhibition of intestinal EP4 in humans will cause intestinal damage 
by the increased levels of gastric acid inability for neutralisation [85]. 
T cell colitis was used as a milder disease model to more easily observe the effect of 
naïve T cells from either wild type or T cell specific EP4 knock-out mice in RAG-/- mice. 
T cell specific EP4 knock-out mice were shown in previous experiments to have a 
greater number of Foxp3+ Tregs within the colon compared to WT mice (chapter 4, 
Fig. 4.6). In the T cell colitis disease model, mice injected with EP4 knock-out naïve 
T cells, had a better disease course and reduced disease symptoms compared to 
mice injected with WT naïve T cells (chapter 6, Fig. 6.3). This may be due to their 
increased ability to be converted into highly suppressive and stable Tregs within the 
intestine, as there was an increased proportion of Foxp3 observed in the colonic 
tissue and reduced inflammatory cytokines compared to mice injected with WT naïve 
T cells. Due to the size of the flow cytometry fluorophore panel, RORɣt was not able 
to be also measured within these cells.  
A T cell colitis curative disease model using Foxp3+ Tregs sorted from colonic tissue 
from vehicle- or indomethacin- treated mice was attempted, however the low number 
of live Foxp3+ Tregs that we collected following the sort was not enough to treat the 






Lastly, a faecal transfer model was utilised as earlier in vitro work had demonstrated 
that caecal content from indomethacin-treated mice was able to greater induce Foxp3 
expression in naïve T cells compared to vehicle-treated mice caecum (data not 
shown), and it also boosted CD103- MNPs ability to induce Tregs (chapter 5, Fig. 
5.5). Short chain fatty acids, such as butyrate, are produced by bacterial fermentation 
of dietary fibres, and can inhibit histone deacetylation in the gut, boosting acetylation 
within the enhancer and promoter regions of various regulatory gene regions, 
increased acetylation enhances stability of protein levels, important within the 
intestinal environment [226]. Thus, affecting the gut microbiota present within the 
intestine, and consequently their metabolite fermentation products, can greatly 
influence epigenetic regulation of gene expression in cells within this environment 
[226]. Western blots could be used to detect whether the acetylation state of the 
Foxp3 gene within regulatory T cells sorted from colonic tissue from vehicle, 
indomethacin, or indomethacin plus an EP4 agonist treated mouse, had been 
affected.   
The importance of the gut microbiota and their subsequent metabolic products, was 
also supported by work by Nakahashi-Oda, C. et al (2016) showing that faecal 
contents promotes IFN-β production from cultured BMDCs in vitro [6]. There was no 
difference in Foxp3 expression observed between naïve T cells cultured with the other 
subsets of DCs, and as previously discussed, increased levels of IFN-β production 
increase the proliferative and suppressive ability of Tregs [6]. Faecal transplants have 
already been used as a method for curing C. difficile infections, demonstrating that 










Mice had greater protection from DSS colitis induction after gavage of fresh caecum 
content solution from indomethacin-treated mice, compared vehicle-treated mice. 
This was supported by findings from Xiao, X. et al (2017), who demonstrated that 
indomethacin-caecum content protected mice against indomethacin-induced injury 
[195]. This was shown to be largely due to the alteration of the gut microbiota phyla 
[195]. There was an increased abundance of Firmicutes in the gut of indomethacin 
treated mice and a reduced level of Bacteroidetes, compared to mice treated with 
vehicle [195]. However PGE2 and COX levels were similarly reduced in both of the 
indomethacin-injury induced groups of mice treated with either the vehicle or 
indomethacin treated mouse faecal content, demonstrating the importance of the gut 
microbiota in the protection of the intestine [195]. In chapter 6, figure 6.5, fresh 
caecum content from indomethacin treated mice had a protective benefit in DSS colitis 
induced mice compared to the mice gavaged with caecal content from vehicle-treated 
mice. Like data observed in Xiao, X et al (2017), they had a reduced disease activity 
score and lower inflammatory cytokines present in colonic tissue from mice given 
faecal transplants from indomethacin treated mice. 
Other experiments that could be used to further confirm our microbiota data is a co-
housing experiment where marked mice are gavaged with either vehicle or 
indomethacin and co-housed with untreated mice. Induce a colitis disease model and 
observe whether mice are protected from disease if co-housed with mice treated with 
the NSAID. Further suggested experiments include a faecal transfer model into germ-
free (GF) mice from vehicle or indomethacin treated, to compose a microbiome, and 
induce T cell colitis, to see whether a microbiome from indomethacin-treated mice has 
a protective benefit. Additionally, it would be useful to phenotype the gut microbiota 
in stored caecum content from the two donor groups using RNA based sequencing 
and PCR to see whether the taxonomic composition of microbiome had been 
increased, and whether any bacterial phyla, or more specifically genera, had been 
reduced during treatment, and to see whether alteration had also been observed in 






There was increased type 1 interferon gene expression detected in sorted colonic 
CD103- mononuclear phagocytes (MNPs) from indomethacin treated mice, compared 
to vehicle treated mice (chapter 5, figure 5.7). Additionally, there was also increased 
STAT-1 signalling, a downstream marker of interferon signalling, detected by 
increased levels of phosphorylation, in both colonic Foxp3+ Tregs and MNPs (chapter 
5, Fig. 5.9). Multiple groups have demonstrated that inducing the type 1 interferon 
signalling pathway via TLR signalling or interferon agonists resulted in a reduction of 
DSS colitis severity [76, 227-230]. Thus, the faecal transplant of caecal content from 
indomethacin treated mice may have induced increased colonic TLR signalling in the 
recipient mice and hence reduced colitis symptoms [76, 227-230]. This may be due 
to the importance of protection against epithelial damage, which is a concern when 
inhibiting PGE2 directly using NSAIDs and negates much benefit from treatment, 
whereas type 1 interferons has been shown to inhibit epithelial apoptosis [76, 229]. 
Genome studies of IBD patients have identified changes in IFNRA1 and subsequent 
downstream signalling molecules including STAT-3, as disease risk loci, 
demonstrating the importance in type 1 interferon in controlling intestinal inflammation 
[76]. The commensal microbiota are key in  establishing a basal type 1 interferon 
response, which then can control the level of immune response with the intestine 
demonstrating the importance of the gut microbiota in regulation of the immune 
system [76]. Additionally, MyD88 and TRIF signalling can influence the interferon 
response in intestinal epithelial cells (IECs) within the colon, and previously we had 
demonstrated the importance of these signalling pathways in PGE2’s modulation of 
colonic Treg or DC levels (Chapter 5. Fig. 5.2 and 5.4) [76]. Bliech. A, et al (2009), 
demonstrated that addition of a CpG-oligodeoxynucleotide, a molecule that mimics 
bacterial signalling and can induce interferon signalling, induced Tregs and protected 
mice from T cell colitis [231]. This was dependent on type 1 interferons and TGF-β 
signalling, both negatively affected by PGE2 signalling [76, 87, 231]. This signalling 
can also retain T cells in the mucosal area, consequently increasing exposure to 






Further evidence demonstrating the importance of IFNβ was demonstrated by Kole, 
A. et al (2013) who injected RAG-/-IFNAR-/- DKO, deficient of both mature B and T 
cells, and interferon receptors, inhibiting interferon signalling, or RAG-/- KO mice with 
CD4+CD45RBhi T cells, and observed less severe symptoms in the RAG-/- mice, due 
to their ability to signal via the IFN pathway [75]. The suppressive ability of interferons 
results in reduced effector T cell proliferation. There is restricted data in human 
studies, however clinical trials treating IBD patients directly with IFN-1 was not highly 
successful [75, 232].  Whereas the role of interferon signalling and the commensal 
microbiota is becoming a widely more studied area and has promising results for 
future reduction of human conditions of intestinal inflammation rather than use of 
NSAIDs or direct administration of interferons as the levels and balance of these can 
affect both the pro- and anti-inflammatory immune response.  
Lastly, a stimulating concept was introduced by Professor Glenn Gibson at an Society 
of Chemical Industry (SCI) lecture titled ‘Getting to the gut of microbiology’ [233]. It 
was suggested that in the future rather than using antibiotics to combat bacterial 
infection, risking negatively affecting the intestinal gut microbiota and causing 
antibiotic-resistant bacteria, phages will be developed to bind to specific bacteria and 
kill it [233]. Therefore, in the future, rather than using broad-spectrum antibiotics to 
influence intestinal microbiota, selectively killing pro—inflammatory bacteria could 
allow regulatory bacteria to fill the remaining niche. This would be able to benefit the 
300,000 people in the UK who have IBD (numbers taken from the UK Inflammatory 
Bowel Disease Audit by the Royal College of Physicians in 2014) [116]. The body of 
work presented here indicates the influence PGE2 has on colonic Tregs and the 
impact this could have on intestinal inflammation, potentially through altering the 
intestinal microbiome. This also introduces the concept of using modulation of 
intestinal PGE2 to selectively foster anti-inflammatory, regulatory microbiota as part of 
a multifaceted treatment regime to tackle gut problems. These problems are reported 
to take up more GP time than any other complaint, and therefore this work may 





Figure 7.1: Summary of the role of PGE2 on intestinal Treg development. (1) PGE2 acts 
via the EP4 receptor to negatively affect naïve T cell differentiation into Foxp3+ Tregs. This 
was observed to the greatest extent within the colon. (2) PGE2 can modulate the gut microbiota 
which consequently influences both Foxp3+ Tregs and Foxp3+RORɣt+ Treg differentiation in 
the colon through detection by TLRs and the adapter molecules MyD88 and TRIF. (3) 
Modulation of the gut microbiota can also affect intestinal CD103- mononuclear phagocyte 
development, which consequently affects colonic Foxp3+ Tregs and Foxp3+RORɣt+ Tregs. (4) 
Inhibition of PGE2 results in increased type 1 interferon gene expression in colonic CD103- 
mononuclear phagocytes, which can increase induction of intestinal Foxp3+ Tregs. Inhibition 
of type 1 interferon signalling prevents an increase in colonic CD103- mononuclear 
phagocytes, Foxp3+ Tregs, co-expressing Foxp3+RORɣt+ Tregs after inhibition of PGE2.  
In conclusion, this thesis has introduced novel concepts in regard to how the well-
known inflammation mediator prostaglandin E2 modulates intestinal Tregs, especially 
the RORɣt+ subset. Figure 7.1 illustrates the model I propose to explain. This is 
possibly through modification of the gut microbiota which consequently influences 
colonic mononuclear phagocyte subsets, and these findings can potentially help 
further enhance research into intestinal inflammation and development of more 
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